id	sid	tid	token	lemma	pos
gsrj-50	1	1	analysis	analysis	NOUN
gsrj-50	1	2	of	of	ADP
gsrj-50	1	3	the	the	DET
gsrj-50	1	4	relationship	relationship	NOUN
gsrj-50	1	5	between	between	ADP
gsrj-50	1	6	parp1	parp1	NOUN
gsrj-50	1	7	and	and	CCONJ
gsrj-50	1	8	brca1	brca1	NOUN
gsrj-50	1	9	suggests	suggest	VERB
gsrj-50	1	10	parp1	parp1	NOUN
gsrj-50	1	11	gene	gene	NOUN
gsrj-50	1	12	has	have	VERB
gsrj-50	1	13	a	a	DET
gsrj-50	1	14	role	role	NOUN
gsrj-50	1	15	in	in	ADP
gsrj-50	1	16	breast	breast	NOUN
gsrj-50	1	17	cancer	cancer	NOUN
gsrj-50	1	18	kush	kush	PROPN
gsrj-50	1	19	modi	modi	PROPN
gsrj-50	1	20	,	,	PUNCT
gsrj-50	1	21	tony	tony	PROPN
gsrj-50	1	22	joseph	joseph	PROPN
gsrj-50	1	23	georgetown	georgetown	PROPN
gsrj-50	1	24	scientific	scientific	PROPN
gsrj-50	1	25	research	research	PROPN
gsrj-50	1	26	journal	journal	PROPN
gsrj-50	1	27	volume	volume	NOUN
gsrj-50	1	28	three	three	NUM
gsrj-50	1	29	edition	edition	NOUN
gsrj-50	1	30	two	two	NUM
gsrj-50	1	31	spring	spring	NOUN
gsrj-50	1	32	2023	2023	NUM
gsrj-50	1	33	6	6	NUM
gsrj-50	1	34	georgetown	georgetown	PROPN
gsrj-50	1	35	scientific	scientific	ADJ
gsrj-50	1	36	research	research	NOUN
gsrj-50	1	37	journal	journal	NOUN
gsrj-50	1	38	analysis	analysis	NOUN
gsrj-50	1	39	of	of	ADP
gsrj-50	1	40	the	the	DET
gsrj-50	1	41	relationship	relationship	NOUN
gsrj-50	1	42	between	between	ADP
gsrj-50	1	43	parp1	parp1	NOUN
gsrj-50	1	44	and	and	CCONJ
gsrj-50	1	45	brca1	brca1	NOUN
gsrj-50	1	46	suggests	suggest	VERB
gsrj-50	1	47	parp1	parp1	NOUN
gsrj-50	1	48	gene	gene	NOUN
gsrj-50	1	49	has	have	VERB
gsrj-50	1	50	a	a	DET
gsrj-50	1	51	role	role	NOUN
gsrj-50	1	52	in	in	ADP
gsrj-50	1	53	breast	breast	NOUN
gsrj-50	1	54	cancer	cancer	NOUN
gsrj-50	1	55	kkuusshh	kkuusshh	PROPN
gsrj-50	1	56	mmooddii11	mmooddii11	PROPN
gsrj-50	1	57	,	,	PUNCT
gsrj-50	1	58	,	,	PUNCT
gsrj-50	1	59	ttoonnyy	ttoonnyy	NOUN
gsrj-50	1	60	jjoosseepphh22	jjoosseepphh22	NOUN
gsrj-50	1	61	1department	1department	NUM
gsrj-50	1	62	of	of	ADP
gsrj-50	1	63	biology	biology	NOUN
gsrj-50	1	64	,	,	PUNCT
gsrj-50	1	65	georgetown	georgetown	PROPN
gsrj-50	1	66	university	university	PROPN
gsrj-50	1	67	,	,	PUNCT
gsrj-50	1	68	washington	washington	PROPN
gsrj-50	1	69	,	,	PUNCT
gsrj-50	1	70	d.c	d.c	PROPN
gsrj-50	1	71	.	.	PROPN
gsrj-50	1	72	,	,	PUNCT
gsrj-50	1	73	united	united	PROPN
gsrj-50	1	74	states	states	PROPN
gsrj-50	1	75	of	of	ADP
gsrj-50	1	76	america	america	PROPN
gsrj-50	1	77	2department	2department	PROPN
gsrj-50	1	78	of	of	ADP
gsrj-50	1	79	biology	biology	NOUN
gsrj-50	1	80	,	,	PUNCT
gsrj-50	1	81	cuny	cuny	PROPN
gsrj-50	1	82	brooklyn	brooklyn	PROPN
gsrj-50	1	83	college	college	PROPN
gsrj-50	1	84	,	,	PUNCT
gsrj-50	1	85	brooklyn	brooklyn	PROPN
gsrj-50	1	86	,	,	PUNCT
gsrj-50	1	87	ny	ny	PROPN
gsrj-50	1	88	,	,	PUNCT
gsrj-50	1	89	united	united	PROPN
gsrj-50	1	90	states	states	PROPN
gsrj-50	1	91	of	of	ADP
gsrj-50	1	92	america	america	PROPN
gsrj-50	1	93	e	e	PROPN
gsrj-50	1	94	-	-	NOUN
gsrj-50	1	95	mail	mail	NOUN
gsrj-50	1	96	:	:	PUNCT
gsrj-50	1	97	kmm488@georgetown.edu	kmm488@georgetown.edu	PROPN
gsrj-50	1	98	hhttttppss::////ddooii	hhttttppss::////ddooii	X
gsrj-50	1	99	..	..	PROPN
gsrj-50	1	100	oorrgg//1100	oorrgg//1100	PROPN
gsrj-50	1	101	..	..	PROPN
gsrj-50	1	102	4488009911//ggssrr	4488009911//ggssrr	NUM
gsrj-50	1	103	..	..	PUNCT
gsrj-50	1	104	vv33ii22	vv33ii22	NOUN
gsrj-50	1	105	..	..	PUNCT
gsrj-50	1	106	5500	5500	NUM
gsrj-50	1	107	aabbssttrraacctt	aabbssttrraacctt	ADV
gsrj-50	1	108	poly	poly	ADJ
gsrj-50	2	1	[	[	X
gsrj-50	2	2	adp	adp	NOUN
gsrj-50	2	3	-	-	PUNCT
gsrj-50	2	4	ribose	ribose	NOUN
gsrj-50	2	5	]	]	PUNCT
gsrj-50	2	6	polymerase	polymerase	NOUN
gsrj-50	2	7	1	1	NUM
gsrj-50	2	8	(	(	PUNCT
gsrj-50	2	9	parp1	parp1	PROPN
gsrj-50	2	10	)	)	PUNCT
gsrj-50	2	11	,	,	PUNCT
gsrj-50	2	12	one	one	NUM
gsrj-50	2	13	of	of	ADP
gsrj-50	2	14	the	the	DET
gsrj-50	2	15	genes	gene	NOUN
gsrj-50	2	16	in	in	ADP
gsrj-50	2	17	the	the	DET
gsrj-50	2	18	parp	parp	ADJ
gsrj-50	2	19	family	family	NOUN
gsrj-50	2	20	,	,	PUNCT
gsrj-50	2	21	is	be	AUX
gsrj-50	2	22	mainly	mainly	ADV
gsrj-50	2	23	involved	involve	VERB
gsrj-50	2	24	in	in	ADP
gsrj-50	2	25	the	the	DET
gsrj-50	2	26	detection	detection	NOUN
gsrj-50	2	27	and	and	CCONJ
gsrj-50	2	28	repair	repair	NOUN
gsrj-50	2	29	of	of	ADP
gsrj-50	2	30	dna	dna	PROPN
gsrj-50	2	31	damage	damage	NOUN
gsrj-50	2	32	in	in	ADP
gsrj-50	2	33	cells	cell	NOUN
gsrj-50	2	34	,	,	PUNCT
gsrj-50	2	35	and	and	CCONJ
gsrj-50	2	36	its	its	PRON
gsrj-50	2	37	upregulation	upregulation	NOUN
gsrj-50	2	38	has	have	AUX
gsrj-50	2	39	been	be	AUX
gsrj-50	2	40	associated	associate	VERB
gsrj-50	2	41	with	with	ADP
gsrj-50	2	42	tumorigenesis	tumorigenesis	NOUN
gsrj-50	2	43	.	.	PUNCT
gsrj-50	3	1	parp1	parp1	PROPN
gsrj-50	3	2	is	be	AUX
gsrj-50	3	3	essential	essential	ADJ
gsrj-50	3	4	to	to	ADP
gsrj-50	3	5	all	all	DET
gsrj-50	3	6	cells	cell	NOUN
gsrj-50	3	7	in	in	ADP
gsrj-50	3	8	the	the	DET
gsrj-50	3	9	body	body	NOUN
gsrj-50	3	10	as	as	SCONJ
gsrj-50	3	11	it	it	PRON
gsrj-50	3	12	ensures	ensure	VERB
gsrj-50	3	13	that	that	SCONJ
gsrj-50	3	14	dna	dna	PROPN
gsrj-50	3	15	is	be	AUX
gsrj-50	3	16	replicated	replicate	VERB
gsrj-50	3	17	correctly	correctly	ADV
gsrj-50	3	18	.	.	PUNCT
gsrj-50	4	1	the	the	DET
gsrj-50	4	2	parp1	parp1	NOUN
gsrj-50	4	3	protein	protein	NOUN
gsrj-50	4	4	addresses	address	NOUN
gsrj-50	4	5	repair	repair	VERB
gsrj-50	4	6	of	of	ADP
gsrj-50	4	7	single	single	ADJ
gsrj-50	4	8	-	-	PUNCT
gsrj-50	4	9	stranded	strand	VERB
gsrj-50	4	10	breaks	break	NOUN
gsrj-50	4	11	(	(	PUNCT
gsrj-50	4	12	ssbs	ssbs	PROPN
gsrj-50	4	13	)	)	PUNCT
gsrj-50	4	14	in	in	ADP
gsrj-50	4	15	dna	dna	PROPN
gsrj-50	4	16	by	by	ADP
gsrj-50	4	17	initially	initially	ADV
gsrj-50	4	18	binding	bind	VERB
gsrj-50	4	19	near	near	ADP
gsrj-50	4	20	the	the	DET
gsrj-50	4	21	point	point	NOUN
gsrj-50	4	22	of	of	ADP
gsrj-50	4	23	break	break	NOUN
gsrj-50	4	24	in	in	ADP
gsrj-50	4	25	the	the	DET
gsrj-50	4	26	dna	dna	NOUN
gsrj-50	4	27	.	.	PUNCT
gsrj-50	5	1	while	while	SCONJ
gsrj-50	5	2	it	it	PRON
gsrj-50	5	3	is	be	AUX
gsrj-50	5	4	bound	bind	VERB
gsrj-50	5	5	to	to	ADP
gsrj-50	5	6	the	the	DET
gsrj-50	5	7	region	region	NOUN
gsrj-50	5	8	of	of	ADP
gsrj-50	5	9	the	the	DET
gsrj-50	5	10	ssb	ssb	PROPN
gsrj-50	5	11	,	,	PUNCT
gsrj-50	5	12	parp1	parp1	NOUN
gsrj-50	5	13	transfers	transfer	NOUN
gsrj-50	5	14	adp	adp	PROPN
gsrj-50	5	15	ribosyl	ribosyl	PROPN
gsrj-50	5	16	moiety	moiety	PROPN
gsrj-50	5	17	from	from	ADP
gsrj-50	5	18	nad+	nad+	NOUN
gsrj-50	5	19	to	to	ADP
gsrj-50	5	20	acceptor	acceptor	NOUN
gsrj-50	5	21	proteins	protein	NOUN
gsrj-50	5	22	.	.	PUNCT
gsrj-50	6	1	this	this	PRON
gsrj-50	6	2	leads	lead	VERB
gsrj-50	6	3	to	to	ADP
gsrj-50	6	4	the	the	DET
gsrj-50	6	5	recruitment	recruitment	NOUN
gsrj-50	6	6	of	of	ADP
gsrj-50	6	7	dna	dna	PROPN
gsrj-50	6	8	repair	repair	NOUN
gsrj-50	6	9	proteins	protein	NOUN
gsrj-50	6	10	to	to	ADP
gsrj-50	6	11	the	the	DET
gsrj-50	6	12	region	region	NOUN
gsrj-50	6	13	of	of	ADP
gsrj-50	6	14	dna	dna	PROPN
gsrj-50	6	15	breaks	break	NOUN
gsrj-50	6	16	.	.	PUNCT
gsrj-50	7	1	the	the	DET
gsrj-50	7	2	parp1	parp1	NOUN
gsrj-50	7	3	protein	protein	NOUN
gsrj-50	7	4	also	also	ADV
gsrj-50	7	5	aids	aid	VERB
gsrj-50	7	6	the	the	DET
gsrj-50	7	7	double	double	ADV
gsrj-50	7	8	-	-	PUNCT
gsrj-50	7	9	stranded	strand	VERB
gsrj-50	7	10	break	break	NOUN
gsrj-50	7	11	(	(	PUNCT
gsrj-50	7	12	dsb	dsb	NOUN
gsrj-50	7	13	)	)	PUNCT
gsrj-50	7	14	repair	repair	NOUN
gsrj-50	7	15	of	of	ADP
gsrj-50	7	16	dna	dna	NOUN
gsrj-50	7	17	by	by	ADP
gsrj-50	7	18	recruiting	recruit	VERB
gsrj-50	7	19	the	the	DET
gsrj-50	7	20	homologous	homologous	ADJ
gsrj-50	7	21	recombination	recombination	NOUN
gsrj-50	7	22	(	(	PUNCT
gsrj-50	7	23	hr	hr	NOUN
gsrj-50	7	24	)	)	PUNCT
gsrj-50	7	25	pathway	pathway	NOUN
gsrj-50	7	26	proteins	protein	NOUN
gsrj-50	7	27	.	.	PUNCT
gsrj-50	8	1	due	due	ADP
gsrj-50	8	2	to	to	ADP
gsrj-50	8	3	this	this	DET
gsrj-50	8	4	role	role	NOUN
gsrj-50	8	5	of	of	ADP
gsrj-50	8	6	parp1	parp1	NOUN
gsrj-50	8	7	in	in	ADP
gsrj-50	8	8	dna	dna	PROPN
gsrj-50	8	9	repair	repair	NOUN
gsrj-50	8	10	,	,	PUNCT
gsrj-50	8	11	it	it	PRON
gsrj-50	8	12	has	have	AUX
gsrj-50	8	13	been	be	AUX
gsrj-50	8	14	associated	associate	VERB
gsrj-50	8	15	with	with	ADP
gsrj-50	8	16	cancer	cancer	NOUN
gsrj-50	8	17	growth	growth	NOUN
gsrj-50	8	18	.	.	PUNCT
gsrj-50	9	1	using	use	VERB
gsrj-50	9	2	databases	database	NOUN
gsrj-50	9	3	,	,	PUNCT
gsrj-50	9	4	including	include	VERB
gsrj-50	9	5	uniprot	uniprot	ADJ
gsrj-50	9	6	,	,	PUNCT
gsrj-50	9	7	xena	xena	PROPN
gsrj-50	9	8	browser	browser	NOUN
gsrj-50	9	9	,	,	PUNCT
gsrj-50	9	10	and	and	CCONJ
gsrj-50	9	11	cbioportal	cbioportal	ADJ
gsrj-50	9	12	,	,	PUNCT
gsrj-50	9	13	this	this	DET
gsrj-50	9	14	article	article	NOUN
gsrj-50	9	15	explores	explore	VERB
gsrj-50	9	16	the	the	DET
gsrj-50	9	17	relationship	relationship	NOUN
gsrj-50	9	18	between	between	ADP
gsrj-50	9	19	parp1	parp1	NOUN
gsrj-50	9	20	mutations	mutation	NOUN
gsrj-50	9	21	and	and	CCONJ
gsrj-50	9	22	brca1	brca1	PROPN
gsrj-50	9	23	-	-	ADJ
gsrj-50	9	24	mutated	mutate	VERB
gsrj-50	9	25	breast	breast	NOUN
gsrj-50	9	26	cancer	cancer	NOUN
gsrj-50	9	27	.	.	PUNCT
gsrj-50	10	1	brca1	brca1	PROPN
gsrj-50	10	2	is	be	AUX
gsrj-50	10	3	a	a	DET
gsrj-50	10	4	tumor	tumor	NOUN
gsrj-50	10	5	suppressor	suppressor	NOUN
gsrj-50	10	6	gene	gene	NOUN
gsrj-50	10	7	,	,	PUNCT
gsrj-50	10	8	which	which	PRON
gsrj-50	10	9	is	be	AUX
gsrj-50	10	10	involved	involve	VERB
gsrj-50	10	11	in	in	ADP
gsrj-50	10	12	dna	dna	PROPN
gsrj-50	10	13	repair	repair	NOUN
gsrj-50	10	14	through	through	ADP
gsrj-50	10	15	the	the	DET
gsrj-50	10	16	hr	hr	NOUN
gsrj-50	10	17	pathway	pathway	NOUN
gsrj-50	10	18	.	.	PUNCT
gsrj-50	11	1	therefore	therefore	ADV
gsrj-50	11	2	,	,	PUNCT
gsrj-50	11	3	in	in	ADP
gsrj-50	11	4	brca1	brca1	PROPN
gsrj-50	11	5	-	-	ADJ
gsrj-50	11	6	mutated	mutate	VERB
gsrj-50	11	7	cells	cell	NOUN
gsrj-50	11	8	,	,	PUNCT
gsrj-50	11	9	the	the	DET
gsrj-50	11	10	lack	lack	NOUN
gsrj-50	11	11	of	of	ADP
gsrj-50	11	12	tumor	tumor	NOUN
gsrj-50	11	13	suppressor	suppressor	NOUN
gsrj-50	11	14	factors	factor	NOUN
gsrj-50	11	15	leads	lead	VERB
gsrj-50	11	16	to	to	ADP
gsrj-50	11	17	cancer	cancer	NOUN
gsrj-50	11	18	growth	growth	NOUN
gsrj-50	11	19	.	.	PUNCT
gsrj-50	12	1	however	however	ADV
gsrj-50	12	2	,	,	PUNCT
gsrj-50	12	3	in	in	ADP
gsrj-50	12	4	a	a	DET
gsrj-50	12	5	cell	cell	NOUN
gsrj-50	12	6	that	that	PRON
gsrj-50	12	7	has	have	VERB
gsrj-50	12	8	both	both	PRON
gsrj-50	12	9	brca1	brca1	NOUN
gsrj-50	12	10	mutations	mutation	NOUN
gsrj-50	12	11	and	and	CCONJ
gsrj-50	12	12	parp1	parp1	NOUN
gsrj-50	12	13	inhibition	inhibition	NOUN
gsrj-50	12	14	,	,	PUNCT
gsrj-50	12	15	dna	dna	NOUN
gsrj-50	12	16	damage	damage	NOUN
gsrj-50	12	17	can	can	AUX
gsrj-50	12	18	not	not	PART
gsrj-50	12	19	be	be	AUX
gsrj-50	12	20	repaired	repair	VERB
gsrj-50	12	21	,	,	PUNCT
gsrj-50	12	22	leading	lead	VERB
gsrj-50	12	23	to	to	ADP
gsrj-50	12	24	apoptosis	apoptosis	NOUN
gsrj-50	12	25	.	.	PUNCT
gsrj-50	13	1	hence	hence	ADV
gsrj-50	13	2	,	,	PUNCT
gsrj-50	13	3	parp1	parp1	NOUN
gsrj-50	13	4	inhibitors	inhibitor	NOUN
gsrj-50	13	5	have	have	AUX
gsrj-50	13	6	become	become	VERB
gsrj-50	13	7	essential	essential	ADJ
gsrj-50	13	8	in	in	ADP
gsrj-50	13	9	brca1	brca1	PROPN
gsrj-50	13	10	-	-	ADJ
gsrj-50	13	11	mutated	mutate	VERB
gsrj-50	13	12	breast	breast	NOUN
gsrj-50	13	13	cancers	cancer	NOUN
gsrj-50	13	14	.	.	PUNCT
gsrj-50	14	1	there	there	PRON
gsrj-50	14	2	are	be	VERB
gsrj-50	14	3	several	several	ADJ
gsrj-50	14	4	parp1	parp1	NOUN
gsrj-50	14	5	inhibitors	inhibitor	NOUN
gsrj-50	14	6	that	that	PRON
gsrj-50	14	7	are	be	AUX
gsrj-50	14	8	currently	currently	ADV
gsrj-50	14	9	being	be	AUX
gsrj-50	14	10	used	use	VERB
gsrj-50	14	11	to	to	PART
gsrj-50	14	12	treat	treat	VERB
gsrj-50	14	13	breast	breast	NOUN
gsrj-50	14	14	cancer	cancer	NOUN
gsrj-50	14	15	,	,	PUNCT
gsrj-50	14	16	which	which	PRON
gsrj-50	14	17	work	work	NOUN
gsrj-50	14	18	using	use	VERB
gsrj-50	14	19	several	several	ADJ
gsrj-50	14	20	mechanisms	mechanism	NOUN
gsrj-50	14	21	of	of	ADP
gsrj-50	14	22	action	action	NOUN
gsrj-50	14	23	,	,	PUNCT
gsrj-50	14	24	including	include	VERB
gsrj-50	14	25	parp1	parp1	NOUN
gsrj-50	14	26	trapping	trapping	NOUN
gsrj-50	14	27	,	,	PUNCT
gsrj-50	14	28	which	which	PRON
gsrj-50	14	29	prevents	prevent	VERB
gsrj-50	14	30	the	the	DET
gsrj-50	14	31	repair	repair	NOUN
gsrj-50	14	32	,	,	PUNCT
gsrj-50	14	33	transcription	transcription	NOUN
gsrj-50	14	34	,	,	PUNCT
gsrj-50	14	35	and	and	CCONJ
gsrj-50	14	36	replication	replication	NOUN
gsrj-50	14	37	of	of	ADP
gsrj-50	14	38	dna	dna	NOUN
gsrj-50	14	39	.	.	PUNCT
gsrj-50	15	1	this	this	DET
gsrj-50	15	2	article	article	NOUN
gsrj-50	15	3	also	also	ADV
gsrj-50	15	4	focuses	focus	VERB
gsrj-50	15	5	on	on	ADP
gsrj-50	15	6	the	the	DET
gsrj-50	15	7	clinical	clinical	ADJ
gsrj-50	15	8	trials	trial	NOUN
gsrj-50	15	9	of	of	ADP
gsrj-50	15	10	three	three	NUM
gsrj-50	15	11	specific	specific	ADJ
gsrj-50	15	12	drugs	drug	NOUN
gsrj-50	15	13	,	,	PUNCT
gsrj-50	15	14	olaparib	olaparib	NOUN
gsrj-50	15	15	,	,	PUNCT
gsrj-50	15	16	iniparib	iniparib	NOUN
gsrj-50	15	17	,	,	PUNCT
gsrj-50	15	18	and	and	CCONJ
gsrj-50	15	19	veliparib	veliparib	NOUN
gsrj-50	15	20	,	,	PUNCT
gsrj-50	15	21	which	which	PRON
gsrj-50	15	22	are	be	AUX
gsrj-50	15	23	used	use	VERB
gsrj-50	15	24	to	to	PART
gsrj-50	15	25	treat	treat	VERB
gsrj-50	15	26	breast	breast	NOUN
gsrj-50	15	27	cancer	cancer	NOUN
gsrj-50	15	28	.	.	PUNCT
gsrj-50	16	1	however	however	ADV
gsrj-50	16	2	,	,	PUNCT
gsrj-50	16	3	due	due	ADP
gsrj-50	16	4	to	to	ADP
gsrj-50	16	5	the	the	DET
gsrj-50	16	6	lack	lack	NOUN
gsrj-50	16	7	of	of	ADP
gsrj-50	16	8	understanding	understand	VERB
gsrj-50	16	9	surrounding	surround	VERB
gsrj-50	16	10	parp1	parp1	NOUN
gsrj-50	16	11	inhibition	inhibition	NOUN
gsrj-50	16	12	mechanisms	mechanism	NOUN
gsrj-50	16	13	and	and	CCONJ
gsrj-50	16	14	potential	potential	ADJ
gsrj-50	16	15	drug	drug	NOUN
gsrj-50	16	16	combinations	combination	NOUN
gsrj-50	16	17	,	,	PUNCT
gsrj-50	16	18	more	more	ADJ
gsrj-50	16	19	research	research	NOUN
gsrj-50	16	20	needs	need	VERB
gsrj-50	16	21	to	to	PART
gsrj-50	16	22	be	be	AUX
gsrj-50	16	23	done	do	VERB
gsrj-50	16	24	to	to	PART
gsrj-50	16	25	understand	understand	VERB
gsrj-50	16	26	potential	potential	ADJ
gsrj-50	16	27	biomarker	biomarker	NOUN
gsrj-50	16	28	targets	target	NOUN
gsrj-50	16	29	and	and	CCONJ
gsrj-50	16	30	parp1	parp1	NOUN
gsrj-50	16	31	inhibitor	inhibitor	NOUN
gsrj-50	16	32	resistance	resistance	NOUN
gsrj-50	16	33	.	.	PUNCT
gsrj-50	17	1	keywords	keyword	NOUN
gsrj-50	17	2	:	:	PUNCT
gsrj-50	17	3	parp1	parp1	PROPN
gsrj-50	17	4	,	,	PUNCT
gsrj-50	17	5	brca1	brca1	PROPN
gsrj-50	17	6	,	,	PUNCT
gsrj-50	17	7	breast	breast	NOUN
gsrj-50	17	8	cancer	cancer	NOUN
gsrj-50	17	9	,	,	PUNCT
gsrj-50	17	10	dna	dna	PROPN
gsrj-50	17	11	repair	repair	NOUN
gsrj-50	17	12	,	,	PUNCT
gsrj-50	17	13	gene	gene	NOUN
gsrj-50	17	14	expression	expression	NOUN
gsrj-50	17	15	11	11	NUM
gsrj-50	17	16	..	..	PUNCT
gsrj-50	17	17	iinnttrroodduuccttiioonn	iinnttrroodduuccttiioonn	PROPN
gsrj-50	17	18	poly	poly	ADJ
gsrj-50	17	19	[	[	X
gsrj-50	17	20	adp	adp	NOUN
gsrj-50	17	21	-	-	PUNCT
gsrj-50	17	22	ribose	ribose	NOUN
gsrj-50	17	23	]	]	PUNCT
gsrj-50	17	24	polymerase	polymerase	NOUN
gsrj-50	17	25	1	1	NUM
gsrj-50	17	26	(	(	PUNCT
gsrj-50	17	27	parp1	parp1	NOUN
gsrj-50	17	28	)	)	PUNCT
gsrj-50	17	29	serves	serve	VERB
gsrj-50	17	30	as	as	ADP
gsrj-50	17	31	a	a	DET
gsrj-50	17	32	first	first	ADJ
gsrj-50	17	33	responder	responder	NOUN
gsrj-50	17	34	enzyme	enzyme	NOUN
gsrj-50	17	35	,	,	PUNCT
gsrj-50	17	36	detecting	detect	VERB
gsrj-50	17	37	dna	dna	NOUN
gsrj-50	17	38	damage	damage	NOUN
gsrj-50	17	39	and	and	CCONJ
gsrj-50	17	40	assisting	assist	VERB
gsrj-50	17	41	in	in	ADP
gsrj-50	17	42	the	the	DET
gsrj-50	17	43	selection	selection	NOUN
gsrj-50	17	44	of	of	ADP
gsrj-50	17	45	a	a	DET
gsrj-50	17	46	repair	repair	NOUN
gsrj-50	17	47	pathway	pathway	NOUN
gsrj-50	17	48	.	.	PUNCT
gsrj-50	18	1	the	the	DET
gsrj-50	18	2	enzyme	enzyme	NOUN
gsrj-50	18	3	works	work	VERB
gsrj-50	18	4	by	by	ADP
gsrj-50	18	5	interacting	interact	VERB
gsrj-50	18	6	with	with	ADP
gsrj-50	18	7	and	and	CCONJ
gsrj-50	18	8	conformationally	conformationally	ADV
gsrj-50	18	9	altering	alter	VERB
gsrj-50	18	10	adp	adp	PROPN
gsrj-50	18	11	-	-	PUNCT
gsrj-50	18	12	ribose	ribose	ADJ
gsrj-50	18	13	units	unit	NOUN
gsrj-50	18	14	on	on	ADP
gsrj-50	18	15	various	various	ADJ
gsrj-50	18	16	dna	dna	PROPN
gsrj-50	18	17	repair	repair	NOUN
gsrj-50	18	18	factors	factor	NOUN
gsrj-50	18	19	,	,	PUNCT
gsrj-50	18	20	such	such	ADJ
gsrj-50	18	21	as	as	ADP
gsrj-50	18	22	rad51	rad51	ADJ
gsrj-50	18	23	and	and	CCONJ
gsrj-50	18	24	53bp1	53bp1	NUM
gsrj-50	18	25	,	,	PUNCT
gsrj-50	18	26	and	and	CCONJ
gsrj-50	18	27	by	by	ADP
gsrj-50	18	28	performing	perform	VERB
gsrj-50	18	29	adp	adp	PROPN
gsrj-50	18	30	-	-	PUNCT
gsrj-50	18	31	ribosylation	ribosylation	NOUN
gsrj-50	18	32	of	of	ADP
gsrj-50	18	33	histones	histone	NOUN
gsrj-50	18	34	,	,	PUNCT
gsrj-50	18	35	which	which	PRON
gsrj-50	18	36	leads	lead	VERB
gsrj-50	18	37	to	to	ADP
gsrj-50	18	38	decompaction	decompaction	NOUN
gsrj-50	18	39	of	of	ADP
gsrj-50	18	40	chromatin	chromatin	NOUN
gsrj-50	18	41	structure	structure	NOUN
gsrj-50	18	42	.	.	PUNCT
gsrj-50	19	1	additionally	additionally	ADV
gsrj-50	19	2	,	,	PUNCT
gsrj-50	19	3	it	it	PRON
gsrj-50	19	4	is	be	AUX
gsrj-50	19	5	involved	involve	VERB
gsrj-50	19	6	in	in	ADP
gsrj-50	19	7	the	the	DET
gsrj-50	19	8	regulation	regulation	NOUN
gsrj-50	19	9	of	of	ADP
gsrj-50	19	10	nucleotide	nucleotide	ADJ
gsrj-50	19	11	excision	excision	NOUN
gsrj-50	19	12	repair	repair	NOUN
gsrj-50	19	13	,	,	PUNCT
gsrj-50	19	14	nonhomologous	nonhomologous	ADJ
gsrj-50	19	15	end	end	NOUN
gsrj-50	19	16	joining	join	VERB
gsrj-50	19	17	,	,	PUNCT
gsrj-50	19	18	microhomologymediated	microhomologymediate	VERB
gsrj-50	19	19	end	end	NOUN
gsrj-50	19	20	joining	join	VERB
gsrj-50	19	21	,	,	PUNCT
gsrj-50	19	22	homologous	homologous	ADJ
gsrj-50	19	23	recombinational	recombinational	ADJ
gsrj-50	19	24	repair	repair	NOUN
gsrj-50	19	25	,	,	PUNCT
gsrj-50	19	26	and	and	CCONJ
gsrj-50	19	27	dna	dna	PROPN
gsrj-50	19	28	mismatch	mismatch	NOUN
gsrj-50	19	29	repair	repair	NOUN
gsrj-50	19	30	,	,	PUNCT
gsrj-50	19	31	among	among	ADP
gsrj-50	19	32	other	other	ADJ
gsrj-50	19	33	dna	dna	PROPN
gsrj-50	19	34	repair	repair	NOUN
gsrj-50	19	35	pathways	pathway	NOUN
gsrj-50	19	36	(	(	PUNCT
gsrj-50	19	37	figure	figure	NOUN
gsrj-50	19	38	1).1,2	1).1,2	NUM
gsrj-50	20	1	the	the	DET
gsrj-50	20	2	parp1	parp1	NOUN
gsrj-50	20	3	enzyme	enzyme	NOUN
gsrj-50	20	4	is	be	AUX
gsrj-50	20	5	also	also	ADV
gsrj-50	20	6	involved	involve	VERB
gsrj-50	20	7	in	in	ADP
gsrj-50	20	8	single	single	ADJ
gsrj-50	20	9	-	-	PUNCT
gsrj-50	20	10	stranded	strand	VERB
gsrj-50	20	11	dna	dna	NOUN
gsrj-50	20	12	(	(	PUNCT
gsrj-50	20	13	ssdna	ssdna	NOUN
gsrj-50	20	14	)	)	PUNCT
gsrj-50	20	15	repair	repair	NOUN
gsrj-50	20	16	in	in	ADP
gsrj-50	20	17	cells	cell	NOUN
gsrj-50	20	18	7	7	NUM
gsrj-50	20	19	georgetown	georgetown	PROPN
gsrj-50	20	20	scientific	scientific	ADJ
gsrj-50	20	21	research	research	NOUN
gsrj-50	20	22	journal	journal	NOUN
gsrj-50	20	23	(	(	PUNCT
gsrj-50	20	24	figure	figure	NOUN
gsrj-50	20	25	1	1	NUM
gsrj-50	20	26	)	)	PUNCT
gsrj-50	20	27	.	.	PUNCT
gsrj-50	21	1	as	as	ADP
gsrj-50	21	2	a	a	DET
gsrj-50	21	3	result	result	NOUN
gsrj-50	21	4	of	of	ADP
gsrj-50	21	5	this	this	DET
gsrj-50	21	6	function	function	NOUN
gsrj-50	21	7	,	,	PUNCT
gsrj-50	21	8	the	the	DET
gsrj-50	21	9	repair	repair	NOUN
gsrj-50	21	10	of	of	ADP
gsrj-50	21	11	ssdna	ssdna	NOUN
gsrj-50	21	12	breaks	break	NOUN
gsrj-50	21	13	in	in	ADP
gsrj-50	21	14	cells	cell	NOUN
gsrj-50	21	15	is	be	AUX
gsrj-50	21	16	slowed	slow	VERB
gsrj-50	21	17	when	when	SCONJ
gsrj-50	21	18	parp1	parp1	NOUN
gsrj-50	21	19	levels	level	NOUN
gsrj-50	21	20	in	in	ADP
gsrj-50	21	21	the	the	DET
gsrj-50	21	22	cell	cell	NOUN
gsrj-50	21	23	are	be	AUX
gsrj-50	21	24	low	low	ADJ
gsrj-50	21	25	or	or	CCONJ
gsrj-50	21	26	when	when	SCONJ
gsrj-50	21	27	parp1	parp1	NOUN
gsrj-50	21	28	activity	activity	NOUN
gsrj-50	21	29	is	be	AUX
gsrj-50	21	30	inhibited	inhibit	VERB
gsrj-50	21	31	by	by	ADP
gsrj-50	21	32	small	small	ADJ
gsrj-50	21	33	molecules	molecule	NOUN
gsrj-50	21	34	.	.	PUNCT
gsrj-50	22	1	when	when	SCONJ
gsrj-50	22	2	ssdna	ssdna	PROPN
gsrj-50	22	3	breaks	break	VERB
gsrj-50	22	4	occur	occur	VERB
gsrj-50	22	5	during	during	ADP
gsrj-50	22	6	dna	dna	NOUN
gsrj-50	22	7	replication	replication	NOUN
gsrj-50	22	8	in	in	ADP
gsrj-50	22	9	the	the	DET
gsrj-50	22	10	absence	absence	NOUN
gsrj-50	22	11	of	of	ADP
gsrj-50	22	12	parp1	parp1	NOUN
gsrj-50	22	13	,	,	PUNCT
gsrj-50	22	14	the	the	DET
gsrj-50	22	15	replication	replication	NOUN
gsrj-50	22	16	fork	fork	NOUN
gsrj-50	22	17	pauses	pause	NOUN
gsrj-50	22	18	,	,	PUNCT
gsrj-50	22	19	resulting	result	VERB
gsrj-50	22	20	in	in	ADP
gsrj-50	22	21	the	the	DET
gsrj-50	22	22	accumulation	accumulation	NOUN
gsrj-50	22	23	of	of	ADP
gsrj-50	22	24	single	single	ADJ
gsrj-50	22	25	-	-	PUNCT
gsrj-50	22	26	strand	strand	NOUN
gsrj-50	22	27	dna	dna	NOUN
gsrj-50	22	28	(	(	PUNCT
gsrj-50	22	29	ssdna	ssdna	ADV
gsrj-50	22	30	)	)	PUNCT
gsrj-50	22	31	breaks.3	breaks.3	ADJ
gsrj-50	22	32	homologous	homologous	ADJ
gsrj-50	22	33	recombination	recombination	NOUN
gsrj-50	22	34	(	(	PUNCT
gsrj-50	22	35	hr	hr	NOUN
gsrj-50	22	36	)	)	PUNCT
gsrj-50	22	37	repair	repair	NOUN
gsrj-50	22	38	,	,	PUNCT
gsrj-50	22	39	a	a	DET
gsrj-50	22	40	potentially	potentially	ADV
gsrj-50	22	41	error	error	NOUN
gsrj-50	22	42	-	-	PUNCT
gsrj-50	22	43	free	free	ADJ
gsrj-50	22	44	repair	repair	NOUN
gsrj-50	22	45	mechanism	mechanism	NOUN
gsrj-50	22	46	,	,	PUNCT
gsrj-50	22	47	is	be	AUX
gsrj-50	22	48	used	use	VERB
gsrj-50	22	49	to	to	PART
gsrj-50	22	50	mend	mend	VERB
gsrj-50	22	51	these	these	DET
gsrj-50	22	52	ssdna	ssdna	NOUN
gsrj-50	22	53	breaks	break	NOUN
gsrj-50	22	54	(	(	PUNCT
gsrj-50	22	55	ssbs	ssbs	PROPN
gsrj-50	22	56	)	)	PUNCT
gsrj-50	22	57	.	.	PUNCT
gsrj-50	23	1	as	as	ADP
gsrj-50	23	2	a	a	DET
gsrj-50	23	3	result	result	NOUN
gsrj-50	23	4	,	,	PUNCT
gsrj-50	23	5	parp1	parp1	NOUN
gsrj-50	23	6	-	-	PUNCT
gsrj-50	23	7	deficient	deficient	ADJ
gsrj-50	23	8	cells	cell	NOUN
gsrj-50	23	9	exhibit	exhibit	VERB
gsrj-50	23	10	a	a	DET
gsrj-50	23	11	hyper	hyper	ADJ
gsrj-50	23	12	-	-	ADJ
gsrj-50	23	13	recombinogenic	recombinogenic	ADJ
gsrj-50	23	14	phenotype	phenotype	NOUN
gsrj-50	23	15	,	,	PUNCT
gsrj-50	23	16	or	or	CCONJ
gsrj-50	23	17	an	an	DET
gsrj-50	23	18	increased	increase	VERB
gsrj-50	23	19	frequency	frequency	NOUN
gsrj-50	23	20	of	of	ADP
gsrj-50	23	21	hr.3	hr.3	PROPN
gsrj-50	23	22	ffiigguurree	ffiigguurree	NOUN
gsrj-50	23	23	11	11	NUM
gsrj-50	23	24	..	..	PUNCT
gsrj-50	23	25	in	in	ADP
gsrj-50	23	26	the	the	DET
gsrj-50	23	27	presence	presence	NOUN
gsrj-50	23	28	of	of	ADP
gsrj-50	23	29	dna	dna	PROPN
gsrj-50	23	30	damage	damage	NOUN
gsrj-50	23	31	,	,	PUNCT
gsrj-50	23	32	parp1	parp1	NOUN
gsrj-50	23	33	is	be	AUX
gsrj-50	23	34	activated	activate	VERB
gsrj-50	23	35	which	which	PRON
gsrj-50	23	36	leads	lead	VERB
gsrj-50	23	37	to	to	ADP
gsrj-50	23	38	adpribosylation	adpribosylation	NOUN
gsrj-50	23	39	.	.	PUNCT
gsrj-50	24	1	this	this	DET
gsrj-50	24	2	process	process	NOUN
gsrj-50	24	3	will	will	AUX
gsrj-50	24	4	either	either	CCONJ
gsrj-50	24	5	lead	lead	VERB
gsrj-50	24	6	to	to	ADP
gsrj-50	24	7	replication	replication	NOUN
gsrj-50	24	8	,	,	PUNCT
gsrj-50	24	9	ssb	ssb	PROPN
gsrj-50	24	10	repair	repair	NOUN
gsrj-50	24	11	,	,	PUNCT
gsrj-50	24	12	dsb	dsb	VERB
gsrj-50	24	13	repair	repair	NOUN
gsrj-50	24	14	,	,	PUNCT
gsrj-50	24	15	or	or	CCONJ
gsrj-50	24	16	will	will	AUX
gsrj-50	24	17	lead	lead	VERB
gsrj-50	24	18	to	to	ADP
gsrj-50	24	19	cell	cell	NOUN
gsrj-50	24	20	death.2	death.2	NOUN
gsrj-50	24	21	parp1	parp1	NOUN
gsrj-50	24	22	transfers	transfer	NOUN
gsrj-50	24	23	the	the	DET
gsrj-50	24	24	adp	adp	PROPN
gsrj-50	24	25	-	-	PUNCT
gsrj-50	24	26	ribosyl	ribosyl	PROPN
gsrj-50	24	27	moiety	moiety	NOUN
gsrj-50	24	28	from	from	ADP
gsrj-50	24	29	nad+	nad+	NOUN
gsrj-50	24	30	to	to	PART
gsrj-50	24	31	acceptor	acceptor	NOUN
gsrj-50	24	32	proteins	protein	NOUN
gsrj-50	24	33	after	after	ADP
gsrj-50	24	34	binding	bind	VERB
gsrj-50	24	35	to	to	PART
gsrj-50	24	36	ssbs	ssbs	VERB
gsrj-50	24	37	,	,	PUNCT
gsrj-50	24	38	resulting	result	VERB
gsrj-50	24	39	in	in	ADP
gsrj-50	24	40	lengthy	lengthy	ADJ
gsrj-50	24	41	chains	chain	NOUN
gsrj-50	24	42	of	of	ADP
gsrj-50	24	43	polyadpribosylated	polyadpribosylated	ADJ
gsrj-50	24	44	(	(	PUNCT
gsrj-50	24	45	parylated	parylate	VERB
gsrj-50	24	46	)	)	PUNCT
gsrj-50	24	47	polymers	polymer	NOUN
gsrj-50	24	48	.	.	PUNCT
gsrj-50	25	1	this	this	PRON
gsrj-50	25	2	permits	permit	VERB
gsrj-50	25	3	dna	dna	PROPN
gsrj-50	25	4	repair	repair	NOUN
gsrj-50	25	5	proteins	protein	NOUN
gsrj-50	25	6	like	like	ADP
gsrj-50	25	7	dna	dna	PROPN
gsrj-50	25	8	polymerase	polymerase	NOUN
gsrj-50	25	9	,	,	PUNCT
gsrj-50	25	10	dna	dna	PROPN
gsrj-50	25	11	ligase	ligase	PROPN
gsrj-50	25	12	iii	iii	PROPN
gsrj-50	25	13	,	,	PUNCT
gsrj-50	25	14	and	and	CCONJ
gsrj-50	25	15	scaffolding	scaffold	VERB
gsrj-50	25	16	proteins	protein	NOUN
gsrj-50	25	17	like	like	ADP
gsrj-50	25	18	xrcc1	xrcc1	NOUN
gsrj-50	25	19	to	to	PART
gsrj-50	25	20	be	be	AUX
gsrj-50	25	21	recruited	recruit	VERB
gsrj-50	25	22	to	to	PART
gsrj-50	25	23	ssb	ssb	VERB
gsrj-50	25	24	sites	site	NOUN
gsrj-50	25	25	.	.	PUNCT
gsrj-50	26	1	parp1	parp1	PROPN
gsrj-50	26	2	has	have	AUX
gsrj-50	26	3	been	be	AUX
gsrj-50	26	4	demonstrated	demonstrate	VERB
gsrj-50	26	5	to	to	PART
gsrj-50	26	6	interact	interact	VERB
gsrj-50	26	7	with	with	ADP
gsrj-50	26	8	the	the	DET
gsrj-50	26	9	dna	dna	PROPN
gsrj-50	26	10	dependent	dependent	ADJ
gsrj-50	26	11	protein	protein	NOUN
gsrj-50	26	12	kinase	kinase	PROPN
gsrj-50	26	13	complex	complex	NOUN
gsrj-50	26	14	involved	involve	VERB
gsrj-50	26	15	in	in	ADP
gsrj-50	26	16	non	non	ADJ
gsrj-50	26	17	-	-	ADJ
gsrj-50	26	18	homologous	homologous	ADJ
gsrj-50	26	19	end	end	NOUN
gsrj-50	26	20	-	-	PUNCT
gsrj-50	26	21	joining	joining	NOUN
gsrj-50	26	22	and	and	CCONJ
gsrj-50	26	23	may	may	AUX
gsrj-50	26	24	also	also	ADV
gsrj-50	26	25	facilitate	facilitate	VERB
gsrj-50	26	26	homologous	homologous	ADJ
gsrj-50	26	27	recombination	recombination	NOUN
gsrj-50	26	28	by	by	ADP
gsrj-50	26	29	recruiting	recruit	VERB
gsrj-50	26	30	components	component	NOUN
gsrj-50	26	31	like	like	ADP
gsrj-50	26	32	atm	atm	PROPN
gsrj-50	26	33	,	,	PUNCT
gsrj-50	26	34	mre11	mre11	ADJ
gsrj-50	26	35	,	,	PUNCT
gsrj-50	26	36	and	and	CCONJ
gsrj-50	26	37	nbs1	nbs1	NOUN
gsrj-50	26	38	to	to	ADP
gsrj-50	26	39	regions	region	NOUN
gsrj-50	26	40	of	of	ADP
gsrj-50	26	41	double	double	ADJ
gsrj-50	26	42	-	-	PUNCT
gsrj-50	26	43	stranded	strand	VERB
gsrj-50	26	44	dna	dna	NOUN
gsrj-50	26	45	damage.4	damage.4	NOUN
gsrj-50	26	46	as	as	SCONJ
gsrj-50	26	47	mentioned	mention	VERB
gsrj-50	26	48	before	before	ADV
gsrj-50	26	49	,	,	PUNCT
gsrj-50	26	50	parp1	parp1	NOUN
gsrj-50	26	51	is	be	AUX
gsrj-50	26	52	required	require	VERB
gsrj-50	26	53	for	for	ADP
gsrj-50	26	54	single	single	ADJ
gsrj-50	26	55	-	-	PUNCT
gsrj-50	26	56	strand	strand	NOUN
gsrj-50	26	57	break	break	NOUN
gsrj-50	26	58	repair	repair	NOUN
gsrj-50	26	59	.	.	PUNCT
gsrj-50	27	1	parp1	parp1	NOUN
gsrj-50	27	2	is	be	AUX
gsrj-50	27	3	also	also	ADV
gsrj-50	27	4	considered	consider	VERB
gsrj-50	27	5	to	to	PART
gsrj-50	27	6	be	be	AUX
gsrj-50	27	7	essential	essential	ADJ
gsrj-50	27	8	for	for	ADP
gsrj-50	27	9	base	base	NOUN
gsrj-50	27	10	excision	excision	NOUN
gsrj-50	27	11	repair	repair	NOUN
gsrj-50	27	12	(	(	PUNCT
gsrj-50	27	13	ber	ber	PROPN
gsrj-50	27	14	)	)	PUNCT
gsrj-50	27	15	,	,	PUNCT
gsrj-50	27	16	as	as	SCONJ
gsrj-50	27	17	various	various	ADJ
gsrj-50	27	18	investigations	investigation	NOUN
gsrj-50	27	19	have	have	AUX
gsrj-50	27	20	suggested	suggest	VERB
gsrj-50	27	21	,	,	PUNCT
gsrj-50	27	22	because	because	SCONJ
gsrj-50	27	23	single	single	ADJ
gsrj-50	27	24	-	-	PUNCT
gsrj-50	27	25	strand	strand	NOUN
gsrj-50	27	26	breaks	break	NOUN
gsrj-50	27	27	are	be	AUX
gsrj-50	27	28	also	also	ADV
gsrj-50	27	29	formed	form	VERB
gsrj-50	27	30	as	as	ADP
gsrj-50	27	31	an	an	DET
gsrj-50	27	32	intermediary	intermediary	NOUN
gsrj-50	27	33	of	of	ADP
gsrj-50	27	34	ber.5	ber.5	PROPN
gsrj-50	27	35	however	however	ADV
gsrj-50	27	36	,	,	PUNCT
gsrj-50	27	37	evidence	evidence	NOUN
gsrj-50	27	38	demonstrating	demonstrate	VERB
gsrj-50	27	39	the	the	DET
gsrj-50	27	40	sensitivity	sensitivity	NOUN
gsrj-50	27	41	of	of	ADP
gsrj-50	27	42	parp1	parp1	NOUN
gsrj-50	27	43	-	-	PUNCT
gsrj-50	27	44	defective	defective	ADJ
gsrj-50	27	45	or	or	CCONJ
gsrj-50	27	46	parp1	parp1	NOUN
gsrj-50	27	47	-	-	PUNCT
gsrj-50	27	48	inhibited	inhibit	VERB
gsrj-50	27	49	cells	cell	NOUN
gsrj-50	27	50	to	to	ADP
gsrj-50	27	51	drugs	drug	NOUN
gsrj-50	27	52	that	that	PRON
gsrj-50	27	53	cause	cause	VERB
gsrj-50	27	54	base	base	NOUN
gsrj-50	27	55	damage	damage	NOUN
gsrj-50	27	56	is	be	AUX
gsrj-50	27	57	conflicting	conflict	VERB
gsrj-50	27	58	.	.	PUNCT
gsrj-50	28	1	another	another	DET
gsrj-50	28	2	study	study	NOUN
gsrj-50	28	3	discovered	discover	VERB
gsrj-50	28	4	that	that	SCONJ
gsrj-50	28	5	while	while	SCONJ
gsrj-50	28	6	parp1	parp1	NOUN
gsrj-50	28	7	was	be	AUX
gsrj-50	28	8	not	not	PART
gsrj-50	28	9	necessary	necessary	ADJ
gsrj-50	28	10	to	to	PART
gsrj-50	28	11	repair	repair	VERB
gsrj-50	28	12	base	base	NOUN
gsrj-50	28	13	damage	damage	NOUN
gsrj-50	28	14	,	,	PUNCT
gsrj-50	28	15	it	it	PRON
gsrj-50	28	16	was	be	AUX
gsrj-50	28	17	essential	essential	ADJ
gsrj-50	28	18	to	to	PART
gsrj-50	28	19	repair	repair	VERB
gsrj-50	28	20	single	single	ADJ
gsrj-50	28	21	-	-	PUNCT
gsrj-50	28	22	strand	strand	NOUN
gsrj-50	28	23	breaks	break	NOUN
gsrj-50	28	24	caused	cause	VERB
gsrj-50	28	25	by	by	ADP
gsrj-50	28	26	hydrogen	hydrogen	NOUN
gsrj-50	28	27	peroxide	peroxide	NOUN
gsrj-50	28	28	.	.	PUNCT
gsrj-50	29	1	there	there	PRON
gsrj-50	29	2	is	be	VERB
gsrj-50	29	3	also	also	ADV
gsrj-50	29	4	evidence	evidence	NOUN
gsrj-50	29	5	that	that	SCONJ
gsrj-50	29	6	parp1	parp1	NOUN
gsrj-50	29	7	-	-	PUNCT
gsrj-50	29	8	dependent	dependent	ADJ
gsrj-50	29	9	and	and	CCONJ
gsrj-50	29	10	parp1independent	parp1independent	ADJ
gsrj-50	29	11	ssbr	ssbr	NOUN
gsrj-50	29	12	pathways	pathway	NOUN
gsrj-50	29	13	exist	exist	VERB
gsrj-50	29	14	,	,	PUNCT
gsrj-50	29	15	with	with	ADP
gsrj-50	29	16	one	one	NUM
gsrj-50	29	17	study	study	NOUN
gsrj-50	29	18	finding	find	VERB
gsrj-50	29	19	that	that	PRON
gsrj-50	29	20	parp1	parp1	NOUN
gsrj-50	29	21	is	be	AUX
gsrj-50	29	22	essential	essential	ADJ
gsrj-50	29	23	for	for	ADP
gsrj-50	29	24	ssbr	ssbr	NOUN
gsrj-50	29	25	in	in	ADP
gsrj-50	29	26	the	the	DET
gsrj-50	29	27	g1	g1	NOUN
gsrj-50	29	28	but	but	CCONJ
gsrj-50	29	29	not	not	PART
gsrj-50	29	30	the	the	DET
gsrj-50	29	31	s	s	NOUN
gsrj-50	29	32	phase	phase	NOUN
gsrj-50	29	33	of	of	ADP
gsrj-50	29	34	the	the	DET
gsrj-50	29	35	cell	cell	NOUN
gsrj-50	29	36	cycle.1	cycle.1	PROPN
gsrj-50	29	37	parp1i	parp1i	PROPN
gsrj-50	29	38	,	,	PUNCT
gsrj-50	29	39	on	on	ADP
gsrj-50	29	40	the	the	DET
gsrj-50	29	41	other	other	ADJ
gsrj-50	29	42	hand	hand	NOUN
gsrj-50	29	43	,	,	PUNCT
gsrj-50	29	44	inhibits	inhibit	VERB
gsrj-50	29	45	ssbr	ssbr	NOUN
gsrj-50	29	46	at	at	ADP
gsrj-50	29	47	all	all	DET
gsrj-50	29	48	stages	stage	NOUN
gsrj-50	29	49	of	of	ADP
gsrj-50	29	50	the	the	DET
gsrj-50	29	51	cell	cell	NOUN
gsrj-50	29	52	cycle.3	cycle.3	PROPN
gsrj-50	29	53	dna	dna	PROPN
gsrj-50	29	54	repair	repair	NOUN
gsrj-50	29	55	pathways	pathway	NOUN
gsrj-50	29	56	are	be	AUX
gsrj-50	29	57	promoted	promote	VERB
gsrj-50	29	58	by	by	ADP
gsrj-50	29	59	parp1	parp1	NOUN
gsrj-50	29	60	,	,	PUNCT
gsrj-50	29	61	including	include	VERB
gsrj-50	29	62	the	the	DET
gsrj-50	29	63	hr	hr	NOUN
gsrj-50	29	64	pathway	pathway	NOUN
gsrj-50	29	65	.	.	PUNCT
gsrj-50	30	1	however	however	ADV
gsrj-50	30	2	,	,	PUNCT
gsrj-50	30	3	the	the	DET
gsrj-50	30	4	inhibition	inhibition	NOUN
gsrj-50	30	5	of	of	ADP
gsrj-50	30	6	parp1	parp1	NOUN
gsrj-50	30	7	can	can	AUX
gsrj-50	30	8	lead	lead	VERB
gsrj-50	30	9	to	to	ADP
gsrj-50	30	10	cancer	cancer	NOUN
gsrj-50	30	11	suppression	suppression	NOUN
gsrj-50	30	12	,	,	PUNCT
gsrj-50	30	13	namely	namely	ADV
gsrj-50	30	14	in	in	ADP
gsrj-50	30	15	breast	breast	NOUN
gsrj-50	30	16	cancers	cancer	NOUN
gsrj-50	30	17	associated	associate	VERB
gsrj-50	30	18	with	with	ADP
gsrj-50	30	19	brca1	brca1	PROPN
gsrj-50	30	20	mutations	mutation	NOUN
gsrj-50	30	21	.	.	PUNCT
gsrj-50	31	1	this	this	DET
gsrj-50	31	2	paper	paper	NOUN
gsrj-50	31	3	aims	aim	VERB
gsrj-50	31	4	to	to	PART
gsrj-50	31	5	provide	provide	VERB
gsrj-50	31	6	a	a	DET
gsrj-50	31	7	meta	meta	ADJ
gsrj-50	31	8	-	-	PUNCT
gsrj-50	31	9	analysis	analysis	NOUN
gsrj-50	31	10	on	on	ADP
gsrj-50	31	11	the	the	DET
gsrj-50	31	12	existing	exist	VERB
gsrj-50	31	13	literature	literature	NOUN
gsrj-50	31	14	as	as	ADV
gsrj-50	31	15	well	well	ADV
gsrj-50	31	16	as	as	ADP
gsrj-50	31	17	genomic	genomic	ADJ
gsrj-50	31	18	data	datum	NOUN
gsrj-50	31	19	from	from	ADP
gsrj-50	31	20	databases	database	NOUN
gsrj-50	31	21	regarding	regard	VERB
gsrj-50	31	22	parp1	parp1	NOUN
gsrj-50	31	23	to	to	PART
gsrj-50	31	24	find	find	VERB
gsrj-50	31	25	a	a	DET
gsrj-50	31	26	possible	possible	ADJ
gsrj-50	31	27	correlation	correlation	NOUN
gsrj-50	31	28	between	between	ADP
gsrj-50	31	29	the	the	DET
gsrj-50	31	30	expression	expression	NOUN
gsrj-50	31	31	of	of	ADP
gsrj-50	31	32	the	the	DET
gsrj-50	31	33	parp1	parp1	NOUN
gsrj-50	31	34	gene	gene	NOUN
gsrj-50	31	35	and	and	CCONJ
gsrj-50	31	36	brca1	brca1	PROPN
gsrj-50	31	37	mutations	mutation	NOUN
gsrj-50	31	38	,	,	PUNCT
gsrj-50	31	39	specifically	specifically	ADV
gsrj-50	31	40	in	in	ADP
gsrj-50	31	41	breast	breast	NOUN
gsrj-50	31	42	cancer	cancer	NOUN
gsrj-50	31	43	.	.	PUNCT
gsrj-50	32	1	multiple	multiple	ADJ
gsrj-50	32	2	tools	tool	NOUN
gsrj-50	32	3	and	and	CCONJ
gsrj-50	32	4	databases	database	NOUN
gsrj-50	32	5	,	,	PUNCT
gsrj-50	32	6	specifically	specifically	ADV
gsrj-50	32	7	uniprot	uniprot	ADJ
gsrj-50	32	8	database	database	NOUN
gsrj-50	32	9	,	,	PUNCT
gsrj-50	32	10	cbioportal	cbioportal	ADJ
gsrj-50	32	11	,	,	PUNCT
gsrj-50	32	12	and	and	CCONJ
gsrj-50	32	13	xena	xena	PROPN
gsrj-50	32	14	browser	browser	PROPN
gsrj-50	32	15	,	,	PUNCT
gsrj-50	32	16	were	be	AUX
gsrj-50	32	17	used	use	VERB
gsrj-50	32	18	to	to	PART
gsrj-50	32	19	determine	determine	VERB
gsrj-50	32	20	such	such	ADJ
gsrj-50	32	21	relationships	relationship	NOUN
gsrj-50	32	22	.	.	PUNCT
gsrj-50	33	1	these	these	PRON
gsrj-50	33	2	are	be	AUX
gsrj-50	33	3	open	open	ADJ
gsrj-50	33	4	-	-	PUNCT
gsrj-50	33	5	access	access	NOUN
gsrj-50	33	6	databases	database	NOUN
gsrj-50	33	7	,	,	PUNCT
gsrj-50	33	8	making	make	VERB
gsrj-50	33	9	them	they	PRON
gsrj-50	33	10	accessible	accessible	ADJ
gsrj-50	33	11	for	for	ADP
gsrj-50	33	12	public	public	ADJ
gsrj-50	33	13	research	research	NOUN
gsrj-50	33	14	.	.	PUNCT
gsrj-50	34	1	specifically	specifically	ADV
gsrj-50	34	2	,	,	PUNCT
gsrj-50	34	3	these	these	DET
gsrj-50	34	4	databases	database	NOUN
gsrj-50	34	5	hold	hold	VERB
gsrj-50	34	6	genomic	genomic	ADJ
gsrj-50	34	7	data	datum	NOUN
gsrj-50	34	8	,	,	PUNCT
gsrj-50	34	9	mutation	mutation	NOUN
gsrj-50	34	10	profiles	profile	NOUN
gsrj-50	34	11	,	,	PUNCT
gsrj-50	34	12	and	and	CCONJ
gsrj-50	34	13	clinical	clinical	ADJ
gsrj-50	34	14	data	datum	NOUN
gsrj-50	34	15	.	.	PUNCT
gsrj-50	35	1	uniprot	uniprot	PROPN
gsrj-50	35	2	database	database	NOUN
gsrj-50	35	3	was	be	AUX
gsrj-50	35	4	used	use	VERB
gsrj-50	35	5	to	to	PART
gsrj-50	35	6	investigate	investigate	VERB
gsrj-50	35	7	the	the	DET
gsrj-50	35	8	mechanism	mechanism	NOUN
gsrj-50	35	9	by	by	ADP
gsrj-50	35	10	which	which	PRON
gsrj-50	35	11	parp1	parp1	NOUN
gsrj-50	35	12	repairs	repair	VERB
gsrj-50	35	13	the	the	DET
gsrj-50	35	14	breaks	break	NOUN
gsrj-50	35	15	in	in	ADP
gsrj-50	35	16	dna	dna	PROPN
gsrj-50	35	17	strands	strand	NOUN
gsrj-50	35	18	and	and	CCONJ
gsrj-50	35	19	how	how	SCONJ
gsrj-50	35	20	parp1	parp1	ADJ
gsrj-50	35	21	inhibitors	inhibitor	NOUN
gsrj-50	35	22	can	can	AUX
gsrj-50	35	23	be	be	AUX
gsrj-50	35	24	used	use	VERB
gsrj-50	35	25	to	to	PART
gsrj-50	35	26	inhibit	inhibit	VERB
gsrj-50	35	27	this	this	DET
gsrj-50	35	28	function	function	NOUN
gsrj-50	35	29	of	of	ADP
gsrj-50	35	30	the	the	DET
gsrj-50	35	31	parp1	parp1	NOUN
gsrj-50	35	32	protein	protein	NOUN
gsrj-50	35	33	.	.	PUNCT
gsrj-50	36	1	cbioportal	cbioportal	PROPN
gsrj-50	36	2	was	be	AUX
gsrj-50	36	3	used	use	VERB
gsrj-50	36	4	to	to	PART
gsrj-50	36	5	investigate	investigate	VERB
gsrj-50	36	6	the	the	DET
gsrj-50	36	7	alteration	alteration	NOUN
gsrj-50	36	8	frequencies	frequency	NOUN
gsrj-50	36	9	of	of	ADP
gsrj-50	36	10	the	the	DET
gsrj-50	36	11	parp1	parp1	NOUN
gsrj-50	36	12	gene	gene	NOUN
gsrj-50	36	13	in	in	ADP
gsrj-50	36	14	different	different	ADJ
gsrj-50	36	15	types	type	NOUN
gsrj-50	36	16	of	of	ADP
gsrj-50	36	17	cancers	cancer	NOUN
gsrj-50	36	18	,	,	PUNCT
gsrj-50	36	19	which	which	PRON
gsrj-50	36	20	helps	help	VERB
gsrj-50	36	21	to	to	PART
gsrj-50	36	22	understand	understand	VERB
gsrj-50	36	23	the	the	DET
gsrj-50	36	24	relationship	relationship	NOUN
gsrj-50	36	25	between	between	ADP
gsrj-50	36	26	the	the	DET
gsrj-50	36	27	parp1	parp1	NOUN
gsrj-50	36	28	gene	gene	NOUN
gsrj-50	36	29	and	and	CCONJ
gsrj-50	36	30	breast	breast	NOUN
gsrj-50	36	31	cancers	cancer	NOUN
gsrj-50	36	32	.	.	PUNCT
gsrj-50	37	1	the	the	DET
gsrj-50	37	2	database	database	NOUN
gsrj-50	37	3	was	be	AUX
gsrj-50	37	4	also	also	ADV
gsrj-50	37	5	used	use	VERB
gsrj-50	37	6	to	to	PART
gsrj-50	37	7	investigate	investigate	VERB
gsrj-50	37	8	8	8	NUM
gsrj-50	37	9	georgetown	georgetown	PROPN
gsrj-50	37	10	scientific	scientific	PROPN
gsrj-50	37	11	research	research	PROPN
gsrj-50	37	12	journal	journal	NOUN
gsrj-50	37	13	which	which	DET
gsrj-50	37	14	tissues	tissue	NOUN
gsrj-50	37	15	had	have	VERB
gsrj-50	37	16	the	the	DET
gsrj-50	37	17	highest	high	ADJ
gsrj-50	37	18	expression	expression	NOUN
gsrj-50	37	19	levels	level	NOUN
gsrj-50	37	20	of	of	ADP
gsrj-50	37	21	the	the	DET
gsrj-50	37	22	parp1	parp1	NOUN
gsrj-50	37	23	gene	gene	NOUN
gsrj-50	37	24	.	.	PUNCT
gsrj-50	38	1	xena	xena	PROPN
gsrj-50	38	2	browser	browser	PROPN
gsrj-50	38	3	was	be	AUX
gsrj-50	38	4	used	use	VERB
gsrj-50	38	5	to	to	PART
gsrj-50	38	6	find	find	VERB
gsrj-50	38	7	the	the	DET
gsrj-50	38	8	extent	extent	NOUN
gsrj-50	38	9	of	of	ADP
gsrj-50	38	10	the	the	DET
gsrj-50	38	11	role	role	NOUN
gsrj-50	38	12	of	of	ADP
gsrj-50	38	13	parp1	parp1	NOUN
gsrj-50	38	14	in	in	ADP
gsrj-50	38	15	the	the	DET
gsrj-50	38	16	prognosis	prognosis	NOUN
gsrj-50	38	17	of	of	ADP
gsrj-50	38	18	patients	patient	NOUN
gsrj-50	38	19	with	with	ADP
gsrj-50	38	20	breast	breast	NOUN
gsrj-50	38	21	cancer	cancer	NOUN
gsrj-50	38	22	.	.	PUNCT
gsrj-50	39	1	using	use	VERB
gsrj-50	39	2	the	the	DET
gsrj-50	39	3	information	information	NOUN
gsrj-50	39	4	and	and	CCONJ
gsrj-50	39	5	results	result	NOUN
gsrj-50	39	6	obtained	obtain	VERB
gsrj-50	39	7	from	from	ADP
gsrj-50	39	8	these	these	DET
gsrj-50	39	9	databases	database	NOUN
gsrj-50	39	10	,	,	PUNCT
gsrj-50	39	11	the	the	DET
gsrj-50	39	12	paper	paper	NOUN
gsrj-50	39	13	further	far	ADV
gsrj-50	39	14	details	detail	NOUN
gsrj-50	39	15	the	the	DET
gsrj-50	39	16	role	role	NOUN
gsrj-50	39	17	of	of	ADP
gsrj-50	39	18	the	the	DET
gsrj-50	39	19	parp1	parp1	NOUN
gsrj-50	39	20	gene	gene	NOUN
gsrj-50	39	21	in	in	ADP
gsrj-50	39	22	breast	breast	NOUN
gsrj-50	39	23	cancer	cancer	NOUN
gsrj-50	39	24	and	and	CCONJ
gsrj-50	39	25	establishes	establish	VERB
gsrj-50	39	26	a	a	DET
gsrj-50	39	27	relationship	relationship	NOUN
gsrj-50	39	28	between	between	ADP
gsrj-50	39	29	brca1	brca1	PROPN
gsrj-50	39	30	mutations	mutation	NOUN
gsrj-50	39	31	and	and	CCONJ
gsrj-50	39	32	parp1	parp1	NOUN
gsrj-50	39	33	inhibition	inhibition	NOUN
gsrj-50	39	34	.	.	PUNCT
gsrj-50	40	1	an	an	DET
gsrj-50	40	2	overview	overview	NOUN
gsrj-50	40	3	of	of	ADP
gsrj-50	40	4	the	the	DET
gsrj-50	40	5	parp1	parp1	NOUN
gsrj-50	40	6	gene	gene	NOUN
gsrj-50	40	7	and	and	CCONJ
gsrj-50	40	8	protein	protein	NOUN
gsrj-50	40	9	was	be	AUX
gsrj-50	40	10	split	split	VERB
gsrj-50	40	11	into	into	ADP
gsrj-50	40	12	six	six	NUM
gsrj-50	40	13	parts	part	NOUN
gsrj-50	40	14	for	for	ADP
gsrj-50	40	15	this	this	DET
gsrj-50	40	16	study	study	NOUN
gsrj-50	40	17	:	:	PUNCT
gsrj-50	40	18	the	the	DET
gsrj-50	40	19	catalytic	catalytic	ADJ
gsrj-50	40	20	domain	domain	NOUN
gsrj-50	40	21	,	,	PUNCT
gsrj-50	40	22	mutation	mutation	NOUN
gsrj-50	40	23	profile	profile	NOUN
gsrj-50	40	24	,	,	PUNCT
gsrj-50	40	25	copy	copy	VERB
gsrj-50	40	26	number	number	NOUN
gsrj-50	40	27	,	,	PUNCT
gsrj-50	40	28	gene	gene	NOUN
gsrj-50	40	29	expression	expression	NOUN
gsrj-50	40	30	in	in	ADP
gsrj-50	40	31	tissues	tissue	NOUN
gsrj-50	40	32	,	,	PUNCT
gsrj-50	40	33	its	its	PRON
gsrj-50	40	34	relevance	relevance	NOUN
gsrj-50	40	35	to	to	ADP
gsrj-50	40	36	breast	breast	NOUN
gsrj-50	40	37	cancer	cancer	NOUN
gsrj-50	40	38	,	,	PUNCT
gsrj-50	40	39	and	and	CCONJ
gsrj-50	40	40	parp1	parp1	NOUN
gsrj-50	40	41	inhibition	inhibition	NOUN
gsrj-50	40	42	.	.	PUNCT
gsrj-50	41	1	22	22	NUM
gsrj-50	41	2	..	..	PUNCT
gsrj-50	41	3	ccaattaallyyttiicc	ccaattaallyyttiicc	NOUN
gsrj-50	41	4	ddoommaaiinn	ddoommaaiinn	VERB
gsrj-50	41	5	the	the	DET
gsrj-50	41	6	uniprot	uniprot	ADJ
gsrj-50	41	7	database	database	NOUN
gsrj-50	41	8	shows	show	VERB
gsrj-50	41	9	the	the	DET
gsrj-50	41	10	catalytic	catalytic	ADJ
gsrj-50	41	11	domain	domain	NOUN
gsrj-50	41	12	of	of	ADP
gsrj-50	41	13	parp1	parp1	NOUN
gsrj-50	41	14	(	(	PUNCT
gsrj-50	41	15	figure	figure	NOUN
gsrj-50	41	16	2	2	NUM
gsrj-50	41	17	)	)	PUNCT
gsrj-50	41	18	,	,	PUNCT
gsrj-50	41	19	which	which	PRON
gsrj-50	41	20	is	be	AUX
gsrj-50	41	21	crucial	crucial	ADJ
gsrj-50	41	22	because	because	SCONJ
gsrj-50	41	23	of	of	ADP
gsrj-50	41	24	its	its	PRON
gsrj-50	41	25	role	role	NOUN
gsrj-50	41	26	during	during	ADP
gsrj-50	41	27	the	the	DET
gsrj-50	41	28	process	process	NOUN
gsrj-50	41	29	of	of	ADP
gsrj-50	41	30	par	par	NOUN
gsrj-50	41	31	synthesis	synthesis	NOUN
gsrj-50	41	32	that	that	PRON
gsrj-50	41	33	is	be	AUX
gsrj-50	41	34	involved	involve	VERB
gsrj-50	41	35	in	in	ADP
gsrj-50	41	36	dna	dna	PROPN
gsrj-50	41	37	repair.6	repair.6	NOUN
gsrj-50	41	38	the	the	DET
gsrj-50	41	39	catalytic	catalytic	ADJ
gsrj-50	41	40	domain	domain	NOUN
gsrj-50	41	41	is	be	AUX
gsrj-50	41	42	involved	involve	VERB
gsrj-50	41	43	in	in	ADP
gsrj-50	41	44	the	the	DET
gsrj-50	41	45	creation	creation	NOUN
gsrj-50	41	46	of	of	ADP
gsrj-50	41	47	the	the	DET
gsrj-50	41	48	ribose	ribose	NOUN
gsrj-50	41	49	-	-	PUNCT
gsrj-50	41	50	ribose	ribose	NOUN
gsrj-50	41	51	glycosidic	glycosidic	ADJ
gsrj-50	41	52	bond	bond	NOUN
gsrj-50	41	53	and	and	CCONJ
gsrj-50	41	54	of	of	ADP
gsrj-50	41	55	a	a	DET
gsrj-50	41	56	riboseribose	riboseribose	ADJ
gsrj-50	41	57	bond	bond	NOUN
gsrj-50	41	58	that	that	PRON
gsrj-50	41	59	allows	allow	VERB
gsrj-50	41	60	for	for	ADP
gsrj-50	41	61	elongation	elongation	NOUN
gsrj-50	41	62	and	and	CCONJ
gsrj-50	41	63	branching	branch	VERB
gsrj-50	41	64	in	in	ADP
gsrj-50	41	65	dna	dna	PROPN
gsrj-50	41	66	repair	repair	NOUN
gsrj-50	41	67	.	.	PUNCT
gsrj-50	42	1	ffiigguurree	ffiigguurree	NOUN
gsrj-50	42	2	22	22	NUM
gsrj-50	42	3	..	..	PUNCT
gsrj-50	42	4	the	the	DET
gsrj-50	42	5	catalytic	catalytic	ADJ
gsrj-50	42	6	domain	domain	NOUN
gsrj-50	42	7	of	of	ADP
gsrj-50	42	8	parp1	parp1	NOUN
gsrj-50	42	9	protein	protein	NOUN
gsrj-50	42	10	is	be	AUX
gsrj-50	42	11	where	where	SCONJ
gsrj-50	42	12	the	the	DET
gsrj-50	42	13	catalysis	catalysis	NOUN
gsrj-50	42	14	of	of	ADP
gsrj-50	42	15	three	three	NUM
gsrj-50	42	16	chemically	chemically	ADV
gsrj-50	42	17	different	different	ADJ
gsrj-50	42	18	enzymatic	enzymatic	ADJ
gsrj-50	42	19	reactions	reaction	NOUN
gsrj-50	42	20	during	during	ADP
gsrj-50	42	21	par	par	NOUN
gsrj-50	42	22	synthesis	synthesis	NOUN
gsrj-50	42	23	occurs	occur	VERB
gsrj-50	42	24	.	.	PUNCT
gsrj-50	43	1	retrieved	retrieve	VERB
gsrj-50	43	2	from	from	ADP
gsrj-50	43	3	uniprot	uniprot	ADJ
gsrj-50	43	4	database.6	database.6	NOUN
gsrj-50	43	5	when	when	SCONJ
gsrj-50	43	6	the	the	DET
gsrj-50	43	7	parp1	parp1	NOUN
gsrj-50	43	8	gene	gene	NOUN
gsrj-50	43	9	is	be	AUX
gsrj-50	43	10	stimulated	stimulate	VERB
gsrj-50	43	11	by	by	ADP
gsrj-50	43	12	dna	dna	PROPN
gsrj-50	43	13	damage	damage	NOUN
gsrj-50	43	14	,	,	PUNCT
gsrj-50	43	15	the	the	DET
gsrj-50	43	16	cterminal	cterminal	ADJ
gsrj-50	43	17	domain	domain	NOUN
gsrj-50	43	18	starts	start	VERB
gsrj-50	43	19	to	to	PART
gsrj-50	43	20	synthesize	synthesize	VERB
gsrj-50	43	21	,	,	PUNCT
gsrj-50	43	22	through	through	ADP
gsrj-50	43	23	the	the	DET
gsrj-50	43	24	catalysis	catalysis	NOUN
gsrj-50	43	25	of	of	ADP
gsrj-50	43	26	nad+	nad+	PROPN
gsrj-50	43	27	,	,	PUNCT
gsrj-50	43	28	chains	chain	NOUN
gsrj-50	43	29	of	of	ADP
gsrj-50	43	30	polyadp	polyadp	PROPN
gsrj-50	43	31	-	-	ADJ
gsrj-50	43	32	ribose	ribose	ADJ
gsrj-50	43	33	(	(	PUNCT
gsrj-50	43	34	par	par	NOUN
gsrj-50	43	35	)	)	PUNCT
gsrj-50	43	36	fanned	fan	VERB
gsrj-50	43	37	chains	chain	NOUN
gsrj-50	43	38	(	(	PUNCT
gsrj-50	43	39	figure	figure	NOUN
gsrj-50	43	40	2	2	NUM
gsrj-50	43	41	)	)	PUNCT
gsrj-50	43	42	.	.	PUNCT
gsrj-50	44	1	numerous	numerous	ADJ
gsrj-50	44	2	inhibitors	inhibitor	NOUN
gsrj-50	44	3	can	can	AUX
gsrj-50	44	4	tie	tie	VERB
gsrj-50	44	5	parp1	parp1	NOUN
gsrj-50	44	6	in	in	ADP
gsrj-50	44	7	a	a	DET
gsrj-50	44	8	direction	direction	NOUN
gsrj-50	44	9	looking	look	VERB
gsrj-50	44	10	like	like	ADP
gsrj-50	44	11	that	that	PRON
gsrj-50	44	12	of	of	ADP
gsrj-50	44	13	its	its	PRON
gsrj-50	44	14	substrate	substrate	NOUN
gsrj-50	44	15	nad+	nad+	NOUN
gsrj-50	44	16	and	and	CCONJ
gsrj-50	44	17	lock	lock	VERB
gsrj-50	44	18	the	the	DET
gsrj-50	44	19	catalytic	catalytic	ADJ
gsrj-50	44	20	site	site	NOUN
gsrj-50	44	21	.	.	PUNCT
gsrj-50	45	1	the	the	DET
gsrj-50	45	2	c	c	NOUN
gsrj-50	45	3	-	-	PUNCT
gsrj-50	45	4	terminal	terminal	ADJ
gsrj-50	45	5	region	region	NOUN
gsrj-50	45	6	,	,	PUNCT
gsrj-50	45	7	otherwise	otherwise	ADV
gsrj-50	45	8	known	know	VERB
gsrj-50	45	9	as	as	ADP
gsrj-50	45	10	the	the	DET
gsrj-50	45	11	active	active	ADJ
gsrj-50	45	12	site	site	NOUN
gsrj-50	45	13	,	,	PUNCT
gsrj-50	45	14	contains	contain	VERB
gsrj-50	45	15	the	the	DET
gsrj-50	45	16	area	area	NOUN
gsrj-50	45	17	that	that	PRON
gsrj-50	45	18	allows	allow	VERB
gsrj-50	45	19	parp1	parp1	NOUN
gsrj-50	45	20	to	to	PART
gsrj-50	45	21	restrict	restrict	VERB
gsrj-50	45	22	nad+	nad+	NOUN
gsrj-50	45	23	and	and	CCONJ
gsrj-50	45	24	competitive	competitive	ADJ
gsrj-50	45	25	inhibitors	inhibitor	NOUN
gsrj-50	45	26	.	.	PUNCT
gsrj-50	46	1	for	for	ADP
gsrj-50	46	2	example	example	NOUN
gsrj-50	46	3	,	,	PUNCT
gsrj-50	46	4	nicotinamide	nicotinamide	NOUN
gsrj-50	46	5	,	,	PUNCT
gsrj-50	46	6	3	3	NUM
gsrj-50	46	7	-	-	PUNCT
gsrj-50	46	8	amino	amino	NOUN
gsrj-50	46	9	benzamide	benzamide	NOUN
gsrj-50	46	10	,	,	PUNCT
gsrj-50	46	11	and	and	CCONJ
gsrj-50	46	12	3	3	NUM
gsrj-50	46	13	-	-	PUNCT
gsrj-50	46	14	methoxy	methoxy	ADJ
gsrj-50	46	15	benzamide	benzamide	NOUN
gsrj-50	46	16	manipulate	manipulate	VERB
gsrj-50	46	17	the	the	DET
gsrj-50	46	18	parp1gene	parp1gene	NOUN
gsrj-50	46	19	in	in	ADP
gsrj-50	46	20	certain	certain	ADJ
gsrj-50	46	21	targeted	target	VERB
gsrj-50	46	22	therapies	therapy	NOUN
gsrj-50	46	23	.	.	PUNCT
gsrj-50	47	1	33	33	NUM
gsrj-50	47	2	..	..	PUNCT
gsrj-50	47	3	mmuuttaattiioonn	mmuuttaattiioonn	ADJ
gsrj-50	47	4	pprrooffiillee	pprrooffiillee	PROPN
gsrj-50	47	5	ffiigguurree	ffiigguurree	NOUN
gsrj-50	47	6	33	33	NUM
gsrj-50	47	7	..	..	PUNCT
gsrj-50	47	8	diagram	diagram	NOUN
gsrj-50	47	9	of	of	ADP
gsrj-50	47	10	all	all	DET
gsrj-50	47	11	mutations	mutation	NOUN
gsrj-50	47	12	that	that	PRON
gsrj-50	47	13	occur	occur	VERB
gsrj-50	47	14	within	within	ADP
gsrj-50	47	15	the	the	DET
gsrj-50	47	16	parp1	parp1	NOUN
gsrj-50	47	17	gene	gene	NOUN
gsrj-50	47	18	.	.	PUNCT
gsrj-50	48	1	a	a	DET
gsrj-50	48	2	majority	majority	NOUN
gsrj-50	48	3	of	of	ADP
gsrj-50	48	4	the	the	DET
gsrj-50	48	5	mutations	mutation	NOUN
gsrj-50	48	6	were	be	AUX
gsrj-50	48	7	missense	missense	NOUN
gsrj-50	48	8	mutations	mutation	NOUN
gsrj-50	48	9	with	with	ADP
gsrj-50	48	10	a	a	DET
gsrj-50	48	11	frequency	frequency	NOUN
gsrj-50	48	12	of	of	ADP
gsrj-50	48	13	134	134	NUM
gsrj-50	48	14	.	.	PUNCT
gsrj-50	49	1	mutations	mutation	NOUN
gsrj-50	49	2	are	be	AUX
gsrj-50	49	3	evenly	evenly	ADV
gsrj-50	49	4	spread	spread	VERB
gsrj-50	49	5	through	through	ADP
gsrj-50	49	6	all	all	DET
gsrj-50	49	7	parts	part	NOUN
gsrj-50	49	8	of	of	ADP
gsrj-50	49	9	the	the	DET
gsrj-50	49	10	parp1	parp1	NOUN
gsrj-50	49	11	genome	genome	NOUN
gsrj-50	49	12	.	.	PUNCT
gsrj-50	50	1	in	in	ADP
gsrj-50	50	2	total	total	ADJ
gsrj-50	50	3	,	,	PUNCT
gsrj-50	50	4	163	163	NUM
gsrj-50	50	5	individual	individual	ADJ
gsrj-50	50	6	data	datum	NOUN
gsrj-50	50	7	points	point	NOUN
gsrj-50	50	8	were	be	AUX
gsrj-50	50	9	used	use	VERB
gsrj-50	50	10	to	to	PART
gsrj-50	50	11	compile	compile	VERB
gsrj-50	50	12	the	the	DET
gsrj-50	50	13	diagram	diagram	NOUN
gsrj-50	50	14	.	.	PUNCT
gsrj-50	51	1	retrieved	retrieve	VERB
gsrj-50	51	2	from	from	ADP
gsrj-50	51	3	cbioportal	cbioportal	ADJ
gsrj-50	51	4	database.7	database.7	PROPN
gsrj-50	51	5	an	an	DET
gsrj-50	51	6	analysis	analysis	NOUN
gsrj-50	51	7	of	of	ADP
gsrj-50	51	8	the	the	DET
gsrj-50	51	9	cbioportal	cbioportal	ADJ
gsrj-50	51	10	database	database	NOUN
gsrj-50	51	11	showed	show	VERB
gsrj-50	51	12	the	the	DET
gsrj-50	51	13	mutation	mutation	NOUN
gsrj-50	51	14	profile	profile	NOUN
gsrj-50	51	15	in	in	ADP
gsrj-50	51	16	figure	figure	NOUN
gsrj-50	51	17	3	3	NUM
gsrj-50	51	18	,	,	PUNCT
gsrj-50	51	19	which	which	PRON
gsrj-50	51	20	suggests	suggest	VERB
gsrj-50	51	21	that	that	SCONJ
gsrj-50	51	22	a	a	DET
gsrj-50	51	23	majority	majority	NOUN
gsrj-50	51	24	of	of	ADP
gsrj-50	51	25	mutations	mutation	NOUN
gsrj-50	51	26	in	in	ADP
gsrj-50	51	27	the	the	DET
gsrj-50	51	28	parp1	parp1	NOUN
gsrj-50	51	29	gene	gene	NOUN
gsrj-50	51	30	are	be	AUX
gsrj-50	51	31	missense	missense	NOUN
gsrj-50	51	32	mutations	mutation	NOUN
gsrj-50	51	33	,	,	PUNCT
gsrj-50	51	34	as	as	SCONJ
gsrj-50	51	35	seen	see	VERB
gsrj-50	51	36	by	by	ADP
gsrj-50	51	37	the	the	DET
gsrj-50	51	38	green	green	ADJ
gsrj-50	51	39	lines.7	lines.7	NOUN
gsrj-50	51	40	however	however	ADV
gsrj-50	51	41	,	,	PUNCT
gsrj-50	51	42	the	the	DET
gsrj-50	51	43	mutations	mutation	NOUN
gsrj-50	51	44	are	be	AUX
gsrj-50	51	45	dispersed	disperse	VERB
gsrj-50	51	46	throughout	throughout	ADV
gsrj-50	51	47	,	,	PUNCT
gsrj-50	51	48	and	and	CCONJ
gsrj-50	51	49	there	there	PRON
gsrj-50	51	50	is	be	VERB
gsrj-50	51	51	no	no	DET
gsrj-50	51	52	single	single	ADJ
gsrj-50	51	53	,	,	PUNCT
gsrj-50	51	54	major	major	ADJ
gsrj-50	51	55	peak	peak	NOUN
gsrj-50	51	56	seen	see	VERB
gsrj-50	51	57	that	that	PRON
gsrj-50	51	58	is	be	AUX
gsrj-50	51	59	significant	significant	ADJ
gsrj-50	51	60	enough	enough	ADV
gsrj-50	51	61	to	to	PART
gsrj-50	51	62	show	show	VERB
gsrj-50	51	63	that	that	SCONJ
gsrj-50	51	64	a	a	DET
gsrj-50	51	65	specific	specific	ADJ
gsrj-50	51	66	region	region	NOUN
gsrj-50	51	67	on	on	ADP
gsrj-50	51	68	the	the	DET
gsrj-50	51	69	gene	gene	NOUN
gsrj-50	51	70	is	be	AUX
gsrj-50	51	71	more	more	ADV
gsrj-50	51	72	susceptible	susceptible	ADJ
gsrj-50	51	73	to	to	ADP
gsrj-50	51	74	mutations	mutation	NOUN
gsrj-50	51	75	.	.	PUNCT
gsrj-50	52	1	in	in	ADP
gsrj-50	52	2	addition	addition	NOUN
gsrj-50	52	3	,	,	PUNCT
gsrj-50	52	4	it	it	PRON
gsrj-50	52	5	is	be	AUX
gsrj-50	52	6	seen	see	VERB
gsrj-50	52	7	that	that	SCONJ
gsrj-50	52	8	most	most	ADJ
gsrj-50	52	9	of	of	ADP
gsrj-50	52	10	the	the	DET
gsrj-50	52	11	mutations	mutation	NOUN
gsrj-50	52	12	are	be	AUX
gsrj-50	52	13	characterized	characterize	VERB
gsrj-50	52	14	as	as	ADP
gsrj-50	52	15	a	a	DET
gsrj-50	52	16	variant	variant	NOUN
gsrj-50	52	17	of	of	ADP
gsrj-50	52	18	uncertain	uncertain	ADJ
gsrj-50	52	19	significance	significance	NOUN
gsrj-50	52	20	(	(	PUNCT
gsrj-50	52	21	vus	vus	NOUN
gsrj-50	52	22	)	)	PUNCT
gsrj-50	52	23	.	.	PUNCT
gsrj-50	53	1	this	this	PRON
gsrj-50	53	2	means	mean	VERB
gsrj-50	53	3	that	that	SCONJ
gsrj-50	53	4	there	there	PRON
gsrj-50	53	5	is	be	VERB
gsrj-50	53	6	an	an	DET
gsrj-50	53	7	alteration	alteration	NOUN
gsrj-50	53	8	in	in	ADP
gsrj-50	53	9	the	the	DET
gsrj-50	53	10	parp1	parp1	NOUN
gsrj-50	53	11	gene	gene	NOUN
gsrj-50	53	12	,	,	PUNCT
gsrj-50	53	13	but	but	CCONJ
gsrj-50	53	14	researchers	researcher	NOUN
gsrj-50	53	15	have	have	AUX
gsrj-50	53	16	not	not	PART
gsrj-50	53	17	yet	yet	ADV
gsrj-50	53	18	found	find	VERB
gsrj-50	53	19	out	out	ADP
gsrj-50	53	20	whether	whether	SCONJ
gsrj-50	53	21	the	the	DET
gsrj-50	53	22	change	change	NOUN
gsrj-50	53	23	is	be	AUX
gsrj-50	53	24	harmless	harmless	ADJ
gsrj-50	53	25	or	or	CCONJ
gsrj-50	53	26	increases	increase	VERB
gsrj-50	53	27	the	the	DET
gsrj-50	53	28	risk	risk	NOUN
gsrj-50	53	29	of	of	ADP
gsrj-50	53	30	developing	develop	VERB
gsrj-50	53	31	cancer	cancer	NOUN
gsrj-50	53	32	.	.	PUNCT
gsrj-50	54	1	there	there	PRON
gsrj-50	54	2	are	be	VERB
gsrj-50	54	3	27	27	NUM
gsrj-50	54	4	mutations	mutation	NOUN
gsrj-50	54	5	that	that	PRON
gsrj-50	54	6	are	be	AUX
gsrj-50	54	7	categorized	categorize	VERB
gsrj-50	54	8	as	as	ADP
gsrj-50	54	9	driver	driver	NOUN
gsrj-50	54	10	mutations	mutation	NOUN
gsrj-50	54	11	that	that	PRON
gsrj-50	54	12	bolster	bolster	VERB
gsrj-50	54	13	the	the	DET
gsrj-50	54	14	development	development	NOUN
gsrj-50	54	15	of	of	ADP
gsrj-50	54	16	cancer.7	cancer.7	PROPN
gsrj-50	54	17	however	however	ADV
gsrj-50	54	18	,	,	PUNCT
gsrj-50	54	19	since	since	SCONJ
gsrj-50	54	20	a	a	DET
gsrj-50	54	21	relatively	relatively	ADV
gsrj-50	54	22	large	large	ADJ
gsrj-50	54	23	number	number	NOUN
gsrj-50	54	24	of	of	ADP
gsrj-50	54	25	mutations	mutation	NOUN
gsrj-50	54	26	are	be	AUX
gsrj-50	54	27	vus	vus	NOUN
gsrj-50	54	28	,	,	PUNCT
gsrj-50	54	29	more	more	ADJ
gsrj-50	54	30	research	research	NOUN
gsrj-50	54	31	needs	need	VERB
gsrj-50	54	32	to	to	PART
gsrj-50	54	33	be	be	AUX
gsrj-50	54	34	done	do	VERB
gsrj-50	54	35	in	in	ADP
gsrj-50	54	36	order	order	NOUN
gsrj-50	54	37	to	to	PART
gsrj-50	54	38	determine	determine	VERB
gsrj-50	54	39	whether	whether	SCONJ
gsrj-50	54	40	the	the	DET
gsrj-50	54	41	mutations	mutation	NOUN
gsrj-50	54	42	in	in	ADP
gsrj-50	54	43	the	the	DET
gsrj-50	54	44	parp1	parp1	NOUN
gsrj-50	54	45	gene	gene	NOUN
gsrj-50	54	46	are	be	AUX
gsrj-50	54	47	directly	directly	ADV
gsrj-50	54	48	linked	link	VERB
gsrj-50	54	49	to	to	ADP
gsrj-50	54	50	the	the	DET
gsrj-50	54	51	development	development	NOUN
gsrj-50	54	52	of	of	ADP
gsrj-50	54	53	cancer	cancer	NOUN
gsrj-50	54	54	.	.	PUNCT
gsrj-50	55	1	9	9	NUM
gsrj-50	55	2	georgetown	georgetown	PROPN
gsrj-50	55	3	scientific	scientific	PROPN
gsrj-50	55	4	research	research	PROPN
gsrj-50	55	5	journal	journal	NOUN
gsrj-50	55	6	44	44	NUM
gsrj-50	55	7	..	..	PUNCT
gsrj-50	55	8	ccooppyy	ccooppyy	VERB
gsrj-50	55	9	nnuummbbeerr	nnuummbbeerr	NOUN
gsrj-50	55	10	as	as	SCONJ
gsrj-50	55	11	shown	show	VERB
gsrj-50	55	12	through	through	ADP
gsrj-50	55	13	the	the	DET
gsrj-50	55	14	cbioportal	cbioportal	ADJ
gsrj-50	55	15	database	database	NOUN
gsrj-50	55	16	,	,	PUNCT
gsrj-50	55	17	parp1	parp1	NOUN
gsrj-50	55	18	has	have	VERB
gsrj-50	55	19	more	more	ADJ
gsrj-50	55	20	instances	instance	NOUN
gsrj-50	55	21	of	of	ADP
gsrj-50	55	22	amplification	amplification	NOUN
gsrj-50	55	23	instead	instead	ADV
gsrj-50	55	24	of	of	ADP
gsrj-50	55	25	deep	deep	ADJ
gsrj-50	55	26	deletion	deletion	NOUN
gsrj-50	55	27	and	and	CCONJ
gsrj-50	55	28	shallow	shallow	ADJ
gsrj-50	55	29	deletion	deletion	NOUN
gsrj-50	55	30	(	(	PUNCT
gsrj-50	55	31	figure	figure	NOUN
gsrj-50	55	32	4).7	4).7	NUM
gsrj-50	55	33	deep	deep	ADJ
gsrj-50	55	34	deletions	deletion	NOUN
gsrj-50	55	35	refer	refer	VERB
gsrj-50	55	36	to	to	ADP
gsrj-50	55	37	possible	possible	ADJ
gsrj-50	55	38	homozygous	homozygous	ADJ
gsrj-50	55	39	deletions	deletion	NOUN
gsrj-50	55	40	,	,	PUNCT
gsrj-50	55	41	while	while	SCONJ
gsrj-50	55	42	shallow	shallow	ADJ
gsrj-50	55	43	deletions	deletion	NOUN
gsrj-50	55	44	refer	refer	VERB
gsrj-50	55	45	to	to	ADP
gsrj-50	55	46	possible	possible	ADJ
gsrj-50	55	47	heterozygous	heterozygous	ADJ
gsrj-50	55	48	deletions	deletion	NOUN
gsrj-50	55	49	.	.	PUNCT
gsrj-50	56	1	increase	increase	VERB
gsrj-50	56	2	in	in	ADP
gsrj-50	56	3	parp1	parp1	NOUN
gsrj-50	56	4	transcript	transcript	NOUN
gsrj-50	56	5	and	and	CCONJ
gsrj-50	56	6	protein	protein	NOUN
gsrj-50	56	7	expression	expression	NOUN
gsrj-50	56	8	are	be	AUX
gsrj-50	56	9	characteristics	characteristic	NOUN
gsrj-50	56	10	of	of	ADP
gsrj-50	56	11	high	high	ADJ
gsrj-50	56	12	-	-	PUNCT
gsrj-50	56	13	grade	grade	NOUN
gsrj-50	56	14	astrocytomas	astrocytoma	NOUN
gsrj-50	56	15	,	,	PUNCT
gsrj-50	56	16	particularly	particularly	ADV
gsrj-50	56	17	of	of	ADP
gsrj-50	56	18	proneural	proneural	ADJ
gsrj-50	56	19	and	and	CCONJ
gsrj-50	56	20	classical	classical	ADJ
gsrj-50	56	21	glioblastoma	glioblastoma	NOUN
gsrj-50	56	22	(	(	PUNCT
gsrj-50	56	23	gbm	gbm	NOUN
gsrj-50	56	24	)	)	PUNCT
gsrj-50	56	25	subtypes.8	subtypes.8	PROPN
gsrj-50	56	26	ffiigguurree	ffiigguurree	NOUN
gsrj-50	56	27	44	44	NUM
gsrj-50	56	28	..	..	PUNCT
gsrj-50	56	29	diagram	diagram	NOUN
gsrj-50	56	30	of	of	ADP
gsrj-50	56	31	all	all	DET
gsrj-50	56	32	mutations	mutation	NOUN
gsrj-50	56	33	that	that	PRON
gsrj-50	56	34	occur	occur	VERB
gsrj-50	56	35	within	within	ADP
gsrj-50	56	36	the	the	DET
gsrj-50	56	37	parp1	parp1	NOUN
gsrj-50	56	38	gene	gene	NOUN
gsrj-50	56	39	,	,	PUNCT
gsrj-50	56	40	with	with	ADP
gsrj-50	56	41	a	a	DET
gsrj-50	56	42	majority	majority	NOUN
gsrj-50	56	43	of	of	ADP
gsrj-50	56	44	mutations	mutation	NOUN
gsrj-50	56	45	being	be	AUX
gsrj-50	56	46	missense	missense	NOUN
gsrj-50	56	47	mutations	mutation	NOUN
gsrj-50	56	48	.	.	PUNCT
gsrj-50	57	1	values	value	NOUN
gsrj-50	57	2	compared	compare	VERB
gsrj-50	57	3	are	be	AUX
gsrj-50	57	4	the	the	DET
gsrj-50	57	5	type	type	NOUN
gsrj-50	57	6	of	of	ADP
gsrj-50	57	7	copy	copy	NOUN
gsrj-50	57	8	number	number	NOUN
gsrj-50	57	9	alterations	alteration	NOUN
gsrj-50	57	10	and	and	CCONJ
gsrj-50	57	11	the	the	DET
gsrj-50	57	12	frequency	frequency	NOUN
gsrj-50	57	13	of	of	ADP
gsrj-50	57	14	each	each	DET
gsrj-50	57	15	alteration	alteration	NOUN
gsrj-50	57	16	.	.	PUNCT
gsrj-50	58	1	amplification	amplification	NOUN
gsrj-50	58	2	alterations	alteration	NOUN
gsrj-50	58	3	showed	show	VERB
gsrj-50	58	4	the	the	DET
gsrj-50	58	5	highest	high	ADJ
gsrj-50	58	6	copy	copy	NOUN
gsrj-50	58	7	number	number	NOUN
gsrj-50	58	8	value	value	NOUN
gsrj-50	58	9	of	of	ADP
gsrj-50	58	10	the	the	DET
gsrj-50	58	11	parp1	parp1	NOUN
gsrj-50	58	12	gene	gene	NOUN
gsrj-50	58	13	.	.	PUNCT
gsrj-50	59	1	deep	deep	ADJ
gsrj-50	59	2	deletion	deletion	NOUN
gsrj-50	59	3	copy	copy	NOUN
gsrj-50	59	4	number	number	NOUN
gsrj-50	59	5	alteration	alteration	NOUN
gsrj-50	59	6	showed	show	VERB
gsrj-50	59	7	the	the	DET
gsrj-50	59	8	lowest	low	ADJ
gsrj-50	59	9	copy	copy	NOUN
gsrj-50	59	10	number	number	NOUN
gsrj-50	59	11	value	value	NOUN
gsrj-50	59	12	of	of	ADP
gsrj-50	59	13	the	the	DET
gsrj-50	59	14	parp1	parp1	NOUN
gsrj-50	59	15	gene	gene	NOUN
gsrj-50	59	16	.	.	PUNCT
gsrj-50	60	1	retrieved	retrieve	VERB
gsrj-50	60	2	from	from	ADP
gsrj-50	60	3	cbioportal	cbioportal	ADJ
gsrj-50	60	4	database.7	database.7	PROPN
gsrj-50	60	5	55	55	NUM
gsrj-50	60	6	..	..	PUNCT
gsrj-50	60	7	ggeennee	ggeennee	PROPN
gsrj-50	60	8	eexxpprreessssiioonn	eexxpprreessssiioonn	PROPN
gsrj-50	60	9	iinn	iinn	PROPN
gsrj-50	60	10	nnoorrmmaall	nnoorrmmaall	PROPN
gsrj-50	60	11	vveerrssuuss	vveerrssuuss	PROPN
gsrj-50	60	12	ccaanncceerr	ccaanncceerr	NOUN
gsrj-50	60	13	ttiissssuueess	ttiissssuueess	NOUN
gsrj-50	60	14	ffiigguurree	ffiigguurree	NOUN
gsrj-50	60	15	55	55	NUM
gsrj-50	60	16	..	..	PUNCT
gsrj-50	60	17	violin	violin	NOUN
gsrj-50	60	18	plot	plot	NOUN
gsrj-50	60	19	of	of	ADP
gsrj-50	60	20	types	type	NOUN
gsrj-50	60	21	of	of	ADP
gsrj-50	60	22	cells	cell	NOUN
gsrj-50	60	23	from	from	ADP
gsrj-50	60	24	different	different	ADJ
gsrj-50	60	25	tissues	tissue	NOUN
gsrj-50	60	26	and	and	CCONJ
gsrj-50	60	27	the	the	DET
gsrj-50	60	28	frequency	frequency	NOUN
gsrj-50	60	29	of	of	ADP
gsrj-50	60	30	parp1	parp1	NOUN
gsrj-50	60	31	expression	expression	NOUN
gsrj-50	60	32	.	.	PUNCT
gsrj-50	61	1	cells	cell	NOUN
gsrj-50	61	2	with	with	ADP
gsrj-50	61	3	ebv	ebv	NOUN
gsrj-50	61	4	-	-	PUNCT
gsrj-50	61	5	transformed	transform	VERB
gsrj-50	61	6	lymphocytes	lymphocyte	NOUN
gsrj-50	61	7	showed	show	VERB
gsrj-50	61	8	the	the	DET
gsrj-50	61	9	highest	high	ADJ
gsrj-50	61	10	bulk	bulk	ADJ
gsrj-50	61	11	tissue	tissue	NOUN
gsrj-50	61	12	gene	gene	NOUN
gsrj-50	61	13	expression	expression	NOUN
gsrj-50	61	14	for	for	ADP
gsrj-50	61	15	parp1	parp1	NOUN
gsrj-50	61	16	.	.	PUNCT
gsrj-50	62	1	however	however	ADV
gsrj-50	62	2	,	,	PUNCT
gsrj-50	62	3	most	most	ADJ
gsrj-50	62	4	bulk	bulk	ADJ
gsrj-50	62	5	tissues	tissue	NOUN
gsrj-50	62	6	showed	show	VERB
gsrj-50	62	7	similar	similar	ADJ
gsrj-50	62	8	levels	level	NOUN
gsrj-50	62	9	of	of	ADP
gsrj-50	62	10	gene	gene	NOUN
gsrj-50	62	11	expression	expression	NOUN
gsrj-50	62	12	.	.	PUNCT
gsrj-50	63	1	retrieved	retrieve	VERB
gsrj-50	63	2	from	from	ADP
gsrj-50	63	3	cbioportal	cbioportal	ADJ
gsrj-50	63	4	database.7	database.7	PROPN
gsrj-50	63	5	gene	gene	NOUN
gsrj-50	63	6	expression	expression	NOUN
gsrj-50	63	7	data	datum	NOUN
gsrj-50	63	8	in	in	ADP
gsrj-50	63	9	figure	figure	NOUN
gsrj-50	63	10	5	5	NUM
gsrj-50	63	11	indicate	indicate	VERB
gsrj-50	63	12	that	that	SCONJ
gsrj-50	63	13	the	the	DET
gsrj-50	63	14	parp1	parp1	NOUN
gsrj-50	63	15	gene	gene	NOUN
gsrj-50	63	16	is	be	AUX
gsrj-50	63	17	normally	normally	ADV
gsrj-50	63	18	expressed	express	VERB
gsrj-50	63	19	the	the	DET
gsrj-50	63	20	most	most	ADJ
gsrj-50	63	21	in	in	ADP
gsrj-50	63	22	ebv	ebv	NOUN
gsrj-50	63	23	-	-	PUNCT
gsrj-50	63	24	transformed	transform	VERB
gsrj-50	63	25	lymphocytes	lymphocyte	NOUN
gsrj-50	63	26	and	and	CCONJ
gsrj-50	63	27	in	in	ADP
gsrj-50	63	28	lymph	lymph	NOUN
gsrj-50	63	29	nodes.7	nodes.7	NOUN
gsrj-50	63	30	epstein	epstein	PROPN
gsrj-50	63	31	barr	barr	PROPN
gsrj-50	63	32	virus	virus	PROPN
gsrj-50	63	33	(	(	PUNCT
gsrj-50	63	34	ebv	ebv	NOUN
gsrj-50	63	35	)	)	PUNCT
gsrj-50	63	36	is	be	AUX
gsrj-50	63	37	a	a	DET
gsrj-50	63	38	double	double	ADJ
gsrj-50	63	39	stranded	strand	VERB
gsrj-50	63	40	dna	dna	PROPN
gsrj-50	63	41	virus	virus	NOUN
gsrj-50	63	42	that	that	PRON
gsrj-50	63	43	is	be	AUX
gsrj-50	63	44	part	part	NOUN
gsrj-50	63	45	of	of	ADP
gsrj-50	63	46	the	the	DET
gsrj-50	63	47	herpes	herpe	NOUN
gsrj-50	63	48	family	family	NOUN
gsrj-50	63	49	.	.	PUNCT
gsrj-50	64	1	ebv	ebv	PROPN
gsrj-50	64	2	has	have	AUX
gsrj-50	64	3	been	be	AUX
gsrj-50	64	4	linked	link	VERB
gsrj-50	64	5	to	to	ADP
gsrj-50	64	6	cancers	cancer	NOUN
gsrj-50	64	7	such	such	ADJ
gsrj-50	64	8	as	as	ADP
gsrj-50	64	9	nasopharyngeal	nasopharyngeal	ADJ
gsrj-50	64	10	cancer	cancer	NOUN
gsrj-50	64	11	and	and	CCONJ
gsrj-50	64	12	fast	fast	ADV
gsrj-50	64	13	-	-	PUNCT
gsrj-50	64	14	growing	grow	VERB
gsrj-50	64	15	lymphomas	lymphoma	NOUN
gsrj-50	64	16	due	due	ADP
gsrj-50	64	17	to	to	ADP
gsrj-50	64	18	its	its	PRON
gsrj-50	64	19	role	role	NOUN
gsrj-50	64	20	in	in	ADP
gsrj-50	64	21	creating	create	VERB
gsrj-50	64	22	b	b	NOUN
gsrj-50	64	23	-	-	PUNCT
gsrj-50	64	24	cell	cell	NOUN
gsrj-50	64	25	lymphoproliferations.9	lymphoproliferations.9	NOUN
gsrj-50	64	26	the	the	DET
gsrj-50	64	27	high	high	ADJ
gsrj-50	64	28	parp1	parp1	NOUN
gsrj-50	64	29	expression	expression	NOUN
gsrj-50	64	30	levels	level	NOUN
gsrj-50	64	31	in	in	ADP
gsrj-50	64	32	ebv	ebv	NOUN
gsrj-50	64	33	-	-	PUNCT
gsrj-50	64	34	transformed	transform	VERB
gsrj-50	64	35	lymphocytes	lymphocyte	NOUN
gsrj-50	64	36	,	,	PUNCT
gsrj-50	64	37	which	which	PRON
gsrj-50	64	38	are	be	AUX
gsrj-50	64	39	involved	involve	VERB
gsrj-50	64	40	in	in	ADP
gsrj-50	64	41	cancers	cancer	NOUN
gsrj-50	64	42	,	,	PUNCT
gsrj-50	64	43	corroborates	corroborate	VERB
gsrj-50	64	44	parp1	parp1	PROPN
gsrj-50	64	45	’s	’s	PART
gsrj-50	64	46	potential	potential	ADJ
gsrj-50	64	47	link	link	NOUN
gsrj-50	64	48	to	to	ADP
gsrj-50	64	49	certain	certain	ADJ
gsrj-50	64	50	types	type	NOUN
gsrj-50	64	51	of	of	ADP
gsrj-50	64	52	cancers.10	cancers.10	NOUN
gsrj-50	64	53	as	as	SCONJ
gsrj-50	64	54	shown	show	VERB
gsrj-50	64	55	in	in	ADP
gsrj-50	64	56	figure	figure	NOUN
gsrj-50	64	57	6	6	NUM
gsrj-50	64	58	,	,	PUNCT
gsrj-50	64	59	parp1	parp1	NOUN
gsrj-50	64	60	mrna	mrna	NOUN
gsrj-50	64	61	expression	expression	NOUN
gsrj-50	64	62	is	be	AUX
gsrj-50	64	63	elevated	elevate	VERB
gsrj-50	64	64	in	in	ADP
gsrj-50	64	65	human	human	ADJ
gsrj-50	64	66	primary	primary	ADJ
gsrj-50	64	67	cancers	cancer	NOUN
gsrj-50	64	68	of	of	ADP
gsrj-50	64	69	the	the	DET
gsrj-50	64	70	breast	breast	NOUN
gsrj-50	64	71	,	,	PUNCT
gsrj-50	64	72	endometrium	endometrium	NOUN
gsrj-50	64	73	,	,	PUNCT
gsrj-50	64	74	lung	lung	NOUN
gsrj-50	64	75	,	,	PUNCT
gsrj-50	64	76	ovary	ovary	ADJ
gsrj-50	64	77	,	,	PUNCT
gsrj-50	64	78	and	and	CCONJ
gsrj-50	64	79	skin.11	skin.11	NOUN
gsrj-50	64	80	ffiigguurree	ffiigguurree	NOUN
gsrj-50	64	81	66	66	NUM
gsrj-50	64	82	..	..	PUNCT
gsrj-50	64	83	a	a	DET
gsrj-50	64	84	boxplot	boxplot	NOUN
gsrj-50	64	85	analysis	analysis	NOUN
gsrj-50	64	86	of	of	ADP
gsrj-50	64	87	reads	read	NOUN
gsrj-50	64	88	per	per	ADP
gsrj-50	64	89	kilobase	kilobase	NOUN
gsrj-50	64	90	of	of	ADP
gsrj-50	64	91	transcript	transcript	NOUN
gsrj-50	64	92	per	per	ADP
gsrj-50	64	93	million	million	NUM
gsrj-50	64	94	mapped	map	VERB
gsrj-50	64	95	reads	read	NOUN
gsrj-50	64	96	(	(	PUNCT
gsrj-50	64	97	rpkm	rpkm	NOUN
gsrj-50	64	98	)	)	PUNCT
gsrj-50	64	99	of	of	ADP
gsrj-50	64	100	parp1	parp1	NOUN
gsrj-50	64	101	in	in	ADP
gsrj-50	64	102	normal	normal	ADJ
gsrj-50	64	103	tissues	tissue	NOUN
gsrj-50	64	104	compared	compare	VERB
gsrj-50	64	105	to	to	ADP
gsrj-50	64	106	cancer	cancer	NOUN
gsrj-50	64	107	tissues	tissue	NOUN
gsrj-50	64	108	.	.	PUNCT
gsrj-50	65	1	the	the	DET
gsrj-50	65	2	mrna	mrna	PROPN
gsrj-50	65	3	expressions	expression	NOUN
gsrj-50	65	4	of	of	ADP
gsrj-50	65	5	parp1	parp1	NOUN
gsrj-50	65	6	are	be	AUX
gsrj-50	65	7	observed	observe	VERB
gsrj-50	65	8	to	to	PART
gsrj-50	65	9	be	be	AUX
gsrj-50	65	10	of	of	ADP
gsrj-50	65	11	similar	similar	ADJ
gsrj-50	65	12	levels	level	NOUN
gsrj-50	65	13	in	in	ADP
gsrj-50	65	14	histologically	histologically	ADV
gsrj-50	65	15	normal	normal	ADJ
gsrj-50	65	16	tissues	tissue	NOUN
gsrj-50	65	17	.	.	PUNCT
gsrj-50	66	1	breast	breast	NOUN
gsrj-50	66	2	,	,	PUNCT
gsrj-50	66	3	endometrium	endometrium	NOUN
gsrj-50	66	4	,	,	PUNCT
gsrj-50	66	5	lung	lung	NOUN
gsrj-50	66	6	,	,	PUNCT
gsrj-50	66	7	ovary	ovary	ADJ
gsrj-50	66	8	,	,	PUNCT
gsrj-50	66	9	and	and	CCONJ
gsrj-50	66	10	skin	skin	NOUN
gsrj-50	66	11	cancer	cancer	NOUN
gsrj-50	66	12	all	all	PRON
gsrj-50	66	13	show	show	VERB
gsrj-50	66	14	elevated	elevated	ADJ
gsrj-50	66	15	levels	level	NOUN
gsrj-50	66	16	of	of	ADP
gsrj-50	66	17	parp1	parp1	NOUN
gsrj-50	66	18	mrna	mrna	NOUN
gsrj-50	66	19	expression	expression	NOUN
gsrj-50	66	20	with	with	ADP
gsrj-50	66	21	high	high	ADJ
gsrj-50	66	22	variability	variability	NOUN
gsrj-50	66	23	compared	compare	VERB
gsrj-50	66	24	to	to	ADP
gsrj-50	66	25	their	their	PRON
gsrj-50	66	26	respective	respective	ADJ
gsrj-50	66	27	normal	normal	ADJ
gsrj-50	66	28	tissue	tissue	NOUN
gsrj-50	66	29	mrna	mrna	NOUN
gsrj-50	66	30	expression	expression	NOUN
gsrj-50	66	31	.	.	PUNCT
gsrj-50	67	1	retrieved	retrieve	VERB
gsrj-50	67	2	from	from	ADP
gsrj-50	67	3	valeria	valeria	PROPN
gsrj-50	67	4	ossovskaya	ossovskaya	NOUN
gsrj-50	67	5	and	and	CCONJ
gsrj-50	67	6	her	her	PRON
gsrj-50	67	7	research	research	NOUN
gsrj-50	67	8	team.11	team.11	VERB
gsrj-50	67	9	66	66	NUM
gsrj-50	67	10	..	..	PUNCT
gsrj-50	67	11	rreelleevvaannccee	rreelleevvaannccee	VERB
gsrj-50	67	12	ttoo	ttoo	PROPN
gsrj-50	67	13	bbrreeaasstt	bbrreeaasstt	PROPN
gsrj-50	67	14	ccaanncceerr	ccaanncceerr	PROPN
gsrj-50	67	15	brca1	brca1	PROPN
gsrj-50	67	16	is	be	AUX
gsrj-50	67	17	a	a	DET
gsrj-50	67	18	tumor	tumor	NOUN
gsrj-50	67	19	suppressor	suppressor	NOUN
gsrj-50	67	20	gene	gene	NOUN
gsrj-50	67	21	that	that	PRON
gsrj-50	67	22	produces	produce	VERB
gsrj-50	67	23	proteins	protein	NOUN
gsrj-50	67	24	that	that	PRON
gsrj-50	67	25	help	help	VERB
gsrj-50	67	26	repair	repair	VERB
gsrj-50	67	27	double	double	ADJ
gsrj-50	67	28	-	-	PUNCT
gsrj-50	67	29	stranded	strand	VERB
gsrj-50	67	30	dna	dna	NOUN
gsrj-50	67	31	breaks	break	NOUN
gsrj-50	67	32	and	and	CCONJ
gsrj-50	67	33	interstrand	interstrand	NOUN
gsrj-50	67	34	crosslinks	crosslink	NOUN
gsrj-50	67	35	through	through	ADP
gsrj-50	67	36	a	a	DET
gsrj-50	67	37	homologous	homologous	ADJ
gsrj-50	67	38	recombination	recombination	NOUN
gsrj-50	67	39	pathway	pathway	NOUN
gsrj-50	67	40	.	.	PUNCT
gsrj-50	68	1	brca1	brca1	PROPN
gsrj-50	68	2	also	also	ADV
gsrj-50	68	3	10	10	NUM
gsrj-50	68	4	georgetown	georgetown	PROPN
gsrj-50	68	5	scientific	scientific	PROPN
gsrj-50	68	6	research	research	NOUN
gsrj-50	68	7	journal	journal	PROPN
gsrj-50	68	8	plays	play	VERB
gsrj-50	68	9	a	a	DET
gsrj-50	68	10	role	role	NOUN
gsrj-50	68	11	in	in	ADP
gsrj-50	68	12	protein	protein	NOUN
gsrj-50	68	13	ubiquitination	ubiquitination	NOUN
gsrj-50	68	14	,	,	PUNCT
gsrj-50	68	15	chromatin	chromatin	NOUN
gsrj-50	68	16	remodeling	remodeling	NOUN
gsrj-50	68	17	,	,	PUNCT
gsrj-50	68	18	and	and	CCONJ
gsrj-50	68	19	transcriptional	transcriptional	NOUN
gsrj-50	68	20	regulation.12	regulation.12	NOUN
gsrj-50	68	21	it	it	PRON
gsrj-50	68	22	is	be	AUX
gsrj-50	68	23	well	well	ADV
gsrj-50	68	24	-	-	PUNCT
gsrj-50	68	25	known	know	VERB
gsrj-50	68	26	to	to	PART
gsrj-50	68	27	be	be	AUX
gsrj-50	68	28	mutated	mutate	VERB
gsrj-50	68	29	in	in	ADP
gsrj-50	68	30	familial	familial	ADJ
gsrj-50	68	31	breast	breast	NOUN
gsrj-50	68	32	cancers	cancer	NOUN
gsrj-50	68	33	and	and	CCONJ
gsrj-50	68	34	ovarian	ovarian	ADJ
gsrj-50	68	35	cancers	cancer	NOUN
gsrj-50	68	36	.	.	PUNCT
gsrj-50	69	1	ffiigguurree	ffiigguurree	NOUN
gsrj-50	69	2	77	77	NUM
gsrj-50	69	3	..	..	PUNCT
gsrj-50	69	4	diagram	diagram	NOUN
gsrj-50	69	5	of	of	ADP
gsrj-50	69	6	the	the	DET
gsrj-50	69	7	alteration	alteration	NOUN
gsrj-50	69	8	frequencies	frequency	NOUN
gsrj-50	69	9	of	of	ADP
gsrj-50	69	10	parp1	parp1	NOUN
gsrj-50	69	11	gene	gene	NOUN
gsrj-50	69	12	in	in	ADP
gsrj-50	69	13	different	different	ADJ
gsrj-50	69	14	types	type	NOUN
gsrj-50	69	15	of	of	ADP
gsrj-50	69	16	carcinomas	carcinoma	NOUN
gsrj-50	69	17	.	.	PUNCT
gsrj-50	70	1	green	green	PROPN
gsrj-50	70	2	represents	represent	VERB
gsrj-50	70	3	mutations	mutation	NOUN
gsrj-50	70	4	,	,	PUNCT
gsrj-50	70	5	purple	purple	NOUN
gsrj-50	70	6	represents	represent	VERB
gsrj-50	70	7	a	a	DET
gsrj-50	70	8	structural	structural	ADJ
gsrj-50	70	9	variant	variant	NOUN
gsrj-50	70	10	,	,	PUNCT
gsrj-50	70	11	red	red	NOUN
gsrj-50	70	12	represents	represent	VERB
gsrj-50	70	13	amplification	amplification	NOUN
gsrj-50	70	14	,	,	PUNCT
gsrj-50	70	15	blue	blue	NOUN
gsrj-50	70	16	represents	represent	VERB
gsrj-50	70	17	deep	deep	ADJ
gsrj-50	70	18	deletion	deletion	NOUN
gsrj-50	70	19	,	,	PUNCT
gsrj-50	70	20	and	and	CCONJ
gsrj-50	70	21	grey	grey	NOUN
gsrj-50	70	22	represents	represent	VERB
gsrj-50	70	23	multiple	multiple	ADJ
gsrj-50	70	24	alterations	alteration	NOUN
gsrj-50	70	25	.	.	PUNCT
gsrj-50	71	1	breast	breast	NOUN
gsrj-50	71	2	invasive	invasive	ADJ
gsrj-50	71	3	carcinoma	carcinoma	NOUN
gsrj-50	71	4	showed	show	VERB
gsrj-50	71	5	the	the	DET
gsrj-50	71	6	highest	high	ADJ
gsrj-50	71	7	alteration	alteration	NOUN
gsrj-50	71	8	frequency	frequency	NOUN
gsrj-50	71	9	of	of	ADP
gsrj-50	71	10	the	the	DET
gsrj-50	71	11	parp1	parp1	NOUN
gsrj-50	71	12	genome	genome	NOUN
gsrj-50	71	13	at	at	ADP
gsrj-50	71	14	approximately	approximately	ADV
gsrj-50	71	15	10	10	NUM
gsrj-50	71	16	%	%	NOUN
gsrj-50	71	17	.	.	PUNCT
gsrj-50	72	1	a	a	DET
gsrj-50	72	2	majority	majority	NOUN
gsrj-50	72	3	of	of	ADP
gsrj-50	72	4	the	the	DET
gsrj-50	72	5	alterations	alteration	NOUN
gsrj-50	72	6	across	across	ADP
gsrj-50	72	7	tissues	tissue	NOUN
gsrj-50	72	8	was	be	AUX
gsrj-50	72	9	observed	observe	VERB
gsrj-50	72	10	to	to	PART
gsrj-50	72	11	be	be	AUX
gsrj-50	72	12	amplification	amplification	NOUN
gsrj-50	72	13	.	.	PUNCT
gsrj-50	73	1	retrieved	retrieve	VERB
gsrj-50	73	2	from	from	ADP
gsrj-50	73	3	cbioportal	cbioportal	ADJ
gsrj-50	73	4	database.7	database.7	PROPN
gsrj-50	73	5	figure	figure	NOUN
gsrj-50	73	6	7	7	NUM
gsrj-50	73	7	shows	show	VERB
gsrj-50	73	8	that	that	SCONJ
gsrj-50	73	9	there	there	PRON
gsrj-50	73	10	is	be	VERB
gsrj-50	73	11	9	9	NUM
gsrj-50	73	12	%	%	NOUN
gsrj-50	73	13	amplification	amplification	NOUN
gsrj-50	73	14	and	and	CCONJ
gsrj-50	73	15	1	1	NUM
gsrj-50	73	16	%	%	NOUN
gsrj-50	73	17	mutation	mutation	NOUN
gsrj-50	73	18	in	in	ADP
gsrj-50	73	19	the	the	DET
gsrj-50	73	20	parp1	parp1	NOUN
gsrj-50	73	21	gene	gene	NOUN
gsrj-50	73	22	in	in	ADP
gsrj-50	73	23	breast	breast	NOUN
gsrj-50	73	24	invasive	invasive	ADJ
gsrj-50	73	25	cancer.7	cancer.7	VERB
gsrj-50	73	26	the	the	DET
gsrj-50	73	27	alteration	alteration	NOUN
gsrj-50	73	28	frequency	frequency	NOUN
gsrj-50	73	29	of	of	ADP
gsrj-50	73	30	the	the	DET
gsrj-50	73	31	parp1	parp1	NOUN
gsrj-50	73	32	gene	gene	NOUN
gsrj-50	73	33	is	be	AUX
gsrj-50	73	34	highest	high	ADJ
gsrj-50	73	35	in	in	ADP
gsrj-50	73	36	breast	breast	NOUN
gsrj-50	73	37	-	-	PUNCT
gsrj-50	73	38	invasive	invasive	ADJ
gsrj-50	73	39	carcinoma	carcinoma	NOUN
gsrj-50	73	40	(	(	PUNCT
gsrj-50	73	41	figure	figure	NOUN
gsrj-50	73	42	7	7	NUM
gsrj-50	73	43	)	)	PUNCT
gsrj-50	73	44	,	,	PUNCT
gsrj-50	73	45	which	which	PRON
gsrj-50	73	46	supports	support	VERB
gsrj-50	73	47	the	the	DET
gsrj-50	73	48	significance	significance	NOUN
gsrj-50	73	49	of	of	ADP
gsrj-50	73	50	exploring	explore	VERB
gsrj-50	73	51	the	the	DET
gsrj-50	73	52	link	link	NOUN
gsrj-50	73	53	between	between	ADP
gsrj-50	73	54	brca1	brca1	PROPN
gsrj-50	73	55	mutations	mutation	NOUN
gsrj-50	73	56	and	and	CCONJ
gsrj-50	73	57	parp1	parp1	NOUN
gsrj-50	73	58	in	in	ADP
gsrj-50	73	59	the	the	DET
gsrj-50	73	60	development	development	NOUN
gsrj-50	73	61	of	of	ADP
gsrj-50	73	62	breast	breast	NOUN
gsrj-50	73	63	cancer	cancer	NOUN
gsrj-50	73	64	.	.	PUNCT
gsrj-50	74	1	ffiigguurree	ffiigguurree	NOUN
gsrj-50	74	2	88	88	NUM
gsrj-50	74	3	..	..	PUNCT
gsrj-50	74	4	brca1	brca1	NOUN
gsrj-50	74	5	-	-	ADJ
gsrj-50	74	6	mutated	mutate	VERB
gsrj-50	74	7	breast	breast	NOUN
gsrj-50	74	8	cancer	cancer	NOUN
gsrj-50	74	9	tissues	tissue	NOUN
gsrj-50	74	10	showed	show	VERB
gsrj-50	74	11	significantly	significantly	ADV
gsrj-50	74	12	greater	great	ADJ
gsrj-50	74	13	parp1	parp1	NOUN
gsrj-50	74	14	levels	level	NOUN
gsrj-50	74	15	and	and	CCONJ
gsrj-50	74	16	activity	activity	NOUN
gsrj-50	74	17	compared	compare	VERB
gsrj-50	74	18	to	to	ADP
gsrj-50	74	19	the	the	DET
gsrj-50	74	20	non	non	ADJ
gsrj-50	74	21	-	-	ADJ
gsrj-50	74	22	brca1	brca1	ADJ
gsrj-50	74	23	-	-	ADJ
gsrj-50	74	24	mutated	mutate	VERB
gsrj-50	74	25	breast	breast	NOUN
gsrj-50	74	26	cancer	cancer	NOUN
gsrj-50	74	27	tissues	tissue	NOUN
gsrj-50	74	28	and	and	CCONJ
gsrj-50	74	29	normal	normal	ADJ
gsrj-50	74	30	tissues	tissue	NOUN
gsrj-50	74	31	.	.	PUNCT
gsrj-50	75	1	blue	blue	ADJ
gsrj-50	75	2	bars	bar	NOUN
gsrj-50	75	3	represent	represent	VERB
gsrj-50	75	4	non	non	ADJ
gsrj-50	75	5	-	-	ADJ
gsrj-50	75	6	brca1	brca1	ADJ
gsrj-50	75	7	-	-	ADJ
gsrj-50	75	8	mutated	mutate	VERB
gsrj-50	75	9	breast	breast	NOUN
gsrj-50	75	10	cancer	cancer	NOUN
gsrj-50	75	11	tissues	tissue	NOUN
gsrj-50	75	12	.	.	PUNCT
gsrj-50	76	1	brown	brown	ADJ
gsrj-50	76	2	bars	bar	NOUN
gsrj-50	76	3	represent	represent	VERB
gsrj-50	76	4	brca1	brca1	PROPN
gsrj-50	76	5	-	-	PUNCT
gsrj-50	76	6	mutated	mutate	VERB
gsrj-50	76	7	breast	breast	NOUN
gsrj-50	76	8	cancer	cancer	NOUN
gsrj-50	76	9	tissues	tissue	NOUN
gsrj-50	76	10	.	.	PUNCT
gsrj-50	77	1	white	white	ADJ
gsrj-50	77	2	bars	bar	NOUN
gsrj-50	77	3	represent	represent	VERB
gsrj-50	77	4	normal	normal	ADJ
gsrj-50	77	5	tissues	tissue	NOUN
gsrj-50	77	6	with	with	ADP
gsrj-50	77	7	or	or	CCONJ
gsrj-50	77	8	without	without	ADP
gsrj-50	77	9	brca1	brca1	NOUN
gsrj-50	77	10	-	-	NOUN
gsrj-50	77	11	mutations	mutation	NOUN
gsrj-50	77	12	.	.	PUNCT
gsrj-50	78	1	41	41	NUM
gsrj-50	78	2	pairs	pair	NOUN
gsrj-50	78	3	of	of	ADP
gsrj-50	78	4	non	non	ADJ
gsrj-50	78	5	-	-	ADJ
gsrj-50	78	6	mutated	mutated	ADJ
gsrj-50	78	7	and	and	CCONJ
gsrj-50	78	8	brca1	brca1	PROPN
gsrj-50	78	9	-	-	ADJ
gsrj-50	78	10	mutated	mutate	VERB
gsrj-50	78	11	cancer	cancer	NOUN
gsrj-50	78	12	and	and	CCONJ
gsrj-50	78	13	normal	normal	ADJ
gsrj-50	78	14	tissues	tissue	NOUN
gsrj-50	78	15	were	be	AUX
gsrj-50	78	16	used	use	VERB
gsrj-50	78	17	.	.	PUNCT
gsrj-50	79	1	the	the	DET
gsrj-50	79	2	bar	bar	NOUN
gsrj-50	79	3	graphs	graph	NOUN
gsrj-50	79	4	show	show	VERB
gsrj-50	79	5	mean	mean	VERB
gsrj-50	79	6	±	±	NUM
gsrj-50	79	7	sd	sd	NOUN
gsrj-50	79	8	.	.	PUNCT
gsrj-50	80	1	a.	a.	NOUN
gsrj-50	80	2	diagram	diagram	PROPN
gsrj-50	80	3	of	of	ADP
gsrj-50	80	4	the	the	DET
gsrj-50	80	5	relative	relative	ADJ
gsrj-50	80	6	parp1	parp1	NOUN
gsrj-50	80	7	protein	protein	NOUN
gsrj-50	80	8	levels	level	NOUN
gsrj-50	80	9	.	.	PUNCT
gsrj-50	81	1	b.	b.	PROPN
gsrj-50	81	2	relative	relative	ADJ
gsrj-50	81	3	parp1	parp1	PROPN
gsrj-50	81	4	mrna	mrna	PROPN
gsrj-50	81	5	levels	level	NOUN
gsrj-50	81	6	.	.	PUNCT
gsrj-50	82	1	c.	c.	PROPN
gsrj-50	82	2	relative	relative	ADJ
gsrj-50	82	3	parp1	parp1	NOUN
gsrj-50	82	4	activity	activity	NOUN
gsrj-50	82	5	in	in	ADP
gsrj-50	82	6	normal	normal	ADJ
gsrj-50	82	7	and	and	CCONJ
gsrj-50	82	8	cancer	cancer	NOUN
gsrj-50	82	9	tissues	tissue	NOUN
gsrj-50	82	10	.	.	PUNCT
gsrj-50	83	1	retrieved	retrieve	VERB
gsrj-50	83	2	from	from	ADP
gsrj-50	83	3	li	li	PROPN
gsrj-50	83	4	and	and	CCONJ
gsrj-50	83	5	her	her	PRON
gsrj-50	83	6	research	research	NOUN
gsrj-50	83	7	team.13	team.13	PROPN
gsrj-50	83	8	as	as	SCONJ
gsrj-50	83	9	seen	see	VERB
gsrj-50	83	10	in	in	ADP
gsrj-50	83	11	figure	figure	NOUN
gsrj-50	83	12	8.a	8.a	NUM
gsrj-50	83	13	,	,	PUNCT
gsrj-50	83	14	which	which	PRON
gsrj-50	83	15	compares	compare	VERB
gsrj-50	83	16	relative	relative	ADJ
gsrj-50	83	17	parp1	parp1	NOUN
gsrj-50	83	18	protein	protein	NOUN
gsrj-50	83	19	levels	level	NOUN
gsrj-50	83	20	and	and	CCONJ
gsrj-50	83	21	the	the	DET
gsrj-50	83	22	presence	presence	NOUN
gsrj-50	83	23	of	of	ADP
gsrj-50	83	24	brca1	brca1	PROPN
gsrj-50	83	25	mutations	mutation	NOUN
gsrj-50	83	26	,	,	PUNCT
gsrj-50	83	27	parp1	parp1	NOUN
gsrj-50	83	28	protein	protein	NOUN
gsrj-50	83	29	levels	level	NOUN
gsrj-50	83	30	are	be	AUX
gsrj-50	83	31	higher	high	ADJ
gsrj-50	83	32	in	in	ADP
gsrj-50	83	33	normal	normal	ADJ
gsrj-50	83	34	tissues	tissue	NOUN
gsrj-50	83	35	with	with	ADP
gsrj-50	83	36	brca1	brca1	PROPN
gsrj-50	83	37	mutation	mutation	NOUN
gsrj-50	83	38	compared	compare	VERB
gsrj-50	83	39	to	to	ADP
gsrj-50	83	40	normal	normal	ADJ
gsrj-50	83	41	tissues	tissue	NOUN
gsrj-50	83	42	without	without	ADP
gsrj-50	83	43	brca1	brca1	PROPN
gsrj-50	83	44	mutations.13	mutations.13	PROPN
gsrj-50	83	45	more	more	ADV
gsrj-50	83	46	importantly	importantly	ADV
gsrj-50	83	47	,	,	PUNCT
gsrj-50	83	48	parp1	parp1	NOUN
gsrj-50	83	49	protein	protein	NOUN
gsrj-50	83	50	levels	level	NOUN
gsrj-50	83	51	are	be	AUX
gsrj-50	83	52	higher	high	ADJ
gsrj-50	83	53	in	in	ADP
gsrj-50	83	54	cancer	cancer	NOUN
gsrj-50	83	55	tissues	tissue	NOUN
gsrj-50	83	56	with	with	ADP
gsrj-50	83	57	brca1	brca1	PROPN
gsrj-50	83	58	mutations	mutation	NOUN
gsrj-50	83	59	than	than	ADP
gsrj-50	83	60	cancer	cancer	NOUN
gsrj-50	83	61	tissues	tissue	NOUN
gsrj-50	83	62	without	without	ADP
gsrj-50	83	63	brca1	brca1	PROPN
gsrj-50	83	64	mutations	mutation	NOUN
gsrj-50	83	65	.	.	PUNCT
gsrj-50	84	1	consistent	consistent	ADJ
gsrj-50	84	2	with	with	ADP
gsrj-50	84	3	the	the	DET
gsrj-50	84	4	data	datum	NOUN
gsrj-50	84	5	that	that	PRON
gsrj-50	84	6	was	be	AUX
gsrj-50	84	7	suggested	suggest	VERB
gsrj-50	84	8	in	in	ADP
gsrj-50	84	9	figure	figure	NOUN
gsrj-50	84	10	8.a	8.a	NUM
gsrj-50	84	11	,	,	PUNCT
gsrj-50	84	12	figure	figure	NOUN
gsrj-50	84	13	8.b	8.b	NUM
gsrj-50	84	14	demonstrates	demonstrate	VERB
gsrj-50	84	15	that	that	PRON
gsrj-50	84	16	relative	relative	ADJ
gsrj-50	84	17	parp1	parp1	NOUN
gsrj-50	84	18	mrna	mrna	PROPN
gsrj-50	84	19	levels	level	NOUN
gsrj-50	84	20	are	be	AUX
gsrj-50	84	21	greater	great	ADJ
gsrj-50	84	22	in	in	ADP
gsrj-50	84	23	tissues	tissue	NOUN
gsrj-50	84	24	with	with	ADP
gsrj-50	84	25	brca1	brca1	PROPN
gsrj-50	84	26	mutations	mutation	NOUN
gsrj-50	84	27	than	than	ADP
gsrj-50	84	28	those	those	DET
gsrj-50	84	29	without.13	without.13	PROPN
gsrj-50	84	30	figure	figure	VERB
gsrj-50	84	31	8.c	8.c	NUM
gsrj-50	84	32	,	,	PUNCT
gsrj-50	84	33	which	which	PRON
gsrj-50	84	34	shows	show	VERB
gsrj-50	84	35	relative	relative	ADJ
gsrj-50	84	36	parp1	parp1	NOUN
gsrj-50	84	37	activity	activity	NOUN
gsrj-50	84	38	,	,	PUNCT
gsrj-50	84	39	suggests	suggest	VERB
gsrj-50	84	40	that	that	SCONJ
gsrj-50	84	41	parp1	parp1	NOUN
gsrj-50	84	42	activity	activity	NOUN
gsrj-50	84	43	levels	level	NOUN
gsrj-50	84	44	are	be	AUX
gsrj-50	84	45	significantly	significantly	ADV
gsrj-50	84	46	higher	high	ADJ
gsrj-50	84	47	in	in	ADP
gsrj-50	84	48	brca	brca	PROPN
gsrj-50	84	49	-	-	PUNCT
gsrj-50	84	50	mutated	mutate	VERB
gsrj-50	84	51	tissues	tissue	NOUN
gsrj-50	84	52	than	than	SCONJ
gsrj-50	84	53	in	in	ADP
gsrj-50	84	54	tissues	tissue	NOUN
gsrj-50	84	55	without	without	ADP
gsrj-50	84	56	the	the	DET
gsrj-50	84	57	brca1	brca1	PROPN
gsrj-50	84	58	mutations.13	mutations.13	PROPN
gsrj-50	84	59	ffiigguurree	ffiigguurree	PROPN
gsrj-50	84	60	99	99	NUM
gsrj-50	84	61	..	..	PUNCT
gsrj-50	84	62	diagram	diagram	NOUN
gsrj-50	84	63	of	of	ADP
gsrj-50	84	64	the	the	DET
gsrj-50	84	65	kaplan	kaplan	PROPN
gsrj-50	84	66	meier	meier	PROPN
gsrj-50	84	67	plot	plot	PROPN
gsrj-50	84	68	for	for	ADP
gsrj-50	84	69	breast	breast	NOUN
gsrj-50	84	70	cancer	cancer	NOUN
gsrj-50	84	71	patients	patient	NOUN
gsrj-50	84	72	after	after	SCONJ
gsrj-50	84	73	the	the	DET
gsrj-50	84	74	germline	germline	NOUN
gsrj-50	84	75	cells	cell	NOUN
gsrj-50	84	76	are	be	AUX
gsrj-50	84	77	removed	remove	VERB
gsrj-50	84	78	.	.	PUNCT
gsrj-50	85	1	as	as	SCONJ
gsrj-50	85	2	shown	show	VERB
gsrj-50	85	3	in	in	ADP
gsrj-50	85	4	the	the	DET
gsrj-50	85	5	diagram	diagram	NOUN
gsrj-50	85	6	,	,	PUNCT
gsrj-50	85	7	the	the	DET
gsrj-50	85	8	red	red	ADJ
gsrj-50	85	9	line	line	NOUN
gsrj-50	85	10	shows	show	VERB
gsrj-50	85	11	patients	patient	NOUN
gsrj-50	85	12	with	with	ADP
gsrj-50	85	13	copy	copy	NOUN
gsrj-50	85	14	numbers	number	NOUN
gsrj-50	85	15	of	of	ADP
gsrj-50	85	16	parp1	parp1	NOUN
gsrj-50	85	17	greater	great	ADJ
gsrj-50	85	18	than	than	ADP
gsrj-50	85	19	or	or	CCONJ
gsrj-50	85	20	equal	equal	ADJ
gsrj-50	85	21	to	to	ADP
gsrj-50	85	22	0.3374	0.3374	NUM
gsrj-50	85	23	and	and	CCONJ
gsrj-50	85	24	the	the	DET
gsrj-50	85	25	blue	blue	ADJ
gsrj-50	85	26	line	line	NOUN
gsrj-50	85	27	shows	show	VERB
gsrj-50	85	28	patients	patient	NOUN
gsrj-50	85	29	with	with	ADP
gsrj-50	85	30	copy	copy	NOUN
gsrj-50	85	31	numbers	number	NOUN
gsrj-50	85	32	fewer	few	ADJ
gsrj-50	85	33	than	than	ADP
gsrj-50	85	34	11	11	NUM
gsrj-50	85	35	georgetown	georgetown	PROPN
gsrj-50	85	36	scientific	scientific	PROPN
gsrj-50	85	37	research	research	NOUN
gsrj-50	85	38	journal	journal	NOUN
gsrj-50	85	39	0.3374	0.3374	NUM
gsrj-50	85	40	.	.	PUNCT
gsrj-50	86	1	a	a	DET
gsrj-50	86	2	total	total	NOUN
gsrj-50	86	3	of	of	ADP
gsrj-50	86	4	1094	1094	NUM
gsrj-50	86	5	patients	patient	NOUN
gsrj-50	86	6	were	be	AUX
gsrj-50	86	7	used	use	VERB
gsrj-50	86	8	in	in	ADP
gsrj-50	86	9	the	the	DET
gsrj-50	86	10	study	study	NOUN
gsrj-50	86	11	.	.	PUNCT
gsrj-50	87	1	retrieved	retrieve	VERB
gsrj-50	87	2	from	from	ADP
gsrj-50	87	3	xena	xena	PROPN
gsrj-50	87	4	browser	browser	PROPN
gsrj-50	87	5	database.14	database.14	PROPN
gsrj-50	87	6	figure	figure	NOUN
gsrj-50	87	7	9	9	NUM
gsrj-50	87	8	displays	display	VERB
gsrj-50	87	9	the	the	DET
gsrj-50	87	10	difference	difference	NOUN
gsrj-50	87	11	in	in	ADP
gsrj-50	87	12	overall	overall	ADJ
gsrj-50	87	13	survival	survival	NOUN
gsrj-50	87	14	of	of	ADP
gsrj-50	87	15	patients	patient	NOUN
gsrj-50	87	16	with	with	ADP
gsrj-50	87	17	high	high	ADJ
gsrj-50	87	18	copy	copy	NOUN
gsrj-50	87	19	numbers	number	NOUN
gsrj-50	87	20	of	of	ADP
gsrj-50	87	21	parp1	parp1	NOUN
gsrj-50	87	22	and	and	CCONJ
gsrj-50	87	23	low	low	ADJ
gsrj-50	87	24	copy	copy	NOUN
gsrj-50	87	25	numbers	number	NOUN
gsrj-50	87	26	of	of	ADP
gsrj-50	87	27	parp1.14	parp1.14	PRON
gsrj-50	87	28	the	the	DET
gsrj-50	87	29	difference	difference	NOUN
gsrj-50	87	30	in	in	ADP
gsrj-50	87	31	overall	overall	ADJ
gsrj-50	87	32	survival	survival	NOUN
gsrj-50	87	33	is	be	AUX
gsrj-50	87	34	not	not	PART
gsrj-50	87	35	significant	significant	ADJ
gsrj-50	87	36	(	(	PUNCT
gsrj-50	87	37	p	p	NOUN
gsrj-50	87	38	=	=	NOUN
gsrj-50	87	39	0.86).14	0.86).14	NOUN
gsrj-50	87	40	this	this	PRON
gsrj-50	87	41	indicates	indicate	VERB
gsrj-50	87	42	that	that	SCONJ
gsrj-50	87	43	the	the	DET
gsrj-50	87	44	parp1	parp1	NOUN
gsrj-50	87	45	copy	copy	NOUN
gsrj-50	87	46	number	number	NOUN
gsrj-50	87	47	does	do	AUX
gsrj-50	87	48	not	not	PART
gsrj-50	87	49	affect	affect	VERB
gsrj-50	87	50	the	the	DET
gsrj-50	87	51	overall	overall	ADJ
gsrj-50	87	52	survival	survival	NOUN
gsrj-50	87	53	of	of	ADP
gsrj-50	87	54	breast	breast	NOUN
gsrj-50	87	55	cancer	cancer	NOUN
gsrj-50	87	56	patients	patient	NOUN
gsrj-50	87	57	.	.	PUNCT
gsrj-50	88	1	the	the	DET
gsrj-50	88	2	results	result	NOUN
gsrj-50	88	3	specifically	specifically	ADV
gsrj-50	88	4	highlight	highlight	VERB
gsrj-50	88	5	the	the	DET
gsrj-50	88	6	positive	positive	ADJ
gsrj-50	88	7	relationship	relationship	NOUN
gsrj-50	88	8	between	between	ADP
gsrj-50	88	9	the	the	DET
gsrj-50	88	10	parp1	parp1	NOUN
gsrj-50	88	11	gene	gene	NOUN
gsrj-50	88	12	and	and	CCONJ
gsrj-50	88	13	the	the	DET
gsrj-50	88	14	brca1	brca1	PROPN
gsrj-50	88	15	mutations	mutation	NOUN
gsrj-50	88	16	in	in	ADP
gsrj-50	88	17	cells	cell	NOUN
gsrj-50	88	18	,	,	PUNCT
gsrj-50	88	19	which	which	PRON
gsrj-50	88	20	further	far	ADV
gsrj-50	88	21	explains	explain	VERB
gsrj-50	88	22	the	the	DET
gsrj-50	88	23	onset	onset	NOUN
gsrj-50	88	24	of	of	ADP
gsrj-50	88	25	breast	breast	NOUN
gsrj-50	88	26	cancer	cancer	NOUN
gsrj-50	88	27	.	.	PUNCT
gsrj-50	89	1	brca1	brca1	PROPN
gsrj-50	89	2	performs	perform	VERB
gsrj-50	89	3	dsb	dsb	VERB
gsrj-50	89	4	repair	repair	NOUN
gsrj-50	89	5	through	through	ADP
gsrj-50	89	6	the	the	DET
gsrj-50	89	7	homologous	homologous	ADJ
gsrj-50	89	8	recombination	recombination	NOUN
gsrj-50	89	9	(	(	PUNCT
gsrj-50	89	10	hr	hr	NOUN
gsrj-50	89	11	)	)	PUNCT
gsrj-50	89	12	pathway	pathway	NOUN
gsrj-50	89	13	.	.	PUNCT
gsrj-50	90	1	however	however	ADV
gsrj-50	90	2	,	,	PUNCT
gsrj-50	90	3	mutations	mutation	NOUN
gsrj-50	90	4	in	in	ADP
gsrj-50	90	5	the	the	DET
gsrj-50	90	6	brca1	brca1	PROPN
gsrj-50	90	7	gene	gene	NOUN
gsrj-50	90	8	,	,	PUNCT
gsrj-50	90	9	such	such	ADJ
gsrj-50	90	10	as	as	ADP
gsrj-50	90	11	in	in	ADP
gsrj-50	90	12	breast	breast	NOUN
gsrj-50	90	13	and	and	CCONJ
gsrj-50	90	14	ovarian	ovarian	ADJ
gsrj-50	90	15	cancer	cancer	NOUN
gsrj-50	90	16	,	,	PUNCT
gsrj-50	90	17	can	can	AUX
gsrj-50	90	18	cause	cause	VERB
gsrj-50	90	19	a	a	DET
gsrj-50	90	20	decrease	decrease	NOUN
gsrj-50	90	21	in	in	ADP
gsrj-50	90	22	brca1	brca1	PROPN
gsrj-50	90	23	levels	level	NOUN
gsrj-50	90	24	due	due	ADP
gsrj-50	90	25	to	to	ADP
gsrj-50	90	26	a	a	DET
gsrj-50	90	27	disruption	disruption	NOUN
gsrj-50	90	28	in	in	ADP
gsrj-50	90	29	the	the	DET
gsrj-50	90	30	hr	hr	NOUN
gsrj-50	90	31	pathway	pathway	NOUN
gsrj-50	90	32	.	.	PUNCT
gsrj-50	91	1	this	this	DET
gsrj-50	91	2	results	result	VERB
gsrj-50	91	3	in	in	ADP
gsrj-50	91	4	an	an	DET
gsrj-50	91	5	increase	increase	NOUN
gsrj-50	91	6	in	in	ADP
gsrj-50	91	7	intracellular	intracellular	ADJ
gsrj-50	91	8	nad	nad	ADJ
gsrj-50	91	9	levels	level	NOUN
gsrj-50	91	10	which	which	PRON
gsrj-50	91	11	,	,	PUNCT
gsrj-50	91	12	in	in	ADP
gsrj-50	91	13	turn	turn	NOUN
gsrj-50	91	14	,	,	PUNCT
gsrj-50	91	15	causes	cause	VERB
gsrj-50	91	16	an	an	DET
gsrj-50	91	17	increase	increase	NOUN
gsrj-50	91	18	in	in	ADP
gsrj-50	91	19	parp	parp	ADJ
gsrj-50	91	20	expression	expression	NOUN
gsrj-50	91	21	and	and	CCONJ
gsrj-50	91	22	activity.15	activity.15	NOUN
gsrj-50	91	23	this	this	DET
gsrj-50	91	24	increase	increase	NOUN
gsrj-50	91	25	helps	help	VERB
gsrj-50	91	26	to	to	PART
gsrj-50	91	27	repair	repair	VERB
gsrj-50	91	28	dna	dna	ADJ
gsrj-50	91	29	damage	damage	NOUN
gsrj-50	91	30	with	with	ADP
gsrj-50	91	31	the	the	DET
gsrj-50	91	32	help	help	NOUN
gsrj-50	91	33	of	of	ADP
gsrj-50	91	34	parps	parps	PROPN
gsrj-50	91	35	.	.	PUNCT
gsrj-50	92	1	as	as	SCONJ
gsrj-50	92	2	nad	nad	PROPN
gsrj-50	92	3	is	be	AUX
gsrj-50	92	4	consumed	consume	VERB
gsrj-50	92	5	,	,	PUNCT
gsrj-50	92	6	its	its	PRON
gsrj-50	92	7	intracellular	intracellular	ADJ
gsrj-50	92	8	quantity	quantity	NOUN
gsrj-50	92	9	falls	fall	VERB
gsrj-50	92	10	,	,	PUNCT
gsrj-50	92	11	which	which	PRON
gsrj-50	92	12	further	far	ADV
gsrj-50	92	13	inhibits	inhibit	VERB
gsrj-50	92	14	brca1	brca1	NOUN
gsrj-50	92	15	expression	expression	NOUN
gsrj-50	92	16	.	.	PUNCT
gsrj-50	93	1	this	this	PRON
gsrj-50	93	2	increases	increase	VERB
gsrj-50	93	3	the	the	DET
gsrj-50	93	4	reliance	reliance	NOUN
gsrj-50	93	5	on	on	ADP
gsrj-50	93	6	parp1	parp1	NOUN
gsrj-50	93	7	in	in	ADP
gsrj-50	93	8	cells	cell	NOUN
gsrj-50	93	9	to	to	PART
gsrj-50	93	10	repair	repair	VERB
gsrj-50	93	11	damaged	damage	VERB
gsrj-50	93	12	dna	dna	NOUN
gsrj-50	93	13	dsbs.16	dsbs.16	PROPN
gsrj-50	93	14	thus	thus	ADV
gsrj-50	93	15	,	,	PUNCT
gsrj-50	93	16	targeting	target	VERB
gsrj-50	93	17	parp1	parp1	NOUN
gsrj-50	93	18	and	and	CCONJ
gsrj-50	93	19	inhibiting	inhibit	VERB
gsrj-50	93	20	its	its	PRON
gsrj-50	93	21	activity	activity	NOUN
gsrj-50	93	22	can	can	AUX
gsrj-50	93	23	prevent	prevent	VERB
gsrj-50	93	24	cancer	cancer	NOUN
gsrj-50	93	25	cells	cell	NOUN
gsrj-50	93	26	with	with	ADP
gsrj-50	93	27	brca1	brca1	PROPN
gsrj-50	93	28	mutations	mutation	NOUN
gsrj-50	93	29	from	from	ADP
gsrj-50	93	30	repairing	repair	VERB
gsrj-50	93	31	damaged	damaged	ADJ
gsrj-50	93	32	dna	dna	NOUN
gsrj-50	93	33	,	,	PUNCT
gsrj-50	93	34	resulting	result	VERB
gsrj-50	93	35	in	in	ADP
gsrj-50	93	36	cell	cell	NOUN
gsrj-50	93	37	apoptosis	apoptosis	NOUN
gsrj-50	93	38	.	.	PUNCT
gsrj-50	94	1	the	the	DET
gsrj-50	94	2	results	result	NOUN
gsrj-50	94	3	seen	see	VERB
gsrj-50	94	4	in	in	ADP
gsrj-50	94	5	figure	figure	NOUN
gsrj-50	94	6	8	8	NUM
gsrj-50	94	7	suggest	suggest	VERB
gsrj-50	94	8	that	that	SCONJ
gsrj-50	94	9	parp1	parp1	NOUN
gsrj-50	94	10	presence	presence	NOUN
gsrj-50	94	11	in	in	ADP
gsrj-50	94	12	cells	cell	NOUN
gsrj-50	94	13	is	be	AUX
gsrj-50	94	14	,	,	PUNCT
gsrj-50	94	15	in	in	ADP
gsrj-50	94	16	general	general	ADJ
gsrj-50	94	17	,	,	PUNCT
gsrj-50	94	18	higher	high	ADJ
gsrj-50	94	19	in	in	ADP
gsrj-50	94	20	tissues	tissue	NOUN
gsrj-50	94	21	with	with	ADP
gsrj-50	94	22	brca1	brca1	PROPN
gsrj-50	94	23	mutations	mutation	NOUN
gsrj-50	94	24	and	and	CCONJ
gsrj-50	94	25	in	in	ADP
gsrj-50	94	26	cancer	cancer	NOUN
gsrj-50	94	27	tissues	tissue	NOUN
gsrj-50	94	28	.	.	PUNCT
gsrj-50	95	1	this	this	PRON
gsrj-50	95	2	provides	provide	VERB
gsrj-50	95	3	significant	significant	ADJ
gsrj-50	95	4	evidence	evidence	NOUN
gsrj-50	95	5	that	that	SCONJ
gsrj-50	95	6	parp1	parp1	NOUN
gsrj-50	95	7	plays	play	VERB
gsrj-50	95	8	an	an	DET
gsrj-50	95	9	important	important	ADJ
gsrj-50	95	10	role	role	NOUN
gsrj-50	95	11	in	in	ADP
gsrj-50	95	12	the	the	DET
gsrj-50	95	13	onset	onset	NOUN
gsrj-50	95	14	of	of	ADP
gsrj-50	95	15	brca1	brca1	PROPN
gsrj-50	95	16	-	-	PUNCT
gsrj-50	95	17	mutated	mutate	VERB
gsrj-50	95	18	breast	breast	NOUN
gsrj-50	95	19	cancers	cancer	NOUN
gsrj-50	95	20	.	.	PUNCT
gsrj-50	96	1	this	this	DET
gsrj-50	96	2	result	result	NOUN
gsrj-50	96	3	collaborates	collaborate	VERB
gsrj-50	96	4	with	with	ADP
gsrj-50	96	5	that	that	PRON
gsrj-50	96	6	of	of	ADP
gsrj-50	96	7	figure	figure	NOUN
gsrj-50	96	8	6	6	NUM
gsrj-50	96	9	,	,	PUNCT
gsrj-50	96	10	which	which	PRON
gsrj-50	96	11	shows	show	VERB
gsrj-50	96	12	that	that	SCONJ
gsrj-50	96	13	breast	breast	NOUN
gsrj-50	96	14	cancer	cancer	NOUN
gsrj-50	96	15	has	have	VERB
gsrj-50	96	16	high	high	ADJ
gsrj-50	96	17	parp1	parp1	NOUN
gsrj-50	96	18	mrna	mrna	NOUN
gsrj-50	96	19	expression	expression	NOUN
gsrj-50	96	20	within	within	ADP
gsrj-50	96	21	its	its	PRON
gsrj-50	96	22	cells	cell	NOUN
gsrj-50	96	23	,	,	PUNCT
gsrj-50	96	24	establishing	establish	VERB
gsrj-50	96	25	the	the	DET
gsrj-50	96	26	relationship	relationship	NOUN
gsrj-50	96	27	between	between	ADP
gsrj-50	96	28	brca1	brca1	PROPN
gsrj-50	96	29	and	and	CCONJ
gsrj-50	96	30	parp1	parp1	NOUN
gsrj-50	96	31	genomes	genome	NOUN
gsrj-50	96	32	.	.	PUNCT
gsrj-50	97	1	these	these	DET
gsrj-50	97	2	results	result	NOUN
gsrj-50	97	3	fit	fit	ADJ
gsrj-50	97	4	with	with	ADP
gsrj-50	97	5	our	our	PRON
gsrj-50	97	6	understanding	understanding	NOUN
gsrj-50	97	7	of	of	ADP
gsrj-50	97	8	the	the	DET
gsrj-50	97	9	function	function	NOUN
gsrj-50	97	10	of	of	ADP
gsrj-50	97	11	parp1	parp1	NOUN
gsrj-50	97	12	and	and	CCONJ
gsrj-50	97	13	brca1	brca1	NOUN
gsrj-50	97	14	genes	gene	NOUN
gsrj-50	97	15	as	as	SCONJ
gsrj-50	97	16	both	both	PRON
gsrj-50	97	17	are	be	AUX
gsrj-50	97	18	involved	involve	VERB
gsrj-50	97	19	in	in	ADP
gsrj-50	97	20	dna	dna	PROPN
gsrj-50	97	21	repair	repair	NOUN
gsrj-50	97	22	,	,	PUNCT
gsrj-50	97	23	a	a	DET
gsrj-50	97	24	function	function	NOUN
gsrj-50	97	25	that	that	SCONJ
gsrj-50	97	26	carcinogenic	carcinogenic	ADJ
gsrj-50	97	27	cells	cell	NOUN
gsrj-50	97	28	aim	aim	VERB
gsrj-50	97	29	to	to	PART
gsrj-50	97	30	manipulate.11	manipulate.11	PROPN
gsrj-50	97	31	as	as	ADP
gsrj-50	97	32	a	a	DET
gsrj-50	97	33	result	result	NOUN
gsrj-50	97	34	,	,	PUNCT
gsrj-50	97	35	it	it	PRON
gsrj-50	97	36	is	be	AUX
gsrj-50	97	37	common	common	ADJ
gsrj-50	97	38	to	to	PART
gsrj-50	97	39	see	see	VERB
gsrj-50	97	40	that	that	SCONJ
gsrj-50	97	41	both	both	CCONJ
gsrj-50	97	42	parp1	parp1	NOUN
gsrj-50	97	43	and	and	CCONJ
gsrj-50	97	44	brca1	brca1	PROPN
gsrj-50	97	45	mutations	mutation	NOUN
gsrj-50	97	46	lead	lead	VERB
gsrj-50	97	47	to	to	ADP
gsrj-50	97	48	cancer	cancer	NOUN
gsrj-50	97	49	.	.	PUNCT
gsrj-50	98	1	more	more	ADV
gsrj-50	98	2	specifically	specifically	ADV
gsrj-50	98	3	,	,	PUNCT
gsrj-50	98	4	the	the	DET
gsrj-50	98	5	parp1	parp1	NOUN
gsrj-50	98	6	gene	gene	NOUN
gsrj-50	98	7	has	have	VERB
gsrj-50	98	8	a	a	DET
gsrj-50	98	9	positive	positive	ADJ
gsrj-50	98	10	correlational	correlational	ADJ
gsrj-50	98	11	relationship	relationship	NOUN
gsrj-50	98	12	with	with	ADP
gsrj-50	98	13	brca1	brca1	PROPN
gsrj-50	98	14	in	in	ADP
gsrj-50	98	15	terms	term	NOUN
gsrj-50	98	16	of	of	ADP
gsrj-50	98	17	invasive	invasive	ADJ
gsrj-50	98	18	breast	breast	NOUN
gsrj-50	98	19	cancer	cancer	NOUN
gsrj-50	98	20	development	development	NOUN
gsrj-50	98	21	.	.	PUNCT
gsrj-50	99	1	figure	figure	NOUN
gsrj-50	99	2	7	7	NUM
gsrj-50	99	3	suggests	suggest	VERB
gsrj-50	99	4	that	that	SCONJ
gsrj-50	99	5	amplification	amplification	NOUN
gsrj-50	99	6	,	,	PUNCT
gsrj-50	99	7	which	which	PRON
gsrj-50	99	8	is	be	AUX
gsrj-50	99	9	an	an	DET
gsrj-50	99	10	increase	increase	NOUN
gsrj-50	99	11	in	in	ADP
gsrj-50	99	12	the	the	DET
gsrj-50	99	13	number	number	NOUN
gsrj-50	99	14	of	of	ADP
gsrj-50	99	15	copies	copy	NOUN
gsrj-50	99	16	of	of	ADP
gsrj-50	99	17	a	a	DET
gsrj-50	99	18	gene	gene	NOUN
gsrj-50	99	19	,	,	PUNCT
gsrj-50	99	20	plays	play	VERB
gsrj-50	99	21	a	a	DET
gsrj-50	99	22	more	more	ADV
gsrj-50	99	23	significant	significant	ADJ
gsrj-50	99	24	role	role	NOUN
gsrj-50	99	25	in	in	ADP
gsrj-50	99	26	the	the	DET
gsrj-50	99	27	development	development	NOUN
gsrj-50	99	28	of	of	ADP
gsrj-50	99	29	breast	breast	NOUN
gsrj-50	99	30	invasive	invasive	ADJ
gsrj-50	99	31	cancer	cancer	NOUN
gsrj-50	99	32	than	than	ADP
gsrj-50	99	33	parp1	parp1	NOUN
gsrj-50	99	34	mutations	mutation	NOUN
gsrj-50	99	35	.	.	PUNCT
gsrj-50	100	1	this	this	DET
gsrj-50	100	2	amplification	amplification	NOUN
gsrj-50	100	3	increases	increase	VERB
gsrj-50	100	4	the	the	DET
gsrj-50	100	5	activity	activity	NOUN
gsrj-50	100	6	of	of	ADP
gsrj-50	100	7	the	the	DET
gsrj-50	100	8	parp1	parp1	NOUN
gsrj-50	100	9	gene	gene	NOUN
gsrj-50	100	10	,	,	PUNCT
gsrj-50	100	11	thus	thus	ADV
gsrj-50	100	12	increasing	increase	VERB
gsrj-50	100	13	the	the	DET
gsrj-50	100	14	repair	repair	NOUN
gsrj-50	100	15	of	of	ADP
gsrj-50	100	16	damaged	damage	VERB
gsrj-50	100	17	dna	dna	NOUN
gsrj-50	100	18	allowing	allow	VERB
gsrj-50	100	19	the	the	DET
gsrj-50	100	20	cancer	cancer	NOUN
gsrj-50	100	21	cell	cell	NOUN
gsrj-50	100	22	to	to	PART
gsrj-50	100	23	divide	divide	VERB
gsrj-50	100	24	quickly	quickly	ADV
gsrj-50	100	25	.	.	PUNCT
gsrj-50	101	1	this	this	PRON
gsrj-50	101	2	prevents	prevent	VERB
gsrj-50	101	3	cell	cell	NOUN
gsrj-50	101	4	apoptosis	apoptosis	NOUN
gsrj-50	101	5	and	and	CCONJ
gsrj-50	101	6	allows	allow	VERB
gsrj-50	101	7	the	the	DET
gsrj-50	101	8	tumor	tumor	NOUN
gsrj-50	101	9	to	to	PART
gsrj-50	101	10	proliferate	proliferate	VERB
gsrj-50	101	11	and	and	CCONJ
gsrj-50	101	12	grow	grow	VERB
gsrj-50	101	13	.	.	PUNCT
gsrj-50	102	1	77	77	NUM
gsrj-50	102	2	..	..	SYM
gsrj-50	102	3	ppaarrpp11	ppaarrpp11	NOUN
gsrj-50	102	4	iinnhhiibbiittiioonn	iinnhhiibbiittiioonn	NOUN
gsrj-50	102	5	mmeecchhaanniissmm	mmeecchhaanniissmm	NOUN
gsrj-50	102	6	due	due	ADP
gsrj-50	102	7	to	to	ADP
gsrj-50	102	8	the	the	DET
gsrj-50	102	9	well	well	ADV
gsrj-50	102	10	-	-	PUNCT
gsrj-50	102	11	established	establish	VERB
gsrj-50	102	12	role	role	NOUN
gsrj-50	102	13	of	of	ADP
gsrj-50	102	14	the	the	DET
gsrj-50	102	15	parp1	parp1	NOUN
gsrj-50	102	16	gene	gene	NOUN
gsrj-50	102	17	in	in	ADP
gsrj-50	102	18	the	the	DET
gsrj-50	102	19	development	development	NOUN
gsrj-50	102	20	of	of	ADP
gsrj-50	102	21	cancer	cancer	NOUN
gsrj-50	102	22	,	,	PUNCT
gsrj-50	102	23	researchers	researcher	NOUN
gsrj-50	102	24	have	have	AUX
gsrj-50	102	25	attempted	attempt	VERB
gsrj-50	102	26	to	to	PART
gsrj-50	102	27	inhibit	inhibit	VERB
gsrj-50	102	28	the	the	DET
gsrj-50	102	29	activity	activity	NOUN
gsrj-50	102	30	of	of	ADP
gsrj-50	102	31	the	the	DET
gsrj-50	102	32	gene	gene	NOUN
gsrj-50	102	33	in	in	ADP
gsrj-50	102	34	certain	certain	ADJ
gsrj-50	102	35	cells	cell	NOUN
gsrj-50	102	36	,	,	PUNCT
gsrj-50	102	37	primarily	primarily	ADV
gsrj-50	102	38	brca1	brca1	NOUN
gsrj-50	102	39	-	-	ADJ
gsrj-50	102	40	mutated	mutate	VERB
gsrj-50	102	41	cells	cell	NOUN
gsrj-50	102	42	.	.	PUNCT
gsrj-50	103	1	one	one	NUM
gsrj-50	103	2	of	of	ADP
gsrj-50	103	3	the	the	DET
gsrj-50	103	4	main	main	ADJ
gsrj-50	103	5	targeted	target	VERB
gsrj-50	103	6	therapies	therapy	NOUN
gsrj-50	103	7	that	that	PRON
gsrj-50	103	8	affect	affect	VERB
gsrj-50	103	9	the	the	DET
gsrj-50	103	10	role	role	NOUN
gsrj-50	103	11	of	of	ADP
gsrj-50	103	12	parp	parp	ADJ
gsrj-50	103	13	enzymes	enzyme	NOUN
gsrj-50	103	14	in	in	ADP
gsrj-50	103	15	dna	dna	PROPN
gsrj-50	103	16	repair	repair	NOUN
gsrj-50	103	17	is	be	AUX
gsrj-50	103	18	the	the	DET
gsrj-50	103	19	parp	parp	ADJ
gsrj-50	103	20	inhibitor.17	inhibitor.17	PROPN
gsrj-50	103	21	in	in	ADP
gsrj-50	103	22	general	general	ADJ
gsrj-50	103	23	,	,	PUNCT
gsrj-50	103	24	these	these	DET
gsrj-50	103	25	parp	parp	ADJ
gsrj-50	103	26	inhibitors	inhibitor	NOUN
gsrj-50	103	27	block	block	VERB
gsrj-50	103	28	off	off	ADP
gsrj-50	103	29	the	the	DET
gsrj-50	103	30	parp	parp	ADJ
gsrj-50	103	31	enzymes	enzyme	NOUN
gsrj-50	103	32	and	and	CCONJ
gsrj-50	103	33	restrict	restrict	VERB
gsrj-50	103	34	them	they	PRON
gsrj-50	103	35	from	from	ADP
gsrj-50	103	36	repairing	repair	VERB
gsrj-50	103	37	the	the	DET
gsrj-50	103	38	ssbs	ssbs	NOUN
gsrj-50	103	39	and	and	CCONJ
gsrj-50	103	40	dsbs	dsbs	ADJ
gsrj-50	103	41	in	in	ADP
gsrj-50	103	42	cancer	cancer	NOUN
gsrj-50	103	43	cells.17	cells.17	NOUN
gsrj-50	103	44	this	this	PRON
gsrj-50	103	45	eventually	eventually	ADV
gsrj-50	103	46	leads	lead	VERB
gsrj-50	103	47	to	to	ADP
gsrj-50	103	48	apoptosis	apoptosis	NOUN
gsrj-50	103	49	of	of	ADP
gsrj-50	103	50	the	the	DET
gsrj-50	103	51	cancer	cancer	NOUN
gsrj-50	103	52	cells	cell	NOUN
gsrj-50	103	53	,	,	PUNCT
gsrj-50	103	54	as	as	SCONJ
gsrj-50	103	55	shown	show	VERB
gsrj-50	103	56	in	in	ADP
gsrj-50	103	57	figure	figure	NOUN
gsrj-50	103	58	10.17	10.17	NUM
gsrj-50	103	59	ffiigguurree	ffiigguurree	NOUN
gsrj-50	103	60	1100	1100	NUM
gsrj-50	103	61	.	.	PUNCT
gsrj-50	104	1	the	the	DET
gsrj-50	104	2	mechanism	mechanism	NOUN
gsrj-50	104	3	of	of	ADP
gsrj-50	104	4	action	action	NOUN
gsrj-50	104	5	by	by	ADP
gsrj-50	104	6	which	which	PRON
gsrj-50	104	7	the	the	DET
gsrj-50	104	8	parp	parp	ADJ
gsrj-50	104	9	inhibitor	inhibitor	NOUN
gsrj-50	104	10	prevents	prevent	VERB
gsrj-50	104	11	dna	dna	PROPN
gsrj-50	104	12	repair	repair	NOUN
gsrj-50	104	13	and	and	CCONJ
gsrj-50	104	14	induces	induce	VERB
gsrj-50	104	15	cell	cell	NOUN
gsrj-50	104	16	death	death	NOUN
gsrj-50	104	17	.	.	PUNCT
gsrj-50	105	1	retrieved	retrieve	VERB
gsrj-50	105	2	from	from	ADP
gsrj-50	105	3	keung	keung	PROPN
gsrj-50	105	4	and	and	CCONJ
gsrj-50	105	5	his	his	PRON
gsrj-50	105	6	research	research	NOUN
gsrj-50	105	7	team.17	team.17	NOUN
gsrj-50	105	8	the	the	DET
gsrj-50	105	9	mechanism	mechanism	NOUN
gsrj-50	105	10	of	of	ADP
gsrj-50	105	11	action	action	NOUN
gsrj-50	105	12	by	by	ADP
gsrj-50	105	13	which	which	PRON
gsrj-50	105	14	the	the	DET
gsrj-50	105	15	parp1	parp1	NOUN
gsrj-50	105	16	inhibitors	inhibitor	NOUN
gsrj-50	105	17	work	work	VERB
gsrj-50	105	18	is	be	AUX
gsrj-50	105	19	yet	yet	ADV
gsrj-50	105	20	to	to	PART
gsrj-50	105	21	be	be	AUX
gsrj-50	105	22	fully	fully	ADV
gsrj-50	105	23	12	12	NUM
gsrj-50	105	24	georgetown	georgetown	PROPN
gsrj-50	105	25	scientific	scientific	PROPN
gsrj-50	105	26	research	research	PROPN
gsrj-50	105	27	journal	journal	PROPN
gsrj-50	105	28	understood	understand	VERB
gsrj-50	105	29	,	,	PUNCT
gsrj-50	105	30	and	and	CCONJ
gsrj-50	105	31	although	although	SCONJ
gsrj-50	105	32	several	several	ADJ
gsrj-50	105	33	theories	theory	NOUN
gsrj-50	105	34	explaining	explain	VERB
gsrj-50	105	35	the	the	DET
gsrj-50	105	36	therapy	therapy	NOUN
gsrj-50	105	37	’s	’s	PART
gsrj-50	105	38	machinery	machinery	NOUN
gsrj-50	105	39	have	have	AUX
gsrj-50	105	40	become	become	AUX
gsrj-50	105	41	known	know	VERB
gsrj-50	105	42	,	,	PUNCT
gsrj-50	105	43	there	there	PRON
gsrj-50	105	44	is	be	VERB
gsrj-50	105	45	yet	yet	ADV
gsrj-50	105	46	to	to	PART
gsrj-50	105	47	be	be	AUX
gsrj-50	105	48	a	a	DET
gsrj-50	105	49	consensus	consensus	NOUN
gsrj-50	105	50	reached	reach	VERB
gsrj-50	105	51	.	.	PUNCT
gsrj-50	106	1	17	17	NUM
gsrj-50	106	2	parp1	parp1	NOUN
gsrj-50	106	3	inhibitors	inhibitor	NOUN
gsrj-50	106	4	work	work	VERB
gsrj-50	106	5	by	by	ADP
gsrj-50	106	6	inducing	induce	VERB
gsrj-50	106	7	synthetic	synthetic	ADJ
gsrj-50	106	8	lethality	lethality	NOUN
gsrj-50	106	9	,	,	PUNCT
gsrj-50	106	10	which	which	PRON
gsrj-50	106	11	is	be	AUX
gsrj-50	106	12	a	a	DET
gsrj-50	106	13	condition	condition	NOUN
gsrj-50	106	14	where	where	SCONJ
gsrj-50	106	15	two	two	NUM
gsrj-50	106	16	independent	independent	ADJ
gsrj-50	106	17	factors	factor	NOUN
gsrj-50	106	18	that	that	PRON
gsrj-50	106	19	would	would	AUX
gsrj-50	106	20	not	not	PART
gsrj-50	106	21	usually	usually	ADV
gsrj-50	106	22	cause	cause	VERB
gsrj-50	106	23	cell	cell	NOUN
gsrj-50	106	24	death	death	NOUN
gsrj-50	106	25	become	become	VERB
gsrj-50	106	26	lethal	lethal	ADJ
gsrj-50	106	27	when	when	SCONJ
gsrj-50	106	28	they	they	PRON
gsrj-50	106	29	occur	occur	VERB
gsrj-50	106	30	together.1	together.1	NOUN
gsrj-50	106	31	in	in	ADP
gsrj-50	106	32	this	this	DET
gsrj-50	106	33	case	case	NOUN
gsrj-50	106	34	,	,	PUNCT
gsrj-50	106	35	synthetic	synthetic	ADJ
gsrj-50	106	36	lethality	lethality	NOUN
gsrj-50	106	37	is	be	AUX
gsrj-50	106	38	caused	cause	VERB
gsrj-50	106	39	by	by	ADP
gsrj-50	106	40	the	the	DET
gsrj-50	106	41	presence	presence	NOUN
gsrj-50	106	42	of	of	ADP
gsrj-50	106	43	brca1	brca1	PROPN
gsrj-50	106	44	mutations	mutation	NOUN
gsrj-50	106	45	and	and	CCONJ
gsrj-50	106	46	the	the	DET
gsrj-50	106	47	action	action	NOUN
gsrj-50	106	48	of	of	ADP
gsrj-50	106	49	parp1	parp1	NOUN
gsrj-50	106	50	inhibitors	inhibitor	NOUN
gsrj-50	106	51	.	.	PUNCT
gsrj-50	107	1	parp1	parp1	NOUN
gsrj-50	107	2	inhibitors	inhibitor	NOUN
gsrj-50	107	3	prevent	prevent	VERB
gsrj-50	107	4	the	the	DET
gsrj-50	107	5	parp1	parp1	NOUN
gsrj-50	107	6	enzymes	enzyme	NOUN
gsrj-50	107	7	from	from	ADP
gsrj-50	107	8	repairing	repair	VERB
gsrj-50	107	9	the	the	DET
gsrj-50	107	10	dna	dna	NOUN
gsrj-50	107	11	,	,	PUNCT
gsrj-50	107	12	which	which	PRON
gsrj-50	107	13	causes	cause	VERB
gsrj-50	107	14	the	the	DET
gsrj-50	107	15	cells	cell	NOUN
gsrj-50	107	16	to	to	PART
gsrj-50	107	17	rely	rely	VERB
gsrj-50	107	18	on	on	ADP
gsrj-50	107	19	the	the	DET
gsrj-50	107	20	hr	hr	NOUN
gsrj-50	107	21	pathway	pathway	NOUN
gsrj-50	107	22	for	for	ADP
gsrj-50	107	23	addressing	address	VERB
gsrj-50	107	24	the	the	DET
gsrj-50	107	25	defects	defect	NOUN
gsrj-50	107	26	in	in	ADP
gsrj-50	107	27	dna.18	dna.18	PROPN
gsrj-50	107	28	however	however	ADV
gsrj-50	107	29	,	,	PUNCT
gsrj-50	107	30	in	in	ADP
gsrj-50	107	31	brca1	brca1	PROPN
gsrj-50	107	32	mutated	mutate	VERB
gsrj-50	107	33	cells	cell	NOUN
gsrj-50	107	34	,	,	PUNCT
gsrj-50	107	35	the	the	DET
gsrj-50	107	36	hr	hr	NOUN
gsrj-50	107	37	pathway	pathway	NOUN
gsrj-50	107	38	is	be	AUX
gsrj-50	107	39	defective	defective	ADJ
gsrj-50	107	40	,	,	PUNCT
gsrj-50	107	41	and	and	CCONJ
gsrj-50	107	42	hence	hence	ADV
gsrj-50	107	43	the	the	DET
gsrj-50	107	44	dna	dna	NOUN
gsrj-50	107	45	can	can	AUX
gsrj-50	107	46	not	not	PART
gsrj-50	107	47	be	be	AUX
gsrj-50	107	48	repaired	repair	VERB
gsrj-50	107	49	.	.	PUNCT
gsrj-50	108	1	this	this	PRON
gsrj-50	108	2	leads	lead	VERB
gsrj-50	108	3	to	to	ADP
gsrj-50	108	4	cell	cell	NOUN
gsrj-50	108	5	apoptosis.18	apoptosis.18	ADP
gsrj-50	108	6	this	this	DET
gsrj-50	108	7	specific	specific	ADJ
gsrj-50	108	8	mechanism	mechanism	NOUN
gsrj-50	108	9	of	of	ADP
gsrj-50	108	10	synthetic	synthetic	ADJ
gsrj-50	108	11	lethality	lethality	NOUN
gsrj-50	108	12	allows	allow	VERB
gsrj-50	108	13	the	the	DET
gsrj-50	108	14	parp1	parp1	NOUN
gsrj-50	108	15	inhibitors	inhibitor	NOUN
gsrj-50	108	16	to	to	PART
gsrj-50	108	17	target	target	VERB
gsrj-50	108	18	the	the	DET
gsrj-50	108	19	tumor	tumor	NOUN
gsrj-50	108	20	cells	cell	NOUN
gsrj-50	108	21	only	only	ADV
gsrj-50	108	22	.	.	PUNCT
gsrj-50	109	1	normal	normal	ADJ
gsrj-50	109	2	cells	cell	NOUN
gsrj-50	109	3	would	would	AUX
gsrj-50	109	4	have	have	VERB
gsrj-50	109	5	the	the	DET
gsrj-50	109	6	hr	hr	NOUN
gsrj-50	109	7	pathway	pathway	NOUN
gsrj-50	109	8	to	to	PART
gsrj-50	109	9	repair	repair	VERB
gsrj-50	109	10	any	any	DET
gsrj-50	109	11	dna	dna	NOUN
gsrj-50	109	12	defects	defect	NOUN
gsrj-50	109	13	even	even	ADV
gsrj-50	109	14	if	if	SCONJ
gsrj-50	109	15	the	the	DET
gsrj-50	109	16	parp1	parp1	NOUN
gsrj-50	109	17	enzymes	enzyme	NOUN
gsrj-50	109	18	are	be	AUX
gsrj-50	109	19	inhibited	inhibit	VERB
gsrj-50	109	20	by	by	ADP
gsrj-50	109	21	the	the	DET
gsrj-50	109	22	parp1	parp1	NOUN
gsrj-50	109	23	inhibitor	inhibitor	NOUN
gsrj-50	109	24	,	,	PUNCT
gsrj-50	109	25	so	so	SCONJ
gsrj-50	109	26	they	they	PRON
gsrj-50	109	27	would	would	AUX
gsrj-50	109	28	survive	survive	VERB
gsrj-50	109	29	.	.	PUNCT
gsrj-50	110	1	the	the	DET
gsrj-50	110	2	parp1	parp1	NOUN
gsrj-50	110	3	enzymes	enzyme	NOUN
gsrj-50	110	4	,	,	PUNCT
gsrj-50	110	5	as	as	SCONJ
gsrj-50	110	6	mentioned	mention	VERB
gsrj-50	110	7	before	before	ADV
gsrj-50	110	8	,	,	PUNCT
gsrj-50	110	9	are	be	AUX
gsrj-50	110	10	known	know	VERB
gsrj-50	110	11	for	for	ADP
gsrj-50	110	12	their	their	PRON
gsrj-50	110	13	action	action	NOUN
gsrj-50	110	14	in	in	ADP
gsrj-50	110	15	single	single	ADJ
gsrj-50	110	16	-	-	PUNCT
gsrj-50	110	17	strand	strand	NOUN
gsrj-50	110	18	break	break	NOUN
gsrj-50	110	19	repair	repair	NOUN
gsrj-50	110	20	(	(	PUNCT
gsrj-50	110	21	ssbr).18	ssbr).18	X
gsrj-50	110	22	the	the	DET
gsrj-50	110	23	inhibition	inhibition	NOUN
gsrj-50	110	24	of	of	ADP
gsrj-50	110	25	these	these	DET
gsrj-50	110	26	enzymes	enzyme	NOUN
gsrj-50	110	27	by	by	ADP
gsrj-50	110	28	the	the	DET
gsrj-50	110	29	parp	parp	ADJ
gsrj-50	110	30	inhibitor	inhibitor	NOUN
gsrj-50	110	31	can	can	AUX
gsrj-50	110	32	lead	lead	VERB
gsrj-50	110	33	to	to	ADP
gsrj-50	110	34	an	an	DET
gsrj-50	110	35	accumulation	accumulation	NOUN
gsrj-50	110	36	of	of	ADP
gsrj-50	110	37	dna	dna	PROPN
gsrj-50	110	38	damage	damage	NOUN
gsrj-50	110	39	in	in	ADP
gsrj-50	110	40	the	the	DET
gsrj-50	110	41	tumor	tumor	NOUN
gsrj-50	110	42	cell	cell	NOUN
gsrj-50	110	43	and	and	CCONJ
gsrj-50	110	44	induce	induce	VERB
gsrj-50	110	45	synthetic	synthetic	ADJ
gsrj-50	110	46	lethality.18	lethality.18	NOUN
gsrj-50	110	47	another	another	DET
gsrj-50	110	48	proposed	propose	VERB
gsrj-50	110	49	mechanism	mechanism	NOUN
gsrj-50	110	50	of	of	ADP
gsrj-50	110	51	action	action	NOUN
gsrj-50	110	52	of	of	ADP
gsrj-50	110	53	the	the	DET
gsrj-50	110	54	parp1	parp1	NOUN
gsrj-50	110	55	inhibitor	inhibitor	NOUN
gsrj-50	110	56	is	be	AUX
gsrj-50	110	57	known	know	VERB
gsrj-50	110	58	as	as	ADP
gsrj-50	110	59	parp1	parp1	NOUN
gsrj-50	110	60	trapping	trapping	NOUN
gsrj-50	110	61	and	and	CCONJ
gsrj-50	110	62	explains	explain	VERB
gsrj-50	110	63	why	why	SCONJ
gsrj-50	110	64	the	the	DET
gsrj-50	110	65	cytotoxic	cytotoxic	ADJ
gsrj-50	110	66	effects	effect	NOUN
gsrj-50	110	67	of	of	ADP
gsrj-50	110	68	parp1	parp1	NOUN
gsrj-50	110	69	inhibitors	inhibitor	NOUN
gsrj-50	110	70	are	be	AUX
gsrj-50	110	71	evidently	evidently	ADV
gsrj-50	110	72	greater	great	ADJ
gsrj-50	110	73	than	than	ADP
gsrj-50	110	74	not	not	PART
gsrj-50	110	75	having	have	VERB
gsrj-50	110	76	any	any	DET
gsrj-50	110	77	parp1	parp1	NOUN
gsrj-50	110	78	protein	protein	NOUN
gsrj-50	110	79	in	in	ADP
gsrj-50	110	80	the	the	DET
gsrj-50	110	81	cell	cell	NOUN
gsrj-50	110	82	.	.	PUNCT
gsrj-50	111	1	the	the	DET
gsrj-50	111	2	binding	binding	NOUN
gsrj-50	111	3	of	of	ADP
gsrj-50	111	4	the	the	DET
gsrj-50	111	5	parp1	parp1	NOUN
gsrj-50	111	6	inhibitors	inhibitor	NOUN
gsrj-50	111	7	to	to	ADP
gsrj-50	111	8	the	the	DET
gsrj-50	111	9	active	active	ADJ
gsrj-50	111	10	site	site	NOUN
gsrj-50	111	11	keeps	keep	VERB
gsrj-50	111	12	the	the	DET
gsrj-50	111	13	parp1	parp1	NOUN
gsrj-50	111	14	and	and	CCONJ
gsrj-50	111	15	parp2	parp2	PROPN
gsrj-50	111	16	enzymes	enzyme	NOUN
gsrj-50	111	17	trapped	trap	VERB
gsrj-50	111	18	on	on	ADP
gsrj-50	111	19	the	the	DET
gsrj-50	111	20	dna	dna	NOUN
gsrj-50	111	21	,	,	PUNCT
gsrj-50	111	22	preventing	prevent	VERB
gsrj-50	111	23	the	the	DET
gsrj-50	111	24	utilization	utilization	NOUN
gsrj-50	111	25	of	of	ADP
gsrj-50	111	26	nad+	nad+	PROPN
gsrj-50	111	27	and	and	CCONJ
gsrj-50	111	28	the	the	DET
gsrj-50	111	29	process	process	NOUN
gsrj-50	111	30	of	of	ADP
gsrj-50	111	31	parylation	parylation	NOUN
gsrj-50	111	32	,	,	PUNCT
gsrj-50	111	33	a	a	DET
gsrj-50	111	34	post	post	ADJ
gsrj-50	111	35	-	-	ADJ
gsrj-50	111	36	translational	translational	ADJ
gsrj-50	111	37	protein	protein	NOUN
gsrj-50	111	38	modification	modification	NOUN
gsrj-50	111	39	that	that	PRON
gsrj-50	111	40	recruits	recruit	VERB
gsrj-50	111	41	dna	dna	ADJ
gsrj-50	111	42	repair	repair	NOUN
gsrj-50	111	43	factors	factor	NOUN
gsrj-50	111	44	,	,	PUNCT
gsrj-50	111	45	as	as	SCONJ
gsrj-50	111	46	seen	see	VERB
gsrj-50	111	47	in	in	ADP
gsrj-50	111	48	figure	figure	NOUN
gsrj-50	111	49	10.17,19	10.17,19	NUM
gsrj-50	111	50	parp1	parp1	NOUN
gsrj-50	111	51	trapping	trap	VERB
gsrj-50	111	52	results	result	NOUN
gsrj-50	111	53	in	in	ADP
gsrj-50	111	54	dna	dna	PROPN
gsrj-50	111	55	lesions	lesion	NOUN
gsrj-50	111	56	,	,	PUNCT
gsrj-50	111	57	which	which	PRON
gsrj-50	111	58	leads	lead	VERB
gsrj-50	111	59	to	to	PART
gsrj-50	111	60	dsbs	dsbs	VERB
gsrj-50	111	61	and	and	CCONJ
gsrj-50	111	62	stalling	stalling	NOUN
gsrj-50	111	63	of	of	ADP
gsrj-50	111	64	replication	replication	NOUN
gsrj-50	111	65	forks	fork	NOUN
gsrj-50	111	66	,	,	PUNCT
gsrj-50	111	67	which	which	PRON
gsrj-50	111	68	can	can	AUX
gsrj-50	111	69	be	be	AUX
gsrj-50	111	70	lethal	lethal	ADJ
gsrj-50	111	71	in	in	ADP
gsrj-50	111	72	hr	hr	NOUN
gsrj-50	111	73	deficient	deficient	ADJ
gsrj-50	111	74	tumors	tumor	NOUN
gsrj-50	111	75	,	,	PUNCT
gsrj-50	111	76	such	such	ADJ
gsrj-50	111	77	as	as	ADP
gsrj-50	111	78	brca1	brca1	PROPN
gsrj-50	111	79	mutation	mutation	NOUN
gsrj-50	111	80	tumors.19	tumors.19	NOUN
gsrj-50	111	81	in	in	ADP
gsrj-50	111	82	addition	addition	NOUN
gsrj-50	111	83	to	to	ADP
gsrj-50	111	84	the	the	DET
gsrj-50	111	85	action	action	NOUN
gsrj-50	111	86	of	of	ADP
gsrj-50	111	87	parp1	parp1	NOUN
gsrj-50	111	88	in	in	ADP
gsrj-50	111	89	dna	dna	PROPN
gsrj-50	111	90	repair	repair	NOUN
gsrj-50	111	91	,	,	PUNCT
gsrj-50	111	92	the	the	DET
gsrj-50	111	93	enzyme	enzyme	NOUN
gsrj-50	111	94	is	be	AUX
gsrj-50	111	95	also	also	ADV
gsrj-50	111	96	involved	involve	VERB
gsrj-50	111	97	in	in	ADP
gsrj-50	111	98	the	the	DET
gsrj-50	111	99	transcription	transcription	NOUN
gsrj-50	111	100	of	of	ADP
gsrj-50	111	101	certain	certain	ADJ
gsrj-50	111	102	proteins	protein	NOUN
gsrj-50	111	103	through	through	ADP
gsrj-50	111	104	chromatin	chromatin	NOUN
gsrj-50	111	105	structure	structure	NOUN
gsrj-50	111	106	regulation	regulation	NOUN
gsrj-50	111	107	and	and	CCONJ
gsrj-50	111	108	histone	histone	NOUN
gsrj-50	111	109	parylation.20	parylation.20	NOUN
gsrj-50	111	110	parp1	parp1	NOUN
gsrj-50	111	111	is	be	AUX
gsrj-50	111	112	specifically	specifically	ADV
gsrj-50	111	113	involved	involve	VERB
gsrj-50	111	114	in	in	ADP
gsrj-50	111	115	the	the	DET
gsrj-50	111	116	transcription	transcription	NOUN
gsrj-50	111	117	of	of	ADP
gsrj-50	111	118	proteins	protein	NOUN
gsrj-50	111	119	involved	involve	VERB
gsrj-50	111	120	in	in	ADP
gsrj-50	111	121	cancer	cancer	NOUN
gsrj-50	111	122	development	development	NOUN
gsrj-50	111	123	,	,	PUNCT
gsrj-50	111	124	such	such	ADJ
gsrj-50	111	125	as	as	ADP
gsrj-50	111	126	p53	p53	NOUN
gsrj-50	111	127	and	and	CCONJ
gsrj-50	111	128	nf	nf	NOUN
gsrj-50	111	129	-	-	PUNCT
gsrj-50	111	130	κb.20	κb.20	NOUN
gsrj-50	111	131	the	the	DET
gsrj-50	111	132	inhibition	inhibition	NOUN
gsrj-50	111	133	of	of	ADP
gsrj-50	111	134	the	the	DET
gsrj-50	111	135	transcription	transcription	NOUN
gsrj-50	111	136	of	of	ADP
gsrj-50	111	137	certain	certain	ADJ
gsrj-50	111	138	oncogenes	oncogene	NOUN
gsrj-50	111	139	caused	cause	VERB
gsrj-50	111	140	by	by	ADP
gsrj-50	111	141	parp1	parp1	NOUN
gsrj-50	111	142	inhibitors	inhibitor	NOUN
gsrj-50	111	143	can	can	AUX
gsrj-50	111	144	prevent	prevent	VERB
gsrj-50	111	145	cell	cell	NOUN
gsrj-50	111	146	proliferation	proliferation	NOUN
gsrj-50	111	147	and	and	CCONJ
gsrj-50	111	148	lead	lead	VERB
gsrj-50	111	149	to	to	ADP
gsrj-50	111	150	cell	cell	NOUN
gsrj-50	111	151	apoptosis	apoptosis	NOUN
gsrj-50	111	152	.	.	PUNCT
gsrj-50	112	1	88	88	NUM
gsrj-50	112	2	..	..	SYM
gsrj-50	112	3	ppaarrpp11	ppaarrpp11	NOUN
gsrj-50	112	4	iinnhhiibbiittoorrss	iinnhhiibbiittoorrss	NOUN
gsrj-50	112	5	aanndd	aanndd	NOUN
gsrj-50	112	6	ssyynneerrggyy	ssyynneerrggyy	NOUN
gsrj-50	112	7	ccoommppoouunnddss	ccoommppoouunnddss	VERB
gsrj-50	112	8	the	the	DET
gsrj-50	112	9	current	current	ADJ
gsrj-50	112	10	generation	generation	NOUN
gsrj-50	112	11	of	of	ADP
gsrj-50	112	12	parp1	parp1	NOUN
gsrj-50	112	13	inhibitors	inhibitor	NOUN
gsrj-50	112	14	is	be	AUX
gsrj-50	112	15	the	the	DET
gsrj-50	112	16	third	third	ADJ
gsrj-50	112	17	one	one	NUM
gsrj-50	112	18	,	,	PUNCT
gsrj-50	112	19	and	and	CCONJ
gsrj-50	112	20	the	the	DET
gsrj-50	112	21	drugs	drug	NOUN
gsrj-50	112	22	being	be	AUX
gsrj-50	112	23	developed	develop	VERB
gsrj-50	112	24	are	be	AUX
gsrj-50	112	25	mainly	mainly	ADV
gsrj-50	112	26	those	those	PRON
gsrj-50	112	27	that	that	PRON
gsrj-50	112	28	restrict	restrict	VERB
gsrj-50	112	29	parp1	parp1	NOUN
gsrj-50	112	30	enzymes	enzyme	NOUN
gsrj-50	112	31	.	.	PUNCT
gsrj-50	113	1	this	this	DET
gsrj-50	113	2	generation	generation	NOUN
gsrj-50	113	3	of	of	ADP
gsrj-50	113	4	parp1	parp1	NOUN
gsrj-50	113	5	inhibitors	inhibitor	NOUN
gsrj-50	113	6	is	be	AUX
gsrj-50	113	7	considered	consider	VERB
gsrj-50	113	8	to	to	PART
gsrj-50	113	9	be	be	AUX
gsrj-50	113	10	more	more	ADV
gsrj-50	113	11	potent	potent	ADJ
gsrj-50	113	12	and	and	CCONJ
gsrj-50	113	13	more	more	ADV
gsrj-50	113	14	specific	specific	ADJ
gsrj-50	113	15	than	than	ADP
gsrj-50	113	16	those	those	PRON
gsrj-50	113	17	from	from	ADP
gsrj-50	113	18	previous	previous	ADJ
gsrj-50	113	19	generations	generation	NOUN
gsrj-50	113	20	.	.	PUNCT
gsrj-50	114	1	the	the	DET
gsrj-50	114	2	first	first	ADJ
gsrj-50	114	3	generation	generation	NOUN
gsrj-50	114	4	of	of	ADP
gsrj-50	114	5	parp1	parp1	NOUN
gsrj-50	114	6	inhibitors	inhibitor	NOUN
gsrj-50	114	7	were	be	AUX
gsrj-50	114	8	nicotinamide	nicotinamide	NOUN
gsrj-50	114	9	analogs	analog	NOUN
gsrj-50	114	10	,	,	PUNCT
gsrj-50	114	11	whose	whose	DET
gsrj-50	114	12	ability	ability	NOUN
gsrj-50	114	13	to	to	PART
gsrj-50	114	14	inhibit	inhibit	VERB
gsrj-50	114	15	parp1	parp1	NOUN
gsrj-50	114	16	was	be	AUX
gsrj-50	114	17	discovered	discover	VERB
gsrj-50	114	18	as	as	ADV
gsrj-50	114	19	early	early	ADV
gsrj-50	114	20	as	as	ADP
gsrj-50	114	21	1971.1	1971.1	NUM
gsrj-50	114	22	the	the	DET
gsrj-50	114	23	third	third	ADJ
gsrj-50	114	24	generation	generation	NOUN
gsrj-50	114	25	of	of	ADP
gsrj-50	114	26	these	these	DET
gsrj-50	114	27	inhibitors	inhibitor	NOUN
gsrj-50	114	28	,	,	PUNCT
gsrj-50	114	29	which	which	PRON
gsrj-50	114	30	is	be	AUX
gsrj-50	114	31	currently	currently	ADV
gsrj-50	114	32	under	under	ADP
gsrj-50	114	33	development	development	NOUN
gsrj-50	114	34	,	,	PUNCT
gsrj-50	114	35	have	have	AUX
gsrj-50	114	36	shown	show	VERB
gsrj-50	114	37	the	the	DET
gsrj-50	114	38	greatest	great	ADJ
gsrj-50	114	39	efficacy	efficacy	NOUN
gsrj-50	114	40	and	and	CCONJ
gsrj-50	114	41	fewest	few	ADJ
gsrj-50	114	42	offtarget	offtarget	NOUN
gsrj-50	114	43	effects	effect	NOUN
gsrj-50	114	44	to	to	ADP
gsrj-50	114	45	date	date	NOUN
gsrj-50	114	46	.	.	PUNCT
gsrj-50	115	1	1	1	NUM
gsrj-50	116	1	the	the	DET
gsrj-50	116	2	parp1	parp1	NOUN
gsrj-50	116	3	inhibitors	inhibitor	NOUN
gsrj-50	116	4	that	that	PRON
gsrj-50	116	5	are	be	AUX
gsrj-50	116	6	present	present	ADJ
gsrj-50	116	7	clinically	clinically	ADV
gsrj-50	116	8	today	today	NOUN
gsrj-50	116	9	vary	vary	VERB
gsrj-50	116	10	in	in	ADP
gsrj-50	116	11	their	their	PRON
gsrj-50	116	12	ability	ability	NOUN
gsrj-50	116	13	to	to	PART
gsrj-50	116	14	trap	trap	VERB
gsrj-50	116	15	the	the	DET
gsrj-50	116	16	parp	parp	ADJ
gsrj-50	116	17	enzymes	enzyme	NOUN
gsrj-50	116	18	.	.	PUNCT
gsrj-50	117	1	the	the	DET
gsrj-50	117	2	ability	ability	NOUN
gsrj-50	117	3	of	of	ADP
gsrj-50	117	4	the	the	DET
gsrj-50	117	5	parp	parp	ADJ
gsrj-50	117	6	inhibitors	inhibitor	NOUN
gsrj-50	117	7	to	to	PART
gsrj-50	117	8	trap	trap	VERB
gsrj-50	117	9	parp	parp	NOUN
gsrj-50	117	10	from	from	ADP
gsrj-50	117	11	most	most	ADJ
gsrj-50	117	12	to	to	ADP
gsrj-50	117	13	least	least	ADJ
gsrj-50	117	14	able	able	ADJ
gsrj-50	117	15	is	be	AUX
gsrj-50	117	16	talazoparib	talazoparib	PROPN
gsrj-50	117	17	,	,	PUNCT
gsrj-50	117	18	followed	follow	VERB
gsrj-50	117	19	by	by	ADP
gsrj-50	117	20	niraparib	niraparib	PROPN
gsrj-50	117	21	,	,	PUNCT
gsrj-50	117	22	followed	follow	VERB
gsrj-50	117	23	by	by	ADP
gsrj-50	117	24	olaparib	olaparib	NOUN
gsrj-50	117	25	and	and	CCONJ
gsrj-50	117	26	rucaparib	rucaparib	PROPN
gsrj-50	117	27	(	(	PUNCT
gsrj-50	117	28	which	which	PRON
gsrj-50	117	29	are	be	AUX
gsrj-50	117	30	roughly	roughly	ADV
gsrj-50	117	31	equal	equal	ADJ
gsrj-50	117	32	in	in	ADP
gsrj-50	117	33	ability	ability	NOUN
gsrj-50	117	34	)	)	PUNCT
gsrj-50	117	35	,	,	PUNCT
gsrj-50	117	36	followed	follow	VERB
gsrj-50	117	37	by	by	ADP
gsrj-50	117	38	veliparib	veliparib	NOUN
gsrj-50	117	39	which	which	PRON
gsrj-50	117	40	is	be	AUX
gsrj-50	117	41	the	the	DET
gsrj-50	117	42	least	least	ADV
gsrj-50	117	43	potent	potent	ADJ
gsrj-50	117	44	and	and	CCONJ
gsrj-50	117	45	is	be	AUX
gsrj-50	117	46	inactive	inactive	ADJ
gsrj-50	117	47	even	even	ADV
gsrj-50	117	48	at	at	ADP
gsrj-50	117	49	100	100	NUM
gsrj-50	117	50	µm.21	µm.21	NOUN
gsrj-50	117	51	this	this	DET
gsrj-50	117	52	difference	difference	NOUN
gsrj-50	117	53	in	in	ADP
gsrj-50	117	54	potency	potency	NOUN
gsrj-50	117	55	can	can	AUX
gsrj-50	117	56	be	be	AUX
gsrj-50	117	57	seen	see	VERB
gsrj-50	117	58	mainly	mainly	ADV
gsrj-50	117	59	due	due	ADP
gsrj-50	117	60	to	to	ADP
gsrj-50	117	61	the	the	DET
gsrj-50	117	62	differences	difference	NOUN
gsrj-50	117	63	in	in	ADP
gsrj-50	117	64	structure	structure	NOUN
gsrj-50	117	65	with	with	ADP
gsrj-50	117	66	veliparib	veliparib	PROPN
gsrj-50	117	67	being	be	AUX
gsrj-50	117	68	a	a	DET
gsrj-50	117	69	simpler	simple	ADJ
gsrj-50	117	70	molecule	molecule	NOUN
gsrj-50	117	71	with	with	ADP
gsrj-50	117	72	a	a	DET
gsrj-50	117	73	molecular	molecular	ADJ
gsrj-50	117	74	weight	weight	NOUN
gsrj-50	117	75	of	of	ADP
gsrj-50	117	76	244	244	NUM
gsrj-50	117	77	g	g	NOUN
gsrj-50	117	78	/	/	SYM
gsrj-50	117	79	mol	mol	NOUN
gsrj-50	117	80	,	,	PUNCT
gsrj-50	117	81	while	while	SCONJ
gsrj-50	117	82	talazoparib	talazoparib	PROPN
gsrj-50	117	83	is	be	AUX
gsrj-50	117	84	a	a	DET
gsrj-50	117	85	much	much	ADV
gsrj-50	117	86	more	more	ADV
gsrj-50	117	87	rigid	rigid	ADJ
gsrj-50	117	88	molecule	molecule	NOUN
gsrj-50	117	89	with	with	ADP
gsrj-50	117	90	two	two	NUM
gsrj-50	117	91	racemic	racemic	ADJ
gsrj-50	117	92	centers.21	centers.21	PROPN
gsrj-50	117	93	using	use	VERB
gsrj-50	117	94	parp1	parp1	NOUN
gsrj-50	117	95	inhibitors	inhibitor	NOUN
gsrj-50	117	96	in	in	ADP
gsrj-50	117	97	combination	combination	NOUN
gsrj-50	117	98	with	with	ADP
gsrj-50	117	99	other	other	ADJ
gsrj-50	117	100	therapies	therapy	NOUN
gsrj-50	117	101	is	be	AUX
gsrj-50	117	102	essential	essential	ADJ
gsrj-50	117	103	in	in	ADP
gsrj-50	117	104	lowering	lower	VERB
gsrj-50	117	105	the	the	DET
gsrj-50	117	106	dosage	dosage	NOUN
gsrj-50	117	107	of	of	ADP
gsrj-50	117	108	the	the	DET
gsrj-50	117	109	parp1	parp1	NOUN
gsrj-50	117	110	inhibitors	inhibitor	NOUN
gsrj-50	117	111	and	and	CCONJ
gsrj-50	117	112	increasing	increase	VERB
gsrj-50	117	113	the	the	DET
gsrj-50	117	114	effectiveness	effectiveness	NOUN
gsrj-50	117	115	of	of	ADP
gsrj-50	117	116	the	the	DET
gsrj-50	117	117	drugs	drug	NOUN
gsrj-50	117	118	.	.	PUNCT
gsrj-50	118	1	parp1	parp1	NOUN
gsrj-50	118	2	inhibitors	inhibitor	NOUN
gsrj-50	118	3	are	be	AUX
gsrj-50	118	4	often	often	ADV
gsrj-50	118	5	combined	combine	VERB
gsrj-50	118	6	in	in	ADP
gsrj-50	118	7	treatment	treatment	NOUN
gsrj-50	118	8	with	with	ADP
gsrj-50	118	9	alkylating	alkylate	VERB
gsrj-50	118	10	agents	agent	NOUN
gsrj-50	118	11	(	(	PUNCT
gsrj-50	118	12	cytotoxic	cytotoxic	ADJ
gsrj-50	118	13	chemotherapies).1	chemotherapies).1	NOUN
gsrj-50	118	14	the	the	DET
gsrj-50	118	15	alkylating	alkylate	VERB
gsrj-50	118	16	agents	agent	NOUN
gsrj-50	118	17	work	work	VERB
gsrj-50	118	18	by	by	ADP
gsrj-50	118	19	joining	join	VERB
gsrj-50	118	20	an	an	DET
gsrj-50	118	21	additional	additional	ADJ
gsrj-50	118	22	alkyl	alkyl	NOUN
gsrj-50	118	23	group	group	NOUN
gsrj-50	118	24	to	to	ADP
gsrj-50	118	25	dna	dna	PROPN
gsrj-50	118	26	,	,	PUNCT
gsrj-50	118	27	which	which	PRON
gsrj-50	118	28	results	result	VERB
gsrj-50	118	29	in	in	ADP
gsrj-50	118	30	dna	dna	PROPN
gsrj-50	118	31	damage	damage	NOUN
gsrj-50	118	32	.	.	PUNCT
gsrj-50	119	1	this	this	PRON
gsrj-50	119	2	prevents	prevent	VERB
gsrj-50	119	3	the	the	DET
gsrj-50	119	4	tumor	tumor	NOUN
gsrj-50	119	5	cells	cell	NOUN
gsrj-50	119	6	from	from	ADP
gsrj-50	119	7	replicating	replicate	VERB
gsrj-50	119	8	,	,	PUNCT
gsrj-50	119	9	resulting	result	VERB
gsrj-50	119	10	in	in	ADP
gsrj-50	119	11	cell	cell	NOUN
gsrj-50	119	12	death.1	death.1	PROPN
gsrj-50	119	13	however	however	ADV
gsrj-50	119	14	,	,	PUNCT
gsrj-50	119	15	these	these	DET
gsrj-50	119	16	chemotherapies	chemotherapy	NOUN
gsrj-50	119	17	have	have	VERB
gsrj-50	119	18	adverse	adverse	ADJ
gsrj-50	119	19	side	side	NOUN
gsrj-50	119	20	effects	effect	NOUN
gsrj-50	119	21	and	and	CCONJ
gsrj-50	119	22	can	can	AUX
gsrj-50	119	23	result	result	VERB
gsrj-50	119	24	in	in	ADP
gsrj-50	119	25	acquired	acquire	VERB
gsrj-50	119	26	13	13	NUM
gsrj-50	119	27	georgetown	georgetown	PROPN
gsrj-50	119	28	scientific	scientific	PROPN
gsrj-50	119	29	research	research	NOUN
gsrj-50	119	30	journal	journal	NOUN
gsrj-50	119	31	mutations	mutation	NOUN
gsrj-50	119	32	,	,	PUNCT
gsrj-50	119	33	causing	cause	VERB
gsrj-50	119	34	chemoresistance.1	chemoresistance.1	PRON
gsrj-50	119	35	this	this	PRON
gsrj-50	119	36	calls	call	VERB
gsrj-50	119	37	for	for	ADP
gsrj-50	119	38	a	a	DET
gsrj-50	119	39	combination	combination	NOUN
gsrj-50	119	40	of	of	ADP
gsrj-50	119	41	parp1	parp1	NOUN
gsrj-50	119	42	inhibitors	inhibitor	NOUN
gsrj-50	119	43	and	and	CCONJ
gsrj-50	119	44	chemotherapies	chemotherapy	NOUN
gsrj-50	119	45	.	.	PUNCT
gsrj-50	120	1	in	in	ADP
gsrj-50	120	2	the	the	DET
gsrj-50	120	3	phase	phase	NOUN
gsrj-50	120	4	iii	iii	PROPN
gsrj-50	120	5	velia	velia	PROPN
gsrj-50	120	6	trial	trial	NOUN
gsrj-50	120	7	,	,	PUNCT
gsrj-50	120	8	in	in	ADP
gsrj-50	120	9	which	which	PRON
gsrj-50	120	10	the	the	DET
gsrj-50	120	11	parp1	parp1	NOUN
gsrj-50	120	12	inhibitor	inhibitor	NOUN
gsrj-50	120	13	,	,	PUNCT
gsrj-50	120	14	veliparib	veliparib	NOUN
gsrj-50	120	15	,	,	PUNCT
gsrj-50	120	16	was	be	AUX
gsrj-50	120	17	used	use	VERB
gsrj-50	120	18	in	in	ADP
gsrj-50	120	19	combination	combination	NOUN
gsrj-50	120	20	with	with	ADP
gsrj-50	120	21	chemotherapy	chemotherapy	NOUN
gsrj-50	120	22	for	for	ADP
gsrj-50	120	23	the	the	DET
gsrj-50	120	24	treatment	treatment	NOUN
gsrj-50	120	25	of	of	ADP
gsrj-50	120	26	stage	stage	NOUN
gsrj-50	120	27	iii	iii	NOUN
gsrj-50	120	28	or	or	CCONJ
gsrj-50	120	29	iv	iv	NUM
gsrj-50	120	30	high	high	ADJ
gsrj-50	120	31	-	-	PUNCT
gsrj-50	120	32	grade	grade	NOUN
gsrj-50	120	33	serous	serous	ADJ
gsrj-50	120	34	ovarian	ovarian	ADJ
gsrj-50	120	35	cancer	cancer	NOUN
gsrj-50	120	36	,	,	PUNCT
gsrj-50	120	37	veliparib	veliparib	PROPN
gsrj-50	120	38	showed	show	VERB
gsrj-50	120	39	positive	positive	ADJ
gsrj-50	120	40	results	result	NOUN
gsrj-50	120	41	for	for	ADP
gsrj-50	120	42	progression	progression	NOUN
gsrj-50	120	43	free	free	ADJ
gsrj-50	120	44	survival	survival	NOUN
gsrj-50	120	45	(	(	PUNCT
gsrj-50	120	46	pfs).22	pfs).22	NOUN
gsrj-50	120	47	another	another	DET
gsrj-50	120	48	study	study	NOUN
gsrj-50	120	49	,	,	PUNCT
gsrj-50	120	50	the	the	DET
gsrj-50	120	51	phase	phase	NOUN
gsrj-50	120	52	iii	iii	NUM
gsrj-50	120	53	brocade3	brocade3	NOUN
gsrj-50	120	54	trial	trial	NOUN
gsrj-50	120	55	,	,	PUNCT
gsrj-50	120	56	showed	show	VERB
gsrj-50	120	57	that	that	SCONJ
gsrj-50	120	58	when	when	SCONJ
gsrj-50	120	59	veliparib	veliparib	PROPN
gsrj-50	120	60	was	be	AUX
gsrj-50	120	61	combined	combine	VERB
gsrj-50	120	62	with	with	ADP
gsrj-50	120	63	carboplatin	carboplatin	NOUN
gsrj-50	120	64	and	and	CCONJ
gsrj-50	120	65	placitaxel	placitaxel	PROPN
gsrj-50	120	66	(	(	PUNCT
gsrj-50	120	67	chemotherapy	chemotherapy	NOUN
gsrj-50	120	68	drugs	drug	NOUN
gsrj-50	120	69	)	)	PUNCT
gsrj-50	120	70	to	to	PART
gsrj-50	120	71	treat	treat	VERB
gsrj-50	120	72	her2	her2	PROPN
gsrj-50	120	73	-	-	PUNCT
gsrj-50	120	74	negative	negative	ADJ
gsrj-50	120	75	and	and	CCONJ
gsrj-50	120	76	brca	brca	PROPN
gsrj-50	120	77	-	-	PUNCT
gsrj-50	120	78	mutated	mutate	VERB
gsrj-50	120	79	breast	breast	NOUN
gsrj-50	120	80	cancer	cancer	NOUN
gsrj-50	120	81	,	,	PUNCT
gsrj-50	120	82	it	it	PRON
gsrj-50	120	83	resulted	result	VERB
gsrj-50	120	84	in	in	ADP
gsrj-50	120	85	34	34	NUM
gsrj-50	120	86	%	%	NOUN
gsrj-50	120	87	of	of	ADP
gsrj-50	120	88	patients	patient	NOUN
gsrj-50	120	89	not	not	PART
gsrj-50	120	90	seeing	see	VERB
gsrj-50	120	91	tumor	tumor	NOUN
gsrj-50	120	92	progression	progression	NOUN
gsrj-50	120	93	at	at	ADP
gsrj-50	120	94	24	24	NUM
gsrj-50	120	95	months	month	NOUN
gsrj-50	120	96	compared	compare	VERB
gsrj-50	120	97	to	to	ADP
gsrj-50	120	98	20	20	NUM
gsrj-50	120	99	%	%	NOUN
gsrj-50	120	100	of	of	ADP
gsrj-50	120	101	patients	patient	NOUN
gsrj-50	120	102	that	that	PRON
gsrj-50	120	103	took	take	VERB
gsrj-50	120	104	carboplatin	carboplatin	NOUN
gsrj-50	120	105	and	and	CCONJ
gsrj-50	120	106	placitaxel	placitaxel	VERB
gsrj-50	120	107	only.22	only.22	VERB
gsrj-50	120	108	another	another	DET
gsrj-50	120	109	alkylating	alkylate	VERB
gsrj-50	120	110	agent	agent	NOUN
gsrj-50	120	111	,	,	PUNCT
gsrj-50	120	112	temozolomide	temozolomide	NOUN
gsrj-50	120	113	,	,	PUNCT
gsrj-50	120	114	works	work	VERB
gsrj-50	120	115	by	by	ADP
gsrj-50	120	116	adding	add	VERB
gsrj-50	120	117	methyl	methyl	NOUN
gsrj-50	120	118	groups	group	NOUN
gsrj-50	120	119	to	to	ADP
gsrj-50	120	120	specific	specific	ADJ
gsrj-50	120	121	sites	site	NOUN
gsrj-50	120	122	on	on	ADP
gsrj-50	120	123	the	the	DET
gsrj-50	120	124	dna	dna	PROPN
gsrj-50	120	125	molecule	molecule	NOUN
gsrj-50	120	126	,	,	PUNCT
gsrj-50	120	127	which	which	PRON
gsrj-50	120	128	leads	lead	VERB
gsrj-50	120	129	to	to	ADP
gsrj-50	120	130	single	single	ADJ
gsrj-50	120	131	-	-	PUNCT
gsrj-50	120	132	strand	strand	NOUN
gsrj-50	120	133	breaks	break	NOUN
gsrj-50	120	134	(	(	PUNCT
gsrj-50	120	135	ssbs).23	ssbs).23	VERB
gsrj-50	120	136	these	these	DET
gsrj-50	120	137	ssbs	ssbs	NOUN
gsrj-50	120	138	then	then	ADV
gsrj-50	120	139	require	require	VERB
gsrj-50	120	140	the	the	DET
gsrj-50	120	141	parp1	parp1	NOUN
gsrj-50	120	142	enzymes	enzyme	NOUN
gsrj-50	120	143	to	to	PART
gsrj-50	120	144	repair	repair	VERB
gsrj-50	120	145	the	the	DET
gsrj-50	120	146	damage	damage	NOUN
gsrj-50	120	147	to	to	ADP
gsrj-50	120	148	the	the	DET
gsrj-50	120	149	dna	dna	NOUN
gsrj-50	120	150	,	,	PUNCT
gsrj-50	120	151	but	but	CCONJ
gsrj-50	120	152	parp1	parp1	NOUN
gsrj-50	120	153	inhibitors	inhibitor	NOUN
gsrj-50	120	154	would	would	AUX
gsrj-50	120	155	trap	trap	VERB
gsrj-50	120	156	the	the	DET
gsrj-50	120	157	parp1	parp1	NOUN
gsrj-50	120	158	in	in	ADP
gsrj-50	120	159	its	its	PRON
gsrj-50	120	160	presence.23	presence.23	NOUN
gsrj-50	120	161	preclinical	preclinical	ADJ
gsrj-50	120	162	studies	study	NOUN
gsrj-50	120	163	have	have	AUX
gsrj-50	120	164	suggested	suggest	VERB
gsrj-50	120	165	that	that	SCONJ
gsrj-50	120	166	talazoparib	talazoparib	PROPN
gsrj-50	120	167	and	and	CCONJ
gsrj-50	120	168	olaparib	olaparib	NOUN
gsrj-50	120	169	in	in	ADP
gsrj-50	120	170	combination	combination	NOUN
gsrj-50	120	171	with	with	ADP
gsrj-50	120	172	temozolomide	temozolomide	NOUN
gsrj-50	120	173	has	have	VERB
gsrj-50	120	174	a	a	DET
gsrj-50	120	175	positive	positive	ADJ
gsrj-50	120	176	synergistic	synergistic	ADJ
gsrj-50	120	177	effect.23	effect.23	NOUN
gsrj-50	120	178	parp1	parp1	NOUN
gsrj-50	120	179	inhibitors	inhibitor	NOUN
gsrj-50	120	180	and	and	CCONJ
gsrj-50	120	181	radiation	radiation	NOUN
gsrj-50	120	182	therapies	therapy	NOUN
gsrj-50	120	183	are	be	AUX
gsrj-50	120	184	also	also	ADV
gsrj-50	120	185	beginning	begin	VERB
gsrj-50	120	186	to	to	PART
gsrj-50	120	187	be	be	AUX
gsrj-50	120	188	used	use	VERB
gsrj-50	120	189	in	in	ADP
gsrj-50	120	190	combination	combination	NOUN
gsrj-50	120	191	to	to	PART
gsrj-50	120	192	improve	improve	VERB
gsrj-50	120	193	efficacy	efficacy	NOUN
gsrj-50	120	194	.	.	PUNCT
gsrj-50	121	1	researchers	researcher	NOUN
gsrj-50	121	2	believe	believe	VERB
gsrj-50	121	3	that	that	SCONJ
gsrj-50	121	4	parp1	parp1	NOUN
gsrj-50	121	5	inhibitors	inhibitor	NOUN
gsrj-50	121	6	prevent	prevent	VERB
gsrj-50	121	7	single	single	ADJ
gsrj-50	121	8	-	-	PUNCT
gsrj-50	121	9	strand	strand	NOUN
gsrj-50	121	10	breaks	break	NOUN
gsrj-50	121	11	caused	cause	VERB
gsrj-50	121	12	by	by	ADP
gsrj-50	121	13	radiation	radiation	NOUN
gsrj-50	121	14	to	to	PART
gsrj-50	121	15	be	be	AUX
gsrj-50	121	16	repaired.1	repaired.1	NOUN
gsrj-50	121	17	this	this	PRON
gsrj-50	121	18	leads	lead	VERB
gsrj-50	121	19	to	to	ADP
gsrj-50	121	20	replication	replication	NOUN
gsrj-50	121	21	fork	fork	NOUN
gsrj-50	121	22	collapse	collapse	NOUN
gsrj-50	121	23	and	and	CCONJ
gsrj-50	121	24	double	double	ADJ
gsrj-50	121	25	-	-	PUNCT
gsrj-50	121	26	strand	strand	NOUN
gsrj-50	121	27	breaks	break	NOUN
gsrj-50	121	28	,	,	PUNCT
gsrj-50	121	29	which	which	PRON
gsrj-50	121	30	damages	damage	VERB
gsrj-50	121	31	the	the	DET
gsrj-50	121	32	dna	dna	NOUN
gsrj-50	121	33	completely.1	completely.1	NOUN
gsrj-50	121	34	however	however	ADV
gsrj-50	121	35	,	,	PUNCT
gsrj-50	121	36	no	no	DET
gsrj-50	121	37	clinical	clinical	ADJ
gsrj-50	121	38	trials	trial	NOUN
gsrj-50	121	39	yet	yet	ADV
gsrj-50	121	40	have	have	AUX
gsrj-50	121	41	proven	prove	VERB
gsrj-50	121	42	the	the	DET
gsrj-50	121	43	effectiveness	effectiveness	NOUN
gsrj-50	121	44	of	of	ADP
gsrj-50	121	45	the	the	DET
gsrj-50	121	46	parp1	parp1	NOUN
gsrj-50	121	47	inhibitor	inhibitor	NOUN
gsrj-50	121	48	in	in	ADP
gsrj-50	121	49	sensitizing	sensitize	VERB
gsrj-50	121	50	tumor	tumor	NOUN
gsrj-50	121	51	cells	cell	NOUN
gsrj-50	121	52	to	to	ADP
gsrj-50	121	53	radiation	radiation	NOUN
gsrj-50	121	54	.	.	PUNCT
gsrj-50	122	1	phosphoinositide	phosphoinositide	NOUN
gsrj-50	122	2	3	3	NUM
gsrj-50	122	3	-	-	PUNCT
gsrj-50	122	4	kinases	kinase	NOUN
gsrj-50	122	5	(	(	PUNCT
gsrj-50	122	6	pi3k	pi3k	NOUN
gsrj-50	122	7	)	)	PUNCT
gsrj-50	122	8	inhibitors	inhibitor	NOUN
gsrj-50	122	9	,	,	PUNCT
gsrj-50	122	10	which	which	PRON
gsrj-50	122	11	inhibit	inhibit	VERB
gsrj-50	122	12	a	a	DET
gsrj-50	122	13	group	group	NOUN
gsrj-50	122	14	of	of	ADP
gsrj-50	122	15	enzymes	enzyme	NOUN
gsrj-50	122	16	that	that	PRON
gsrj-50	122	17	are	be	AUX
gsrj-50	122	18	involved	involve	VERB
gsrj-50	122	19	in	in	ADP
gsrj-50	122	20	tumor	tumor	NOUN
gsrj-50	122	21	proliferation	proliferation	NOUN
gsrj-50	122	22	and	and	CCONJ
gsrj-50	122	23	growth	growth	NOUN
gsrj-50	122	24	,	,	PUNCT
gsrj-50	122	25	are	be	AUX
gsrj-50	122	26	also	also	ADV
gsrj-50	122	27	said	say	VERB
gsrj-50	122	28	to	to	PART
gsrj-50	122	29	be	be	AUX
gsrj-50	122	30	more	more	ADV
gsrj-50	122	31	effective	effective	ADJ
gsrj-50	122	32	in	in	ADP
gsrj-50	122	33	combination	combination	NOUN
gsrj-50	122	34	with	with	ADP
gsrj-50	122	35	the	the	DET
gsrj-50	122	36	parp	parp	ADJ
gsrj-50	122	37	inhibitors.1	inhibitors.1	NOUN
gsrj-50	122	38	the	the	DET
gsrj-50	122	39	combination	combination	NOUN
gsrj-50	122	40	of	of	ADP
gsrj-50	122	41	the	the	DET
gsrj-50	122	42	pi3k	pi3k	PROPN
gsrj-50	122	43	inhibitor	inhibitor	NOUN
gsrj-50	122	44	,	,	PUNCT
gsrj-50	122	45	buparlisib	buparlisib	NOUN
gsrj-50	122	46	,	,	PUNCT
gsrj-50	122	47	and	and	CCONJ
gsrj-50	122	48	parp	parp	ADJ
gsrj-50	122	49	inhibitor	inhibitor	NOUN
gsrj-50	122	50	,	,	PUNCT
gsrj-50	122	51	olaparib	olaparib	NOUN
gsrj-50	122	52	,	,	PUNCT
gsrj-50	122	53	to	to	PART
gsrj-50	122	54	treat	treat	VERB
gsrj-50	122	55	cellular	cellular	ADJ
gsrj-50	122	56	ovarian	ovarian	ADJ
gsrj-50	122	57	cancer	cancer	NOUN
gsrj-50	122	58	showed	show	VERB
gsrj-50	122	59	significant	significant	ADJ
gsrj-50	122	60	inhibition	inhibition	NOUN
gsrj-50	122	61	of	of	ADP
gsrj-50	122	62	tumor	tumor	NOUN
gsrj-50	122	63	progression	progression	NOUN
gsrj-50	122	64	and	and	CCONJ
gsrj-50	122	65	disease	disease	NOUN
gsrj-50	122	66	proliferation.24	proliferation.24	PROPN
gsrj-50	122	67	wee1	wee1	PROPN
gsrj-50	122	68	kinase	kinase	PROPN
gsrj-50	122	69	inhibitor	inhibitor	PROPN
gsrj-50	122	70	,	,	PUNCT
gsrj-50	122	71	which	which	PRON
gsrj-50	122	72	inhibits	inhibit	VERB
gsrj-50	122	73	wee1	wee1	NOUN
gsrj-50	122	74	kinases	kinase	NOUN
gsrj-50	122	75	that	that	PRON
gsrj-50	122	76	regulate	regulate	VERB
gsrj-50	122	77	the	the	DET
gsrj-50	122	78	g2	g2	PROPN
gsrj-50	122	79	-	-	PUNCT
gsrj-50	122	80	m	m	PROPN
gsrj-50	122	81	cell	cell	NOUN
gsrj-50	122	82	cycle	cycle	NOUN
gsrj-50	122	83	checkpoint	checkpoint	NOUN
gsrj-50	122	84	,	,	PUNCT
gsrj-50	122	85	is	be	AUX
gsrj-50	122	86	another	another	DET
gsrj-50	122	87	potential	potential	ADJ
gsrj-50	122	88	drug	drug	NOUN
gsrj-50	122	89	to	to	PART
gsrj-50	122	90	be	be	AUX
gsrj-50	122	91	used	use	VERB
gsrj-50	122	92	in	in	ADP
gsrj-50	122	93	combination	combination	NOUN
gsrj-50	122	94	with	with	ADP
gsrj-50	122	95	parp	parp	ADJ
gsrj-50	122	96	inhibitors.1	inhibitors.1	PROPN
gsrj-50	122	97	wee1	wee1	PROPN
gsrj-50	122	98	kinase	kinase	PROPN
gsrj-50	122	99	is	be	AUX
gsrj-50	122	100	an	an	DET
gsrj-50	122	101	enzyme	enzyme	NOUN
gsrj-50	122	102	that	that	PRON
gsrj-50	122	103	,	,	PUNCT
gsrj-50	122	104	when	when	SCONJ
gsrj-50	122	105	inhibited	inhibited	ADJ
gsrj-50	122	106	,	,	PUNCT
gsrj-50	122	107	results	result	NOUN
gsrj-50	122	108	in	in	ADP
gsrj-50	122	109	large	large	ADJ
gsrj-50	122	110	magnitudes	magnitude	NOUN
gsrj-50	122	111	of	of	ADP
gsrj-50	122	112	genomic	genomic	ADJ
gsrj-50	122	113	instability	instability	NOUN
gsrj-50	122	114	and	and	CCONJ
gsrj-50	122	115	eventual	eventual	ADJ
gsrj-50	122	116	cell	cell	NOUN
gsrj-50	122	117	death.1	death.1	PROPN
gsrj-50	122	118	some	some	DET
gsrj-50	122	119	studies	study	NOUN
gsrj-50	122	120	have	have	AUX
gsrj-50	122	121	even	even	ADV
gsrj-50	122	122	shown	show	VERB
gsrj-50	122	123	that	that	SCONJ
gsrj-50	122	124	a	a	DET
gsrj-50	122	125	combination	combination	NOUN
gsrj-50	122	126	of	of	ADP
gsrj-50	122	127	wee1	wee1	NOUN
gsrj-50	122	128	inhibitor	inhibitor	NOUN
gsrj-50	122	129	and	and	CCONJ
gsrj-50	122	130	parp1	parp1	NOUN
gsrj-50	122	131	inhibitor	inhibitor	NOUN
gsrj-50	122	132	reduces	reduce	VERB
gsrj-50	122	133	off	off	ADP
gsrj-50	122	134	-	-	PUNCT
gsrj-50	122	135	target	target	NOUN
gsrj-50	122	136	toxicity	toxicity	NOUN
gsrj-50	122	137	and	and	CCONJ
gsrj-50	122	138	increases	increase	VERB
gsrj-50	122	139	the	the	DET
gsrj-50	122	140	tumor	tumor	NOUN
gsrj-50	122	141	cell	cell	NOUN
gsrj-50	122	142	’s	’s	PART
gsrj-50	122	143	sensitivity	sensitivity	NOUN
gsrj-50	122	144	to	to	ADP
gsrj-50	122	145	radiation.1	radiation.1	PROPN
gsrj-50	122	146	however	however	ADV
gsrj-50	122	147	,	,	PUNCT
gsrj-50	122	148	there	there	PRON
gsrj-50	122	149	has	have	AUX
gsrj-50	122	150	also	also	ADV
gsrj-50	122	151	been	be	AUX
gsrj-50	122	152	some	some	DET
gsrj-50	122	153	resistance	resistance	NOUN
gsrj-50	122	154	recorded	record	VERB
gsrj-50	122	155	to	to	ADP
gsrj-50	122	156	parp1	parp1	VERB
gsrj-50	122	157	inhibitors	inhibitor	NOUN
gsrj-50	122	158	.	.	PUNCT
gsrj-50	123	1	brca1	brca1	NOUN
gsrj-50	123	2	deficiency	deficiency	NOUN
gsrj-50	123	3	in	in	ADP
gsrj-50	123	4	tumor	tumor	NOUN
gsrj-50	123	5	cells	cell	NOUN
gsrj-50	123	6	can	can	AUX
gsrj-50	123	7	be	be	AUX
gsrj-50	123	8	reversed	reverse	VERB
gsrj-50	123	9	through	through	ADP
gsrj-50	123	10	crossovers	crossover	NOUN
gsrj-50	123	11	or	or	CCONJ
gsrj-50	123	12	mutations	mutation	NOUN
gsrj-50	123	13	to	to	PART
gsrj-50	123	14	form	form	VERB
gsrj-50	123	15	the	the	DET
gsrj-50	123	16	wild	wild	ADJ
gsrj-50	123	17	-	-	PUNCT
gsrj-50	123	18	type	type	NOUN
gsrj-50	123	19	brca	brca	PROPN
gsrj-50	123	20	proteins.25	proteins.25	NOUN
gsrj-50	123	21	this	this	PRON
gsrj-50	123	22	means	mean	VERB
gsrj-50	123	23	that	that	SCONJ
gsrj-50	123	24	the	the	DET
gsrj-50	123	25	hr	hr	NOUN
gsrj-50	123	26	pathway	pathway	NOUN
gsrj-50	123	27	is	be	AUX
gsrj-50	123	28	not	not	PART
gsrj-50	123	29	defective	defective	ADJ
gsrj-50	123	30	anymore	anymore	ADV
gsrj-50	123	31	,	,	PUNCT
gsrj-50	123	32	and	and	CCONJ
gsrj-50	123	33	thus	thus	ADV
gsrj-50	123	34	there	there	PRON
gsrj-50	123	35	is	be	VERB
gsrj-50	123	36	no	no	DET
gsrj-50	123	37	synthetic	synthetic	ADJ
gsrj-50	123	38	lethality	lethality	NOUN
gsrj-50	123	39	in	in	ADP
gsrj-50	123	40	the	the	DET
gsrj-50	123	41	cancer	cancer	NOUN
gsrj-50	123	42	cells	cell	NOUN
gsrj-50	123	43	in	in	ADP
gsrj-50	123	44	the	the	DET
gsrj-50	123	45	presence	presence	NOUN
gsrj-50	123	46	of	of	ADP
gsrj-50	123	47	parp1	parp1	NOUN
gsrj-50	123	48	inhibitors	inhibitor	NOUN
gsrj-50	123	49	.	.	PUNCT
gsrj-50	124	1	another	another	DET
gsrj-50	124	2	mechanism	mechanism	NOUN
gsrj-50	124	3	of	of	ADP
gsrj-50	124	4	parp1	parp1	NOUN
gsrj-50	124	5	resistance	resistance	NOUN
gsrj-50	124	6	is	be	AUX
gsrj-50	124	7	the	the	DET
gsrj-50	124	8	upregulation	upregulation	NOUN
gsrj-50	124	9	of	of	ADP
gsrj-50	124	10	pglycoprotein	pglycoprotein	ADJ
gsrj-50	124	11	efflux	efflux	NOUN
gsrj-50	124	12	pump	pump	NOUN
gsrj-50	124	13	,	,	PUNCT
gsrj-50	124	14	which	which	PRON
gsrj-50	124	15	pumps	pump	VERB
gsrj-50	124	16	foreign	foreign	ADJ
gsrj-50	124	17	molecules	molecule	NOUN
gsrj-50	124	18	out	out	ADP
gsrj-50	124	19	of	of	ADP
gsrj-50	124	20	the	the	DET
gsrj-50	124	21	cell.25	cell.25	NOUN
gsrj-50	124	22	this	this	PRON
gsrj-50	124	23	reduces	reduce	VERB
gsrj-50	124	24	the	the	DET
gsrj-50	124	25	concentration	concentration	NOUN
gsrj-50	124	26	of	of	ADP
gsrj-50	124	27	parp1	parp1	NOUN
gsrj-50	124	28	inhibitors	inhibitor	NOUN
gsrj-50	124	29	present	present	ADJ
gsrj-50	124	30	inside	inside	ADP
gsrj-50	124	31	the	the	DET
gsrj-50	124	32	cancer	cancer	NOUN
gsrj-50	124	33	cell	cell	NOUN
gsrj-50	124	34	,	,	PUNCT
gsrj-50	124	35	thereby	thereby	ADV
gsrj-50	124	36	increasing	increase	VERB
gsrj-50	124	37	resistance	resistance	NOUN
gsrj-50	124	38	.	.	PUNCT
gsrj-50	125	1	iniparib	iniparib	PROPN
gsrj-50	125	2	or	or	CCONJ
gsrj-50	125	3	bsi	bsi	PROPN
gsrj-50	125	4	201	201	NUM
gsrj-50	125	5	by	by	ADP
gsrj-50	125	6	sanofi	sanofi	PROPN
gsrj-50	125	7	-	-	PUNCT
gsrj-50	125	8	aventis	aventis	PROPN
gsrj-50	125	9	is	be	AUX
gsrj-50	125	10	another	another	DET
gsrj-50	125	11	drug	drug	NOUN
gsrj-50	125	12	that	that	PRON
gsrj-50	125	13	has	have	AUX
gsrj-50	125	14	gained	gain	VERB
gsrj-50	125	15	some	some	DET
gsrj-50	125	16	momentum	momentum	NOUN
gsrj-50	125	17	from	from	ADP
gsrj-50	125	18	its	its	PRON
gsrj-50	125	19	clinical	clinical	ADJ
gsrj-50	125	20	data	datum	NOUN
gsrj-50	125	21	.	.	PUNCT
gsrj-50	126	1	it	it	PRON
gsrj-50	126	2	is	be	AUX
gsrj-50	126	3	a	a	DET
gsrj-50	126	4	drug	drug	NOUN
gsrj-50	126	5	that	that	PRON
gsrj-50	126	6	has	have	VERB
gsrj-50	126	7	a	a	DET
gsrj-50	126	8	halflife	halflife	NOUN
gsrj-50	126	9	of	of	ADP
gsrj-50	126	10	4	4	NUM
gsrj-50	126	11	minutes	minute	NOUN
gsrj-50	126	12	,	,	PUNCT
gsrj-50	126	13	after	after	ADP
gsrj-50	126	14	which	which	PRON
gsrj-50	126	15	it	it	PRON
gsrj-50	126	16	breaks	break	VERB
gsrj-50	126	17	down	down	ADP
gsrj-50	126	18	into	into	ADP
gsrj-50	126	19	an	an	DET
gsrj-50	126	20	active	active	ADJ
gsrj-50	126	21	metabolite.26	metabolite.26	NOUN
gsrj-50	126	22	in	in	ADP
gsrj-50	126	23	a	a	DET
gsrj-50	126	24	phase	phase	NOUN
gsrj-50	126	25	i	i	PRON
gsrj-50	126	26	trial	trial	NOUN
gsrj-50	126	27	,	,	PUNCT
gsrj-50	126	28	where	where	SCONJ
gsrj-50	126	29	bsi	bsi	PROPN
gsrj-50	126	30	201	201	NUM
gsrj-50	126	31	was	be	AUX
gsrj-50	126	32	administered	administer	VERB
gsrj-50	126	33	as	as	ADP
gsrj-50	126	34	a	a	DET
gsrj-50	126	35	single	single	ADJ
gsrj-50	126	36	agent	agent	NOUN
gsrj-50	126	37	to	to	ADP
gsrj-50	126	38	solid	solid	ADJ
gsrj-50	126	39	tumors	tumor	NOUN
gsrj-50	126	40	,	,	PUNCT
gsrj-50	126	41	the	the	DET
gsrj-50	126	42	2.8	2.8	NUM
gsrj-50	126	43	mg	mg	PROPN
gsrj-50	126	44	/	/	SYM
gsrj-50	126	45	kg	kg	PROPN
gsrj-50	126	46	dose	dose	NOUN
gsrj-50	126	47	showed	show	VERB
gsrj-50	126	48	approximately	approximately	ADV
gsrj-50	126	49	50	50	NUM
gsrj-50	126	50	%	%	NOUN
gsrj-50	126	51	parp1	parp1	NOUN
gsrj-50	126	52	inhibition	inhibition	NOUN
gsrj-50	126	53	,	,	PUNCT
gsrj-50	126	54	and	and	CCONJ
gsrj-50	126	55	further	further	ADJ
gsrj-50	126	56	doses	dose	NOUN
gsrj-50	126	57	increased	increase	VERB
gsrj-50	126	58	the	the	DET
gsrj-50	126	59	inhibition	inhibition	NOUN
gsrj-50	126	60	to	to	ADP
gsrj-50	126	61	around	around	ADP
gsrj-50	126	62	80%.26	80%.26	NUM
gsrj-50	126	63	in	in	ADP
gsrj-50	126	64	addition	addition	NOUN
gsrj-50	126	65	,	,	PUNCT
gsrj-50	126	66	there	there	PRON
gsrj-50	126	67	were	be	VERB
gsrj-50	126	68	no	no	DET
gsrj-50	126	69	serious	serious	ADJ
gsrj-50	126	70	side	side	NOUN
gsrj-50	126	71	effects	effect	NOUN
gsrj-50	126	72	observed	observe	VERB
gsrj-50	126	73	and	and	CCONJ
gsrj-50	126	74	stable	stable	ADJ
gsrj-50	126	75	disease	disease	NOUN
gsrj-50	126	76	(	(	PUNCT
gsrj-50	126	77	sd	sd	NOUN
gsrj-50	126	78	)	)	PUNCT
gsrj-50	126	79	was	be	AUX
gsrj-50	126	80	seen	see	VERB
gsrj-50	126	81	in	in	ADP
gsrj-50	126	82	6	6	NUM
gsrj-50	126	83	out	out	ADP
gsrj-50	126	84	of	of	ADP
gsrj-50	126	85	23	23	NUM
gsrj-50	126	86	patients.26	patients.26	NOUN
gsrj-50	126	87	in	in	ADP
gsrj-50	126	88	another	another	DET
gsrj-50	126	89	phase	phase	NOUN
gsrj-50	126	90	i	i	PRON
gsrj-50	126	91	trial	trial	NOUN
gsrj-50	126	92	,	,	PUNCT
gsrj-50	126	93	where	where	SCONJ
gsrj-50	126	94	bsi	bsi	PROPN
gsrj-50	126	95	201	201	NUM
gsrj-50	126	96	was	be	AUX
gsrj-50	126	97	combined	combine	VERB
gsrj-50	126	98	with	with	ADP
gsrj-50	126	99	taxol	taxol	PROPN
gsrj-50	126	100	and	and	CCONJ
gsrj-50	126	101	administered	administer	VERB
gsrj-50	126	102	,	,	PUNCT
gsrj-50	126	103	positive	positive	ADJ
gsrj-50	126	104	results	result	NOUN
gsrj-50	126	105	were	be	AUX
gsrj-50	126	106	seen.26	seen.26	ADJ
gsrj-50	126	107	one	one	NUM
gsrj-50	126	108	patient	patient	NOUN
gsrj-50	126	109	of	of	ADP
gsrj-50	126	110	ovarian	ovarian	ADJ
gsrj-50	126	111	cancer	cancer	NOUN
gsrj-50	126	112	showed	show	VERB
gsrj-50	126	113	complete	complete	ADJ
gsrj-50	126	114	response	response	NOUN
gsrj-50	126	115	(	(	PUNCT
gsrj-50	126	116	cr	cr	NOUN
gsrj-50	126	117	)	)	PUNCT
gsrj-50	126	118	for	for	ADP
gsrj-50	126	119	six	six	NUM
gsrj-50	126	120	months	month	NOUN
gsrj-50	126	121	,	,	PUNCT
gsrj-50	126	122	and	and	CCONJ
gsrj-50	126	123	partial	partial	ADJ
gsrj-50	126	124	response	response	NOUN
gsrj-50	126	125	(	(	PUNCT
gsrj-50	126	126	pr	pr	NOUN
gsrj-50	126	127	)	)	PUNCT
gsrj-50	126	128	was	be	AUX
gsrj-50	126	129	seen	see	VERB
gsrj-50	126	130	in	in	ADP
gsrj-50	126	131	five	five	NUM
gsrj-50	126	132	patients	patient	NOUN
gsrj-50	126	133	with	with	ADP
gsrj-50	126	134	renal	renal	ADJ
gsrj-50	126	135	cancer	cancer	NOUN
gsrj-50	126	136	,	,	PUNCT
gsrj-50	126	137	uterine	uterine	ADJ
gsrj-50	126	138	cancer	cancer	NOUN
gsrj-50	126	139	,	,	PUNCT
gsrj-50	126	140	breast	breast	NOUN
gsrj-50	126	141	cancer	cancer	NOUN
gsrj-50	126	142	,	,	PUNCT
gsrj-50	126	143	or	or	CCONJ
gsrj-50	126	144	sarcoma.26	sarcoma.26	VERB
gsrj-50	126	145	another	another	DET
gsrj-50	126	146	phase	phase	NOUN
gsrj-50	126	147	ii	ii	NOUN
gsrj-50	126	148	combination	combination	NOUN
gsrj-50	126	149	clinical	clinical	ADJ
gsrj-50	126	150	trial	trial	NOUN
gsrj-50	126	151	was	be	AUX
gsrj-50	126	152	conducted	conduct	VERB
gsrj-50	126	153	where	where	SCONJ
gsrj-50	126	154	116	116	NUM
gsrj-50	126	155	patients	patient	NOUN
gsrj-50	126	156	with	with	ADP
gsrj-50	126	157	triple	triple	ADJ
gsrj-50	126	158	negative	negative	ADJ
gsrj-50	126	159	breast	breast	NOUN
gsrj-50	126	160	cancer	cancer	NOUN
gsrj-50	126	161	(	(	PUNCT
gsrj-50	126	162	tnbc	tnbc	ADV
gsrj-50	126	163	)	)	PUNCT
gsrj-50	126	164	were	be	AUX
gsrj-50	126	165	randomly	randomly	ADV
gsrj-50	126	166	placed	place	VERB
gsrj-50	126	167	into	into	ADP
gsrj-50	126	168	one	one	NUM
gsrj-50	126	169	of	of	ADP
gsrj-50	126	170	the	the	DET
gsrj-50	126	171	two	two	NUM
gsrj-50	126	172	groups	group	NOUN
gsrj-50	126	173	:	:	PUNCT
gsrj-50	126	174	gemcitabine	gemcitabine	NOUN
gsrj-50	126	175	with	with	ADP
gsrj-50	126	176	carboplatin	carboplatin	NOUN
gsrj-50	126	177	or	or	CCONJ
gsrj-50	126	178	gemcitabine	gemcitabine	NOUN
gsrj-50	126	179	with	with	ADP
gsrj-50	126	180	carboplatin	carboplatin	NOUN
gsrj-50	126	181	and	and	CCONJ
gsrj-50	126	182	iniparib.26	iniparib.26	ADJ
gsrj-50	126	183	the	the	DET
gsrj-50	126	184	median	median	ADJ
gsrj-50	126	185	clinical	clinical	ADJ
gsrj-50	126	186	benefit	benefit	NOUN
gsrj-50	126	187	rate	rate	NOUN
gsrj-50	126	188	of	of	ADP
gsrj-50	126	189	55.7	55.7	NUM
gsrj-50	126	190	%	%	NOUN
gsrj-50	126	191	and	and	CCONJ
gsrj-50	126	192	median	median	PROPN
gsrj-50	126	193	14	14	NUM
gsrj-50	126	194	georgetown	georgetown	PROPN
gsrj-50	126	195	scientific	scientific	PROPN
gsrj-50	126	196	research	research	PROPN
gsrj-50	126	197	journal	journal	PROPN
gsrj-50	126	198	progression	progression	NOUN
gsrj-50	126	199	free	free	ADJ
gsrj-50	126	200	survival	survival	NOUN
gsrj-50	126	201	(	(	PUNCT
gsrj-50	126	202	pfs	pfs	PROPN
gsrj-50	126	203	)	)	PUNCT
gsrj-50	126	204	of	of	ADP
gsrj-50	126	205	5.9	5.9	NUM
gsrj-50	126	206	months	month	NOUN
gsrj-50	126	207	was	be	AUX
gsrj-50	126	208	observed	observe	VERB
gsrj-50	126	209	with	with	ADP
gsrj-50	126	210	the	the	DET
gsrj-50	126	211	iniparib	iniparib	PROPN
gsrj-50	126	212	arm	arm	NOUN
gsrj-50	126	213	group	group	NOUN
gsrj-50	126	214	compared	compare	VERB
gsrj-50	126	215	to	to	ADP
gsrj-50	126	216	33.9	33.9	NUM
gsrj-50	126	217	%	%	NOUN
gsrj-50	126	218	and	and	CCONJ
gsrj-50	126	219	3.6	3.6	NUM
gsrj-50	126	220	months	month	NOUN
gsrj-50	126	221	with	with	ADP
gsrj-50	126	222	the	the	DET
gsrj-50	126	223	carboplatin	carboplatin	NOUN
gsrj-50	126	224	arm	arm	NOUN
gsrj-50	126	225	group.26	group.26	ADJ
gsrj-50	126	226	these	these	DET
gsrj-50	126	227	positive	positive	ADJ
gsrj-50	126	228	results	result	NOUN
gsrj-50	126	229	pushed	push	VERB
gsrj-50	126	230	for	for	ADP
gsrj-50	126	231	a	a	DET
gsrj-50	126	232	phase	phase	NOUN
gsrj-50	126	233	iii	iii	NOUN
gsrj-50	126	234	trial	trial	NOUN
gsrj-50	126	235	with	with	ADP
gsrj-50	126	236	iniparib	iniparib	NOUN
gsrj-50	126	237	as	as	ADP
gsrj-50	126	238	a	a	DET
gsrj-50	126	239	potential	potential	ADJ
gsrj-50	126	240	drug	drug	NOUN
gsrj-50	126	241	to	to	PART
gsrj-50	126	242	treat	treat	VERB
gsrj-50	126	243	tnbc	tnbc	ADV
gsrj-50	126	244	.	.	PUNCT
gsrj-50	127	1	olaparib	olaparib	PROPN
gsrj-50	127	2	is	be	AUX
gsrj-50	127	3	another	another	DET
gsrj-50	127	4	parp1	parp1	NOUN
gsrj-50	127	5	inhibitor	inhibitor	NOUN
gsrj-50	127	6	that	that	PRON
gsrj-50	127	7	has	have	AUX
gsrj-50	127	8	been	be	AUX
gsrj-50	127	9	part	part	NOUN
gsrj-50	127	10	of	of	ADP
gsrj-50	127	11	many	many	ADJ
gsrj-50	127	12	clinical	clinical	ADJ
gsrj-50	127	13	trials	trial	NOUN
gsrj-50	127	14	and	and	CCONJ
gsrj-50	127	15	is	be	AUX
gsrj-50	127	16	known	know	VERB
gsrj-50	127	17	to	to	PART
gsrj-50	127	18	be	be	AUX
gsrj-50	127	19	effective	effective	ADJ
gsrj-50	127	20	in	in	ADP
gsrj-50	127	21	ovarian	ovarian	ADJ
gsrj-50	127	22	and	and	CCONJ
gsrj-50	127	23	breast	breast	NOUN
gsrj-50	127	24	cancers	cancer	NOUN
gsrj-50	127	25	with	with	ADP
gsrj-50	127	26	brca	brca	PROPN
gsrj-50	127	27	mutations	mutation	NOUN
gsrj-50	127	28	.	.	PUNCT
gsrj-50	128	1	olaparib	olaparib	PROPN
gsrj-50	128	2	binds	bind	VERB
gsrj-50	128	3	to	to	ADP
gsrj-50	128	4	parp1	parp1	PROPN
gsrj-50	128	5	’s	’s	PART
gsrj-50	128	6	catalytic	catalytic	ADJ
gsrj-50	128	7	domain	domain	NOUN
gsrj-50	128	8	and	and	CCONJ
gsrj-50	128	9	traps	trap	NOUN
gsrj-50	128	10	it	it	PRON
gsrj-50	128	11	on	on	ADP
gsrj-50	128	12	damaged	damage	VERB
gsrj-50	128	13	dna	dna	NOUN
gsrj-50	128	14	sites	site	NOUN
gsrj-50	128	15	,	,	PUNCT
gsrj-50	128	16	preventing	prevent	VERB
gsrj-50	128	17	it	it	PRON
gsrj-50	128	18	from	from	ADP
gsrj-50	128	19	repairing	repair	VERB
gsrj-50	128	20	the	the	DET
gsrj-50	128	21	dna	dna	PROPN
gsrj-50	128	22	molecule.26	molecule.26	NOUN
gsrj-50	128	23	in	in	ADP
gsrj-50	128	24	a	a	DET
gsrj-50	128	25	phase	phase	NOUN
gsrj-50	128	26	i	i	PRON
gsrj-50	128	27	trial	trial	NOUN
gsrj-50	128	28	,	,	PUNCT
gsrj-50	128	29	50	50	NUM
gsrj-50	128	30	ovarian	ovarian	ADJ
gsrj-50	128	31	cancer	cancer	NOUN
gsrj-50	128	32	patients	patient	NOUN
gsrj-50	128	33	were	be	AUX
gsrj-50	128	34	given	give	VERB
gsrj-50	128	35	olaparib	olaparib	PROPN
gsrj-50	128	36	as	as	ADP
gsrj-50	128	37	a	a	DET
gsrj-50	128	38	single	single	ADJ
gsrj-50	128	39	agent	agent	NOUN
gsrj-50	128	40	,	,	PUNCT
gsrj-50	128	41	out	out	ADP
gsrj-50	128	42	of	of	ADP
gsrj-50	128	43	which	which	PRON
gsrj-50	128	44	20	20	NUM
gsrj-50	128	45	patients	patient	NOUN
gsrj-50	128	46	had	have	VERB
gsrj-50	128	47	complete	complete	ADJ
gsrj-50	128	48	or	or	CCONJ
gsrj-50	128	49	partial	partial	ADJ
gsrj-50	128	50	response	response	NOUN
gsrj-50	128	51	and	and	CCONJ
gsrj-50	128	52	3	3	NUM
gsrj-50	128	53	had	have	VERB
gsrj-50	128	54	stable	stable	ADJ
gsrj-50	128	55	disease	disease	NOUN
gsrj-50	128	56	(	(	PUNCT
gsrj-50	128	57	sd	sd	NOUN
gsrj-50	128	58	)	)	PUNCT
gsrj-50	128	59	for	for	ADP
gsrj-50	128	60	longer	long	ADJ
gsrj-50	128	61	than	than	ADP
gsrj-50	128	62	4	4	NUM
gsrj-50	128	63	months.26	months.26	NOUN
gsrj-50	128	64	there	there	PRON
gsrj-50	128	65	were	be	VERB
gsrj-50	128	66	also	also	ADV
gsrj-50	128	67	some	some	DET
gsrj-50	128	68	mild	mild	ADJ
gsrj-50	128	69	side	side	NOUN
gsrj-50	128	70	effects	effect	NOUN
gsrj-50	128	71	observed	observe	VERB
gsrj-50	128	72	,	,	PUNCT
gsrj-50	128	73	including	include	VERB
gsrj-50	128	74	gastrointestinal	gastrointestinal	ADJ
gsrj-50	128	75	upset	upset	ADJ
gsrj-50	128	76	and	and	CCONJ
gsrj-50	128	77	fatigue.26	fatigue.26	ADJ
gsrj-50	128	78	however	however	ADV
gsrj-50	128	79	,	,	PUNCT
gsrj-50	128	80	olaparib	olaparib	PROPN
gsrj-50	128	81	is	be	AUX
gsrj-50	128	82	less	less	ADV
gsrj-50	128	83	effective	effective	ADJ
gsrj-50	128	84	in	in	ADP
gsrj-50	128	85	cancers	cancer	NOUN
gsrj-50	128	86	that	that	PRON
gsrj-50	128	87	do	do	AUX
gsrj-50	128	88	not	not	PART
gsrj-50	128	89	have	have	VERB
gsrj-50	128	90	brca	brca	PROPN
gsrj-50	128	91	mutations	mutation	NOUN
gsrj-50	128	92	.	.	PUNCT
gsrj-50	129	1	this	this	PRON
gsrj-50	129	2	was	be	AUX
gsrj-50	129	3	shown	show	VERB
gsrj-50	129	4	by	by	ADP
gsrj-50	129	5	a	a	DET
gsrj-50	129	6	clinical	clinical	ADJ
gsrj-50	129	7	trial	trial	NOUN
gsrj-50	129	8	where	where	SCONJ
gsrj-50	129	9	55	55	NUM
gsrj-50	129	10	patients	patient	NOUN
gsrj-50	129	11	with	with	ADP
gsrj-50	129	12	high	high	ADJ
gsrj-50	129	13	grade	grade	NOUN
gsrj-50	129	14	serous	serous	ADJ
gsrj-50	129	15	ovarian	ovarian	ADJ
gsrj-50	129	16	cancer	cancer	NOUN
gsrj-50	129	17	(	(	PUNCT
gsrj-50	129	18	hgsoc	hgsoc	NOUN
gsrj-50	129	19	)	)	PUNCT
gsrj-50	129	20	,	,	PUNCT
gsrj-50	129	21	regardless	regardless	ADV
gsrj-50	129	22	of	of	ADP
gsrj-50	129	23	brca	brca	PROPN
gsrj-50	129	24	status	status	NOUN
gsrj-50	129	25	,	,	PUNCT
gsrj-50	129	26	were	be	AUX
gsrj-50	129	27	given	give	VERB
gsrj-50	129	28	400	400	NUM
gsrj-50	129	29	mg	mg	NOUN
gsrj-50	129	30	doses	dose	NOUN
gsrj-50	129	31	of	of	ADP
gsrj-50	129	32	olaparib	olaparib	NOUN
gsrj-50	129	33	as	as	ADP
gsrj-50	129	34	a	a	DET
gsrj-50	129	35	single	single	ADJ
gsrj-50	129	36	agent.26	agent.26	ADJ
gsrj-50	129	37	partial	partial	ADJ
gsrj-50	129	38	responses	response	NOUN
gsrj-50	129	39	were	be	AUX
gsrj-50	129	40	seen	see	VERB
gsrj-50	129	41	in	in	ADP
gsrj-50	129	42	14	14	NUM
gsrj-50	129	43	patients.26	patients.26	ADJ
gsrj-50	129	44	7	7	NUM
gsrj-50	129	45	patients	patient	NOUN
gsrj-50	129	46	in	in	ADP
gsrj-50	129	47	the	the	DET
gsrj-50	129	48	study	study	NOUN
gsrj-50	129	49	had	have	VERB
gsrj-50	129	50	brca	brca	PROPN
gsrj-50	129	51	mutations	mutation	NOUN
gsrj-50	129	52	and	and	CCONJ
gsrj-50	129	53	3	3	NUM
gsrj-50	129	54	of	of	ADP
gsrj-50	129	55	them	they	PRON
gsrj-50	129	56	had	have	VERB
gsrj-50	129	57	a	a	DET
gsrj-50	129	58	response	response	NOUN
gsrj-50	129	59	,	,	PUNCT
gsrj-50	129	60	putting	put	VERB
gsrj-50	129	61	the	the	DET
gsrj-50	129	62	response	response	NOUN
gsrj-50	129	63	rate	rate	NOUN
gsrj-50	129	64	at	at	ADP
gsrj-50	129	65	43%.26	43%.26	NUM
gsrj-50	129	66	forty	forty	NUM
gsrj-50	129	67	-	-	PUNCT
gsrj-50	129	68	six	six	NUM
gsrj-50	129	69	patients	patient	NOUN
gsrj-50	129	70	from	from	ADP
gsrj-50	129	71	the	the	DET
gsrj-50	129	72	study	study	NOUN
gsrj-50	129	73	did	do	AUX
gsrj-50	129	74	not	not	PART
gsrj-50	129	75	have	have	VERB
gsrj-50	129	76	brca	brca	PROPN
gsrj-50	129	77	mutations	mutation	NOUN
gsrj-50	129	78	,	,	PUNCT
gsrj-50	129	79	out	out	ADP
gsrj-50	129	80	of	of	ADP
gsrj-50	129	81	which	which	PRON
gsrj-50	129	82	11	11	NUM
gsrj-50	129	83	had	have	VERB
gsrj-50	129	84	a	a	DET
gsrj-50	129	85	response	response	NOUN
gsrj-50	129	86	,	,	PUNCT
gsrj-50	129	87	putting	put	VERB
gsrj-50	129	88	the	the	DET
gsrj-50	129	89	response	response	NOUN
gsrj-50	129	90	rate	rate	NOUN
gsrj-50	129	91	at	at	ADP
gsrj-50	129	92	23.9%.26	23.9%.26	ADJ
gsrj-50	129	93	this	this	PRON
gsrj-50	129	94	indicates	indicate	VERB
gsrj-50	129	95	that	that	SCONJ
gsrj-50	129	96	,	,	PUNCT
gsrj-50	129	97	although	although	SCONJ
gsrj-50	129	98	olaparib	olaparib	PROPN
gsrj-50	129	99	was	be	AUX
gsrj-50	129	100	effective	effective	ADJ
gsrj-50	129	101	regardless	regardless	ADV
gsrj-50	129	102	of	of	ADP
gsrj-50	129	103	brca	brca	PROPN
gsrj-50	129	104	integrity	integrity	NOUN
gsrj-50	129	105	,	,	PUNCT
gsrj-50	129	106	it	it	PRON
gsrj-50	129	107	is	be	AUX
gsrj-50	129	108	more	more	ADV
gsrj-50	129	109	effective	effective	ADJ
gsrj-50	129	110	in	in	ADP
gsrj-50	129	111	tumors	tumor	NOUN
gsrj-50	129	112	with	with	ADP
gsrj-50	129	113	brca	brca	PROPN
gsrj-50	129	114	mutations	mutation	NOUN
gsrj-50	129	115	.	.	PUNCT
gsrj-50	130	1	olaparib	olaparib	PROPN
gsrj-50	130	2	was	be	AUX
gsrj-50	130	3	also	also	ADV
gsrj-50	130	4	combined	combine	VERB
gsrj-50	130	5	with	with	ADP
gsrj-50	130	6	paclitaxel	paclitaxel	PROPN
gsrj-50	130	7	in	in	ADP
gsrj-50	130	8	a	a	DET
gsrj-50	130	9	phase	phase	NOUN
gsrj-50	130	10	i	i	PRON
gsrj-50	130	11	and	and	CCONJ
gsrj-50	130	12	ii	ii	PROPN
gsrj-50	130	13	study	study	NOUN
gsrj-50	130	14	on	on	ADP
gsrj-50	130	15	19	19	NUM
gsrj-50	130	16	tnbc	tnbc	NOUN
gsrj-50	130	17	patients.26	patients.26	ADJ
gsrj-50	130	18	200	200	NUM
gsrj-50	130	19	mg	mg	NOUN
gsrj-50	130	20	of	of	ADP
gsrj-50	130	21	olaparib	olaparib	PROPN
gsrj-50	130	22	was	be	AUX
gsrj-50	130	23	administered	administer	VERB
gsrj-50	130	24	daily	daily	ADV
gsrj-50	130	25	and	and	CCONJ
gsrj-50	130	26	90	90	NUM
gsrj-50	130	27	mg	mg	NUM
gsrj-50	130	28	/	/	SYM
gsrj-50	130	29	m²	m²	PROPN
gsrj-50	130	30	of	of	ADP
gsrj-50	130	31	paclitaxel	paclitaxel	PROPN
gsrj-50	130	32	was	be	AUX
gsrj-50	130	33	given	give	VERB
gsrj-50	130	34	for	for	ADP
gsrj-50	130	35	3	3	NUM
gsrj-50	130	36	out	out	ADP
gsrj-50	130	37	of	of	ADP
gsrj-50	130	38	4	4	NUM
gsrj-50	130	39	weeks.26	weeks.26	ADJ
gsrj-50	130	40	37	37	NUM
gsrj-50	130	41	%	%	NOUN
gsrj-50	130	42	of	of	ADP
gsrj-50	130	43	the	the	DET
gsrj-50	130	44	patients	patient	NOUN
gsrj-50	130	45	reported	report	VERB
gsrj-50	130	46	partial	partial	ADJ
gsrj-50	130	47	response	response	NOUN
gsrj-50	130	48	,	,	PUNCT
gsrj-50	130	49	although	although	SCONJ
gsrj-50	130	50	there	there	PRON
gsrj-50	130	51	was	be	VERB
gsrj-50	130	52	neutropenia	neutropenia	NOUN
gsrj-50	130	53	observed	observe	VERB
gsrj-50	130	54	in	in	ADP
gsrj-50	130	55	patients.26	patients.26	ADJ
gsrj-50	130	56	more	more	ADV
gsrj-50	130	57	clinical	clinical	ADJ
gsrj-50	130	58	studies	study	NOUN
gsrj-50	130	59	have	have	AUX
gsrj-50	130	60	shown	show	VERB
gsrj-50	130	61	that	that	SCONJ
gsrj-50	130	62	the	the	DET
gsrj-50	130	63	combination	combination	NOUN
gsrj-50	130	64	of	of	ADP
gsrj-50	130	65	olaparib	olaparib	NOUN
gsrj-50	130	66	and	and	CCONJ
gsrj-50	130	67	chemotherapy	chemotherapy	NOUN
gsrj-50	130	68	drugs	drug	NOUN
gsrj-50	130	69	leads	lead	VERB
gsrj-50	130	70	to	to	ADP
gsrj-50	130	71	myelosuppression	myelosuppression	NOUN
gsrj-50	130	72	,	,	PUNCT
gsrj-50	130	73	and	and	CCONJ
gsrj-50	130	74	more	more	ADV
gsrj-50	130	75	clinical	clinical	ADJ
gsrj-50	130	76	research	research	NOUN
gsrj-50	130	77	needs	need	VERB
gsrj-50	130	78	to	to	PART
gsrj-50	130	79	be	be	AUX
gsrj-50	130	80	carried	carry	VERB
gsrj-50	130	81	out	out	ADP
gsrj-50	130	82	to	to	PART
gsrj-50	130	83	determine	determine	VERB
gsrj-50	130	84	whether	whether	SCONJ
gsrj-50	130	85	the	the	DET
gsrj-50	130	86	lower	low	ADJ
gsrj-50	130	87	dose	dose	NOUN
gsrj-50	130	88	of	of	ADP
gsrj-50	130	89	chemotherapy	chemotherapy	NOUN
gsrj-50	130	90	with	with	ADP
gsrj-50	130	91	parp1	parp1	NOUN
gsrj-50	130	92	inhibitors	inhibitor	NOUN
gsrj-50	130	93	is	be	AUX
gsrj-50	130	94	more	more	ADV
gsrj-50	130	95	advantageous	advantageous	ADJ
gsrj-50	130	96	than	than	ADP
gsrj-50	130	97	a	a	DET
gsrj-50	130	98	higher	high	ADJ
gsrj-50	130	99	dose	dose	NOUN
gsrj-50	130	100	of	of	ADP
gsrj-50	130	101	chemotherapy	chemotherapy	NOUN
gsrj-50	130	102	.	.	PUNCT
gsrj-50	131	1	from	from	ADP
gsrj-50	131	2	the	the	DET
gsrj-50	131	3	results	result	NOUN
gsrj-50	131	4	,	,	PUNCT
gsrj-50	131	5	the	the	DET
gsrj-50	131	6	relationship	relationship	NOUN
gsrj-50	131	7	between	between	ADP
gsrj-50	131	8	parp1	parp1	NOUN
gsrj-50	131	9	and	and	CCONJ
gsrj-50	131	10	brca1	brca1	PROPN
gsrj-50	131	11	mutations	mutation	NOUN
gsrj-50	131	12	were	be	AUX
gsrj-50	131	13	depicted	depict	VERB
gsrj-50	131	14	more	more	ADV
gsrj-50	131	15	clearly	clearly	ADV
gsrj-50	131	16	.	.	PUNCT
gsrj-50	132	1	it	it	PRON
gsrj-50	132	2	was	be	AUX
gsrj-50	132	3	shown	show	VERB
gsrj-50	132	4	that	that	SCONJ
gsrj-50	132	5	parp1	parp1	NOUN
gsrj-50	132	6	presence	presence	NOUN
gsrj-50	132	7	was	be	AUX
gsrj-50	132	8	greater	great	ADJ
gsrj-50	132	9	in	in	ADP
gsrj-50	132	10	cancer	cancer	NOUN
gsrj-50	132	11	cells	cell	NOUN
gsrj-50	132	12	,	,	PUNCT
gsrj-50	132	13	more	more	ADV
gsrj-50	132	14	specifically	specifically	ADV
gsrj-50	132	15	breast	breast	NOUN
gsrj-50	132	16	cancer	cancer	NOUN
gsrj-50	132	17	cells	cell	NOUN
gsrj-50	132	18	,	,	PUNCT
gsrj-50	132	19	than	than	ADP
gsrj-50	132	20	other	other	ADJ
gsrj-50	132	21	cells	cell	NOUN
gsrj-50	132	22	.	.	PUNCT
gsrj-50	133	1	this	this	PRON
gsrj-50	133	2	suggests	suggest	VERB
gsrj-50	133	3	the	the	DET
gsrj-50	133	4	role	role	NOUN
gsrj-50	133	5	that	that	PRON
gsrj-50	133	6	parp1	parp1	NOUN
gsrj-50	133	7	may	may	AUX
gsrj-50	133	8	play	play	VERB
gsrj-50	133	9	in	in	ADP
gsrj-50	133	10	the	the	DET
gsrj-50	133	11	development	development	NOUN
gsrj-50	133	12	of	of	ADP
gsrj-50	133	13	cancer	cancer	NOUN
gsrj-50	133	14	.	.	PUNCT
gsrj-50	134	1	another	another	DET
gsrj-50	134	2	significant	significant	ADJ
gsrj-50	134	3	finding	finding	NOUN
gsrj-50	134	4	from	from	ADP
gsrj-50	134	5	this	this	DET
gsrj-50	134	6	study	study	NOUN
gsrj-50	134	7	was	be	AUX
gsrj-50	134	8	that	that	PRON
gsrj-50	134	9	parp1	parp1	NOUN
gsrj-50	134	10	amplification	amplification	NOUN
gsrj-50	134	11	plays	play	VERB
gsrj-50	134	12	a	a	DET
gsrj-50	134	13	greater	great	ADJ
gsrj-50	134	14	role	role	NOUN
gsrj-50	134	15	in	in	ADP
gsrj-50	134	16	the	the	DET
gsrj-50	134	17	development	development	NOUN
gsrj-50	134	18	of	of	ADP
gsrj-50	134	19	breast	breast	NOUN
gsrj-50	134	20	invasive	invasive	ADJ
gsrj-50	134	21	carcinoma	carcinoma	NOUN
gsrj-50	134	22	than	than	ADP
gsrj-50	134	23	parp1	parp1	NOUN
gsrj-50	134	24	mutations	mutation	NOUN
gsrj-50	134	25	.	.	PUNCT
gsrj-50	135	1	99	99	NUM
gsrj-50	135	2	..	..	PUNCT
gsrj-50	135	3	ccoonncclluussiioonn	ccoonncclluussiioonn	PROPN
gsrj-50	135	4	parp1	parp1	PROPN
gsrj-50	135	5	plays	play	VERB
gsrj-50	135	6	a	a	DET
gsrj-50	135	7	significant	significant	ADJ
gsrj-50	135	8	role	role	NOUN
gsrj-50	135	9	in	in	ADP
gsrj-50	135	10	several	several	ADJ
gsrj-50	135	11	cellular	cellular	ADJ
gsrj-50	135	12	processes	process	NOUN
gsrj-50	135	13	,	,	PUNCT
gsrj-50	135	14	including	include	VERB
gsrj-50	135	15	transcription	transcription	NOUN
gsrj-50	135	16	and	and	CCONJ
gsrj-50	135	17	dna	dna	PROPN
gsrj-50	135	18	repair	repair	NOUN
gsrj-50	135	19	.	.	PUNCT
gsrj-50	136	1	research	research	NOUN
gsrj-50	136	2	on	on	ADP
gsrj-50	136	3	their	their	PRON
gsrj-50	136	4	contribution	contribution	NOUN
gsrj-50	136	5	to	to	ADP
gsrj-50	136	6	the	the	DET
gsrj-50	136	7	development	development	NOUN
gsrj-50	136	8	of	of	ADP
gsrj-50	136	9	tumors	tumor	NOUN
gsrj-50	136	10	led	lead	VERB
gsrj-50	136	11	to	to	ADP
gsrj-50	136	12	the	the	DET
gsrj-50	136	13	discovery	discovery	NOUN
gsrj-50	136	14	of	of	ADP
gsrj-50	136	15	parp1	parp1	NOUN
gsrj-50	136	16	inhibitors	inhibitor	NOUN
gsrj-50	136	17	,	,	PUNCT
gsrj-50	136	18	which	which	PRON
gsrj-50	136	19	have	have	AUX
gsrj-50	136	20	proven	prove	VERB
gsrj-50	136	21	effective	effective	ADJ
gsrj-50	136	22	in	in	ADP
gsrj-50	136	23	treating	treat	VERB
gsrj-50	136	24	certain	certain	ADJ
gsrj-50	136	25	types	type	NOUN
gsrj-50	136	26	of	of	ADP
gsrj-50	136	27	cancers	cancer	NOUN
gsrj-50	136	28	.	.	PUNCT
gsrj-50	137	1	several	several	ADJ
gsrj-50	137	2	clinical	clinical	ADJ
gsrj-50	137	3	and	and	CCONJ
gsrj-50	137	4	preclinical	preclinical	ADJ
gsrj-50	137	5	trials	trial	NOUN
gsrj-50	137	6	have	have	AUX
gsrj-50	137	7	also	also	ADV
gsrj-50	137	8	suggested	suggest	VERB
gsrj-50	137	9	that	that	SCONJ
gsrj-50	137	10	these	these	DET
gsrj-50	137	11	parp1	parp1	NOUN
gsrj-50	137	12	inhibitors	inhibitor	NOUN
gsrj-50	137	13	may	may	AUX
gsrj-50	137	14	be	be	AUX
gsrj-50	137	15	more	more	ADV
gsrj-50	137	16	effective	effective	ADJ
gsrj-50	137	17	in	in	ADP
gsrj-50	137	18	combination	combination	NOUN
gsrj-50	137	19	with	with	ADP
gsrj-50	137	20	specific	specific	ADJ
gsrj-50	137	21	types	type	NOUN
gsrj-50	137	22	of	of	ADP
gsrj-50	137	23	drugs	drug	NOUN
gsrj-50	137	24	.	.	PUNCT
gsrj-50	138	1	the	the	DET
gsrj-50	138	2	clinical	clinical	ADJ
gsrj-50	138	3	relevance	relevance	NOUN
gsrj-50	138	4	of	of	ADP
gsrj-50	138	5	parp1	parp1	NOUN
gsrj-50	138	6	inhibitors	inhibitor	NOUN
gsrj-50	138	7	remains	remain	VERB
gsrj-50	138	8	clear	clear	ADJ
gsrj-50	138	9	.	.	PUNCT
gsrj-50	139	1	however	however	ADV
gsrj-50	139	2	,	,	PUNCT
gsrj-50	139	3	more	more	ADJ
gsrj-50	139	4	research	research	NOUN
gsrj-50	139	5	needs	need	VERB
gsrj-50	139	6	to	to	PART
gsrj-50	139	7	be	be	AUX
gsrj-50	139	8	done	do	VERB
gsrj-50	139	9	in	in	ADP
gsrj-50	139	10	order	order	NOUN
gsrj-50	139	11	to	to	PART
gsrj-50	139	12	thoroughly	thoroughly	ADV
gsrj-50	139	13	understand	understand	VERB
gsrj-50	139	14	the	the	DET
gsrj-50	139	15	mechanism	mechanism	NOUN
gsrj-50	139	16	of	of	ADP
gsrj-50	139	17	action	action	NOUN
gsrj-50	139	18	of	of	ADP
gsrj-50	139	19	both	both	PRON
gsrj-50	139	20	parp1	parp1	NOUN
gsrj-50	139	21	inhibitors	inhibitor	NOUN
gsrj-50	139	22	and	and	CCONJ
gsrj-50	139	23	therapy	therapy	NOUN
gsrj-50	139	24	resistance	resistance	NOUN
gsrj-50	139	25	.	.	PUNCT
gsrj-50	140	1	furthermore	furthermore	ADV
gsrj-50	140	2	,	,	PUNCT
gsrj-50	140	3	additional	additional	ADJ
gsrj-50	140	4	research	research	NOUN
gsrj-50	140	5	has	have	VERB
gsrj-50	140	6	the	the	DET
gsrj-50	140	7	potential	potential	NOUN
gsrj-50	140	8	to	to	PART
gsrj-50	140	9	increase	increase	VERB
gsrj-50	140	10	the	the	DET
gsrj-50	140	11	benefit	benefit	NOUN
gsrj-50	140	12	that	that	PRON
gsrj-50	140	13	parp1	parp1	NOUN
gsrj-50	140	14	inhibitors	inhibitor	NOUN
gsrj-50	140	15	provide	provide	VERB
gsrj-50	140	16	to	to	ADP
gsrj-50	140	17	patients	patient	NOUN
gsrj-50	140	18	.	.	PUNCT
gsrj-50	141	1	aacckknnoowwlleeddggeemmeennttss	aacckknnoowwlleeddggeemmeennttss	NOUN
gsrj-50	141	2	we	we	PRON
gsrj-50	141	3	thank	thank	VERB
gsrj-50	141	4	dr	dr	PROPN
gsrj-50	141	5	.	.	PROPN
gsrj-50	141	6	jagath	jagath	PROPN
gsrj-50	141	7	reddy	reddy	PROPN
gsrj-50	141	8	junutula	junutula	PROPN
gsrj-50	141	9	,	,	PUNCT
gsrj-50	141	10	phd	phd	NOUN
gsrj-50	141	11	and	and	CCONJ
gsrj-50	141	12	dr	dr	PROPN
gsrj-50	141	13	.	.	PROPN
gsrj-50	141	14	meenakshi	meenakshi	PROPN
gsrj-50	141	15	vengarai	vengarai	PROPN
gsrj-50	141	16	,	,	PUNCT
gsrj-50	141	17	phd	phd	NOUN
gsrj-50	141	18	for	for	ADP
gsrj-50	141	19	providing	provide	VERB
gsrj-50	141	20	continued	continued	ADJ
gsrj-50	141	21	support	support	NOUN
gsrj-50	141	22	and	and	CCONJ
gsrj-50	141	23	mentoring	mentor	VERB
gsrj-50	141	24	throughout	throughout	ADP
gsrj-50	141	25	this	this	DET
gsrj-50	141	26	research	research	NOUN
gsrj-50	141	27	.	.	PUNCT
gsrj-50	142	1	we	we	PRON
gsrj-50	142	2	also	also	ADV
gsrj-50	142	3	extend	extend	VERB
gsrj-50	142	4	our	our	PRON
gsrj-50	142	5	gratitude	gratitude	NOUN
gsrj-50	142	6	to	to	ADP
gsrj-50	142	7	the	the	DET
gsrj-50	142	8	science	science	NOUN
gsrj-50	142	9	gurus	gurus	NOUN
gsrj-50	142	10	team	team	NOUN
gsrj-50	142	11	for	for	ADP
gsrj-50	142	12	providing	provide	VERB
gsrj-50	142	13	us	we	PRON
gsrj-50	142	14	the	the	DET
gsrj-50	142	15	opportunity	opportunity	NOUN
gsrj-50	142	16	to	to	PART
gsrj-50	142	17	learn	learn	VERB
gsrj-50	142	18	and	and	CCONJ
gsrj-50	142	19	perform	perform	VERB
gsrj-50	142	20	this	this	DET
gsrj-50	142	21	research	research	NOUN
gsrj-50	142	22	under	under	ADP
gsrj-50	142	23	their	their	PRON
gsrj-50	142	24	guidance	guidance	NOUN
gsrj-50	142	25	.	.	PUNCT
gsrj-50	143	1	lastly	lastly	ADV
gsrj-50	143	2	,	,	PUNCT
gsrj-50	143	3	we	we	PRON
gsrj-50	143	4	would	would	AUX
gsrj-50	143	5	like	like	VERB
gsrj-50	143	6	to	to	PART
gsrj-50	143	7	acknowledge	acknowledge	VERB
gsrj-50	143	8	the	the	DET
gsrj-50	143	9	2021	2021	NUM
gsrj-50	143	10	cell	cell	NOUN
gsrj-50	143	11	science	science	NOUN
gsrj-50	143	12	gurus	guru	NOUN
gsrj-50	143	13	interns	intern	NOUN
gsrj-50	143	14	.	.	PUNCT
gsrj-50	144	1	rreeffeerreenncceess	rreeffeerreenncceess	PROPN
gsrj-50	144	2	1	1	NUM
gsrj-50	144	3	.	.	PUNCT
gsrj-50	144	4	rose	rise	VERB
gsrj-50	144	5	,	,	PUNCT
gsrj-50	144	6	m.	m.	NOUN
gsrj-50	144	7	,	,	PUNCT
gsrj-50	144	8	burgess	burgess	PROPN
gsrj-50	144	9	,	,	PUNCT
gsrj-50	144	10	j.	j.	PROPN
gsrj-50	144	11	t.	t.	PROPN
gsrj-50	144	12	,	,	PUNCT
gsrj-50	144	13	o’byrne	o’byrne	PROPN
gsrj-50	144	14	,	,	PUNCT
gsrj-50	144	15	k.	k.	PROPN
gsrj-50	144	16	,	,	PUNCT
gsrj-50	144	17	richard	richard	PROPN
gsrj-50	144	18	,	,	PUNCT
gsrj-50	144	19	d.	d.	PROPN
gsrj-50	144	20	j.	j.	PROPN
gsrj-50	144	21	,	,	PUNCT
gsrj-50	144	22	&	&	CCONJ
gsrj-50	144	23	bolderson	bolderson	PROPN
gsrj-50	144	24	,	,	PUNCT
gsrj-50	144	25	e.	e.	PROPN
gsrj-50	144	26	(	(	PUNCT
gsrj-50	144	27	2020	2020	NUM
gsrj-50	144	28	)	)	PUNCT
gsrj-50	144	29	.	.	PUNCT
gsrj-50	145	1	parp	parp	ADJ
gsrj-50	145	2	inhibitors	inhibitor	NOUN
gsrj-50	145	3	:	:	PUNCT
gsrj-50	145	4	clinical	clinical	ADJ
gsrj-50	145	5	relevance	relevance	NOUN
gsrj-50	145	6	,	,	PUNCT
gsrj-50	145	7	mechanisms	mechanism	NOUN
gsrj-50	145	8	of	of	ADP
gsrj-50	145	9	action	action	NOUN
gsrj-50	145	10	and	and	CCONJ
gsrj-50	145	11	tumor	tumor	NOUN
gsrj-50	145	12	resistance	resistance	NOUN
gsrj-50	145	13	.	.	PUNCT
gsrj-50	146	1	frontiers	frontier	NOUN
gsrj-50	146	2	in	in	ADP
gsrj-50	146	3	cell	cell	NOUN
gsrj-50	146	4	and	and	CCONJ
gsrj-50	146	5	15	15	NUM
gsrj-50	146	6	georgetown	georgetown	PROPN
gsrj-50	146	7	scientific	scientific	PROPN
gsrj-50	146	8	research	research	NOUN
gsrj-50	146	9	journal	journal	NOUN
gsrj-50	146	10	developmental	developmental	ADJ
gsrj-50	146	11	biology	biology	NOUN
gsrj-50	146	12	,	,	PUNCT
gsrj-50	146	13	8	8	NUM
gsrj-50	146	14	.	.	PUNCT
gsrj-50	147	1	https://doi.org/10.3389/fcell.2020.564601	https://doi.org/10.3389/fcell.2020.564601	PROPN
gsrj-50	147	2	2	2	X
gsrj-50	147	3	.	.	X
gsrj-50	147	4	wang	wang	PROPN
gsrj-50	147	5	,	,	PUNCT
gsrj-50	147	6	y.	y.	PROPN
gsrj-50	147	7	,	,	PUNCT
gsrj-50	147	8	luo	luo	PROPN
gsrj-50	147	9	,	,	PUNCT
gsrj-50	147	10	w.	w.	PROPN
gsrj-50	147	11	,	,	PUNCT
gsrj-50	147	12	&	&	CCONJ
gsrj-50	147	13	wang	wang	PROPN
gsrj-50	147	14	,	,	PUNCT
gsrj-50	147	15	y.	y.	PROPN
gsrj-50	147	16	(	(	PUNCT
gsrj-50	147	17	2019	2019	NUM
gsrj-50	147	18	)	)	PUNCT
gsrj-50	147	19	.	.	PUNCT
gsrj-50	148	1	parp1	parp1	NOUN
gsrj-50	148	2	and	and	CCONJ
gsrj-50	148	3	its	its	PRON
gsrj-50	148	4	associated	associated	ADJ
gsrj-50	148	5	nucleases	nuclease	NOUN
gsrj-50	148	6	in	in	ADP
gsrj-50	148	7	dna	dna	PROPN
gsrj-50	148	8	damage	damage	NOUN
gsrj-50	148	9	response	response	NOUN
gsrj-50	148	10	.	.	PUNCT
gsrj-50	149	1	dna	dna	PROPN
gsrj-50	149	2	repair	repair	NOUN
gsrj-50	149	3	,	,	PUNCT
gsrj-50	149	4	81	81	NUM
gsrj-50	149	5	,	,	PUNCT
gsrj-50	149	6	102651	102651	NUM
gsrj-50	149	7	.	.	PUNCT
gsrj-50	150	1	https://doi.org/10.1016/j.dnarep.2019.10	https://doi.org/10.1016/j.dnarep.2019.10	PROPN
gsrj-50	150	2	2651	2651	NUM
gsrj-50	150	3	3	3	NUM
gsrj-50	150	4	.	.	PUNCT
gsrj-50	150	5	alemasova	alemasova	PROPN
gsrj-50	150	6	,	,	PUNCT
gsrj-50	150	7	e.	e.	PROPN
gsrj-50	150	8	e.	e.	PROPN
gsrj-50	150	9	,	,	PUNCT
gsrj-50	150	10	&	&	CCONJ
gsrj-50	150	11	lavrik	lavrik	PROPN
gsrj-50	150	12	,	,	PUNCT
gsrj-50	150	13	o.	o.	PROPN
gsrj-50	150	14	i.	i.	PROPN
gsrj-50	150	15	(	(	PUNCT
gsrj-50	150	16	2019	2019	NUM
gsrj-50	150	17	)	)	PUNCT
gsrj-50	150	18	.	.	PUNCT
gsrj-50	151	1	poly(adp	poly(adp	PROPN
gsrj-50	151	2	-	-	PUNCT
gsrj-50	151	3	ribosyl)ation	ribosyl)ation	PROPN
gsrj-50	151	4	by	by	ADP
gsrj-50	151	5	parp1	parp1	NOUN
gsrj-50	151	6	:	:	PUNCT
gsrj-50	151	7	reaction	reaction	NOUN
gsrj-50	151	8	mechanism	mechanism	NOUN
gsrj-50	151	9	and	and	CCONJ
gsrj-50	151	10	regulatory	regulatory	ADJ
gsrj-50	151	11	proteins	protein	NOUN
gsrj-50	151	12	.	.	PUNCT
gsrj-50	152	1	nucleic	nucleic	ADJ
gsrj-50	152	2	acids	acid	NOUN
gsrj-50	152	3	research	research	NOUN
gsrj-50	152	4	,	,	PUNCT
gsrj-50	152	5	47(8	47(8	NOUN
gsrj-50	152	6	)	)	PUNCT
gsrj-50	152	7	,	,	PUNCT
gsrj-50	152	8	3811–3827	3811–3827	NUM
gsrj-50	152	9	.	.	PUNCT
gsrj-50	153	1	https://doi.org/10.1093/nar/gkz120	https://doi.org/10.1093/nar/gkz120	PROPN
gsrj-50	153	2	4	4	NUM
gsrj-50	153	3	.	.	X
gsrj-50	153	4	rosado	rosado	NOUN
gsrj-50	153	5	,	,	PUNCT
gsrj-50	153	6	m.	m.	NOUN
gsrj-50	153	7	m.	m.	NOUN
gsrj-50	153	8	,	,	PUNCT
gsrj-50	153	9	bennici	bennici	PROPN
gsrj-50	153	10	,	,	PUNCT
gsrj-50	153	11	e.	e.	PROPN
gsrj-50	153	12	,	,	PUNCT
gsrj-50	153	13	novelli	novelli	PROPN
gsrj-50	153	14	,	,	PUNCT
gsrj-50	153	15	f.	f.	PROPN
gsrj-50	153	16	,	,	PUNCT
gsrj-50	153	17	&	&	CCONJ
gsrj-50	153	18	pioli	pioli	PROPN
gsrj-50	153	19	,	,	PUNCT
gsrj-50	153	20	c.	c.	PROPN
gsrj-50	153	21	(	(	PUNCT
gsrj-50	153	22	2013	2013	NUM
gsrj-50	153	23	)	)	PUNCT
gsrj-50	153	24	.	.	PUNCT
gsrj-50	154	1	beyond	beyond	ADP
gsrj-50	154	2	dna	dna	PROPN
gsrj-50	154	3	repair	repair	NOUN
gsrj-50	154	4	,	,	PUNCT
gsrj-50	154	5	the	the	DET
gsrj-50	154	6	immunological	immunological	ADJ
gsrj-50	154	7	role	role	NOUN
gsrj-50	154	8	of	of	ADP
gsrj-50	154	9	parp-1	parp-1	PROPN
gsrj-50	154	10	and	and	CCONJ
gsrj-50	154	11	its	its	PRON
gsrj-50	154	12	siblings	sibling	NOUN
gsrj-50	154	13	.	.	PUNCT
gsrj-50	155	1	immunology	immunology	NOUN
gsrj-50	155	2	,	,	PUNCT
gsrj-50	155	3	139(4	139(4	NOUN
gsrj-50	155	4	)	)	PUNCT
gsrj-50	155	5	,	,	PUNCT
gsrj-50	155	6	428–437	428–437	NUM
gsrj-50	155	7	.	.	PUNCT
gsrj-50	156	1	https://doi.org/10.1111/imm.12099	https://doi.org/10.1111/imm.12099	PROPN
gsrj-50	156	2	5	5	NUM
gsrj-50	156	3	.	.	PUNCT
gsrj-50	156	4	ko	ko	PROPN
gsrj-50	156	5	,	,	PUNCT
gsrj-50	156	6	h.	h.	PROPN
gsrj-50	156	7	l.	l.	PROPN
gsrj-50	156	8	,	,	PUNCT
gsrj-50	156	9	&	&	CCONJ
gsrj-50	156	10	ren	ren	PROPN
gsrj-50	156	11	,	,	PUNCT
gsrj-50	156	12	e.	e.	PROPN
gsrj-50	156	13	c.	c.	PROPN
gsrj-50	156	14	(	(	PUNCT
gsrj-50	156	15	2012	2012	NUM
gsrj-50	156	16	)	)	PUNCT
gsrj-50	156	17	.	.	PUNCT
gsrj-50	157	1	functional	functional	ADJ
gsrj-50	157	2	aspects	aspect	NOUN
gsrj-50	157	3	of	of	ADP
gsrj-50	157	4	parp1	parp1	NOUN
gsrj-50	157	5	in	in	ADP
gsrj-50	157	6	dna	dna	PROPN
gsrj-50	157	7	repair	repair	NOUN
gsrj-50	157	8	and	and	CCONJ
gsrj-50	157	9	transcription	transcription	NOUN
gsrj-50	157	10	.	.	PUNCT
gsrj-50	158	1	biomolecules	biomolecule	NOUN
gsrj-50	158	2	,	,	PUNCT
gsrj-50	158	3	2(4	2(4	NUM
gsrj-50	158	4	)	)	PUNCT
gsrj-50	158	5	,	,	PUNCT
gsrj-50	158	6	524–548	524–548	NUM
gsrj-50	158	7	.	.	PUNCT
gsrj-50	159	1	https://doi.org/10.3390/biom2040524	https://doi.org/10.3390/biom2040524	PROPN
gsrj-50	159	2	6	6	NUM
gsrj-50	159	3	.	.	PUNCT
gsrj-50	159	4	uniprot	uniprot	ADJ
gsrj-50	159	5	consortium	consortium	PROPN
gsrj-50	159	6	european	european	PROPN
gsrj-50	159	7	bioinformatics	bioinformatics	PROPN
gsrj-50	159	8	institute	institute	NOUN
gsrj-50	159	9	protein	protein	NOUN
gsrj-50	159	10	information	information	NOUN
gsrj-50	159	11	resource	resource	NOUN
gsrj-50	159	12	sib	sib	PROPN
gsrj-50	159	13	swiss	swiss	PROPN
gsrj-50	159	14	institute	institute	PROPN
gsrj-50	159	15	of	of	ADP
gsrj-50	159	16	bioinformatics	bioinformatics	PROPN
gsrj-50	159	17	.	.	PUNCT
gsrj-50	160	1	(	(	PUNCT
gsrj-50	160	2	2022	2022	NUM
gsrj-50	160	3	,	,	PUNCT
gsrj-50	160	4	may	may	AUX
gsrj-50	160	5	25	25	NUM
gsrj-50	160	6	)	)	PUNCT
gsrj-50	160	7	.	.	PUNCT
gsrj-50	161	1	poly	poly	PROPN
gsrj-50	161	2	[	[	X
gsrj-50	161	3	adp	adp	NOUN
gsrj-50	161	4	-	-	PUNCT
gsrj-50	161	5	ribose	ribose	NOUN
gsrj-50	161	6	]	]	PUNCT
gsrj-50	161	7	polymerase	polymerase	NOUN
gsrj-50	161	8	1	1	NUM
gsrj-50	161	9	.	.	PUNCT
gsrj-50	162	1	https://www.uniprot.org/uniprot/p09874	https://www.uniprot.org/uniprot/p09874	PRON
gsrj-50	162	2	7	7	X
gsrj-50	162	3	.	.	X
gsrj-50	162	4	cbioportal	cbioportal	ADJ
gsrj-50	162	5	for	for	ADP
gsrj-50	162	6	cancer	cancer	NOUN
gsrj-50	162	7	genomics	genomic	NOUN
gsrj-50	162	8	.	.	PUNCT
gsrj-50	163	1	(	(	PUNCT
gsrj-50	163	2	n.d	n.d	PROPN
gsrj-50	163	3	.	.	PROPN
gsrj-50	163	4	)	)	PUNCT
gsrj-50	163	5	.	.	PUNCT
gsrj-50	164	1	tcga	tcga	PROPN
gsrj-50	164	2	pancancer	pancancer	NOUN
gsrj-50	164	3	atlas	atlas	PROPN
gsrj-50	164	4	studies	study	NOUN
gsrj-50	164	5	.	.	PUNCT
gsrj-50	165	1	https://www.cbioportal.org/results/mutations?case	https://www.cbioportal.org/results/mutations?case	PROPN
gsrj-50	165	2	_	_	PUNCT
gsrj-50	165	3	set_id	set_id	X
gsrj-50	166	1	=	=	NOUN
gsrj-50	166	2	all&gene_list	all&gene_list	NOUN
gsrj-50	166	3	=	=	NOUN
gsrj-50	166	4	parp1&cancer_study_list	parp1&cancer_study_list	NOUN
gsrj-50	166	5	=	=	SYM
gsrj-50	166	6	5c8a7d55e4b046111fee2296	5c8a7d55e4b046111fee2296	NUM
gsrj-50	166	7	8	8	NUM
gsrj-50	166	8	.	.	PUNCT
gsrj-50	167	1	murnyák	murnyák	PROPN
gsrj-50	167	2	,	,	PUNCT
gsrj-50	167	3	b.	b.	PROPN
gsrj-50	167	4	,	,	PUNCT
gsrj-50	167	5	kouhsari	kouhsari	PROPN
gsrj-50	167	6	,	,	PUNCT
gsrj-50	167	7	m.	m.	PROPN
gsrj-50	167	8	c.	c.	PROPN
gsrj-50	167	9	,	,	PUNCT
gsrj-50	167	10	hershkovitch	hershkovitch	PROPN
gsrj-50	167	11	,	,	PUNCT
gsrj-50	167	12	r.	r.	PROPN
gsrj-50	167	13	,	,	PUNCT
gsrj-50	167	14	kálmán	kálmán	PROPN
gsrj-50	167	15	,	,	PUNCT
gsrj-50	167	16	b.	b.	PROPN
gsrj-50	167	17	,	,	PUNCT
gsrj-50	167	18	marko	marko	PROPN
gsrj-50	167	19	-	-	PUNCT
gsrj-50	167	20	varga	varga	PROPN
gsrj-50	167	21	,	,	PUNCT
gsrj-50	167	22	g.	g.	PROPN
gsrj-50	167	23	,	,	PUNCT
gsrj-50	167	24	klekner	klekner	PROPN
gsrj-50	167	25	,	,	PUNCT
gsrj-50	167	26	á	á	PROPN
gsrj-50	167	27	.	.	PROPN
gsrj-50	167	28	,	,	PUNCT
gsrj-50	167	29	&	&	CCONJ
gsrj-50	167	30	hortobágyi	hortobágyi	PROPN
gsrj-50	167	31	,	,	PUNCT
gsrj-50	167	32	t.	t.	PROPN
gsrj-50	167	33	(	(	PUNCT
gsrj-50	167	34	2017	2017	NUM
gsrj-50	167	35	)	)	PUNCT
gsrj-50	167	36	.	.	PUNCT
gsrj-50	168	1	parp1	parp1	NOUN
gsrj-50	168	2	expression	expression	NOUN
gsrj-50	168	3	and	and	CCONJ
gsrj-50	168	4	its	its	PRON
gsrj-50	168	5	correlation	correlation	NOUN
gsrj-50	168	6	with	with	ADP
gsrj-50	168	7	survival	survival	NOUN
gsrj-50	168	8	is	be	AUX
gsrj-50	168	9	tumour	tumour	ADJ
gsrj-50	168	10	molecular	molecular	ADJ
gsrj-50	168	11	subtype	subtype	NOUN
gsrj-50	168	12	dependent	dependent	ADJ
gsrj-50	168	13	in	in	ADP
gsrj-50	168	14	glioblastoma	glioblastoma	NOUN
gsrj-50	168	15	.	.	PUNCT
gsrj-50	169	1	oncotarget	oncotarget	NOUN
gsrj-50	169	2	,	,	PUNCT
gsrj-50	169	3	8(28	8(28	NUM
gsrj-50	169	4	)	)	PUNCT
gsrj-50	169	5	,	,	PUNCT
gsrj-50	169	6	46348–46362	46348–46362	NUM
gsrj-50	169	7	.	.	PUNCT
gsrj-50	170	1	https://doi.org/10.18632/oncotarget.18013	https://doi.org/10.18632/oncotarget.18013	X
gsrj-50	170	2	9	9	NUM
gsrj-50	170	3	.	.	PUNCT
gsrj-50	171	1	ayee	ayee	PROPN
gsrj-50	171	2	,	,	PUNCT
gsrj-50	171	3	r.	r.	PROPN
gsrj-50	171	4	,	,	PUNCT
gsrj-50	171	5	ofori	ofori	ADV
gsrj-50	171	6	,	,	PUNCT
gsrj-50	171	7	m.	m.	PROPN
gsrj-50	171	8	e.	e.	PROPN
gsrj-50	171	9	o.	o.	PROPN
gsrj-50	171	10	,	,	PUNCT
gsrj-50	171	11	wright	wright	PROPN
gsrj-50	171	12	,	,	PUNCT
gsrj-50	171	13	e.	e.	PROPN
gsrj-50	171	14	,	,	PUNCT
gsrj-50	171	15	&	&	CCONJ
gsrj-50	171	16	quaye	quaye	PROPN
gsrj-50	171	17	,	,	PUNCT
gsrj-50	171	18	o.	o.	PROPN
gsrj-50	171	19	(	(	PUNCT
gsrj-50	171	20	2020	2020	NUM
gsrj-50	171	21	)	)	PUNCT
gsrj-50	171	22	.	.	PUNCT
gsrj-50	172	1	epstein	epstein	PROPN
gsrj-50	172	2	barr	barr	PROPN
gsrj-50	172	3	virus	virus	PROPN
gsrj-50	172	4	associated	associate	VERB
gsrj-50	172	5	lymphomas	lymphoma	NOUN
gsrj-50	172	6	and	and	CCONJ
gsrj-50	172	7	epithelia	epithelia	NOUN
gsrj-50	172	8	cancers	cancer	NOUN
gsrj-50	172	9	in	in	ADP
gsrj-50	172	10	humans	human	NOUN
gsrj-50	172	11	.	.	PUNCT
gsrj-50	173	1	journal	journal	NOUN
gsrj-50	173	2	of	of	ADP
gsrj-50	173	3	cancer	cancer	NOUN
gsrj-50	173	4	,	,	PUNCT
gsrj-50	173	5	11(7	11(7	NUM
gsrj-50	173	6	)	)	PUNCT
gsrj-50	173	7	,	,	PUNCT
gsrj-50	173	8	1737	1737	NUM
gsrj-50	173	9	-	-	SYM
gsrj-50	173	10	1750	1750	NUM
gsrj-50	173	11	.	.	PUNCT
gsrj-50	174	1	https://doi.org/10.7150/jca.37282	https://doi.org/10.7150/jca.37282	PROPN
gsrj-50	174	2	10	10	NUM
gsrj-50	174	3	.	.	PUNCT
gsrj-50	175	1	rosado	rosado	NOUN
gsrj-50	175	2	,	,	PUNCT
gsrj-50	175	3	m.	m.	NOUN
gsrj-50	175	4	m.	m.	NOUN
gsrj-50	175	5	,	,	PUNCT
gsrj-50	175	6	bennici	bennici	PROPN
gsrj-50	175	7	,	,	PUNCT
gsrj-50	175	8	e.	e.	PROPN
gsrj-50	175	9	,	,	PUNCT
gsrj-50	175	10	novelli	novelli	PROPN
gsrj-50	175	11	,	,	PUNCT
gsrj-50	175	12	f.	f.	PROPN
gsrj-50	175	13	,	,	PUNCT
gsrj-50	175	14	&	&	CCONJ
gsrj-50	175	15	pioli	pioli	PROPN
gsrj-50	175	16	,	,	PUNCT
gsrj-50	175	17	c.	c.	PROPN
gsrj-50	175	18	(	(	PUNCT
gsrj-50	175	19	2013	2013	NUM
gsrj-50	175	20	)	)	PUNCT
gsrj-50	175	21	.	.	PUNCT
gsrj-50	176	1	beyond	beyond	ADP
gsrj-50	176	2	dna	dna	PROPN
gsrj-50	176	3	repair	repair	NOUN
gsrj-50	176	4	,	,	PUNCT
gsrj-50	176	5	the	the	DET
gsrj-50	176	6	immunological	immunological	ADJ
gsrj-50	176	7	role	role	NOUN
gsrj-50	176	8	of	of	ADP
gsrj-50	176	9	parp-1	parp-1	PROPN
gsrj-50	176	10	and	and	CCONJ
gsrj-50	176	11	its	its	PRON
gsrj-50	176	12	siblings	sibling	NOUN
gsrj-50	176	13	.	.	PUNCT
gsrj-50	177	1	immunology	immunology	NOUN
gsrj-50	177	2	,	,	PUNCT
gsrj-50	177	3	139(4	139(4	NOUN
gsrj-50	177	4	)	)	PUNCT
gsrj-50	177	5	,	,	PUNCT
gsrj-50	177	6	428–437	428–437	NUM
gsrj-50	177	7	.	.	PUNCT
gsrj-50	178	1	https://doi.org/10.1111/imm.12099	https://doi.org/10.1111/imm.12099	PROPN
gsrj-50	178	2	11	11	NUM
gsrj-50	178	3	.	.	PUNCT
gsrj-50	179	1	ossovskaya	ossovskaya	PROPN
gsrj-50	179	2	,	,	PUNCT
gsrj-50	179	3	v.	v.	PROPN
gsrj-50	179	4	,	,	PUNCT
gsrj-50	179	5	koo	koo	PROPN
gsrj-50	179	6	,	,	PUNCT
gsrj-50	179	7	i.	i.	PROPN
gsrj-50	179	8	c.	c.	PROPN
gsrj-50	179	9	,	,	PUNCT
gsrj-50	179	10	kaldjian	kaldjian	PROPN
gsrj-50	179	11	,	,	PUNCT
gsrj-50	179	12	e.	e.	PROPN
gsrj-50	179	13	p.	p.	PROPN
gsrj-50	179	14	,	,	PUNCT
gsrj-50	179	15	alvares	alvares	PROPN
gsrj-50	179	16	,	,	PUNCT
gsrj-50	179	17	c.	c.	PROPN
gsrj-50	179	18	,	,	PUNCT
gsrj-50	179	19	&	&	CCONJ
gsrj-50	179	20	sherman	sherman	PROPN
gsrj-50	179	21	,	,	PUNCT
gsrj-50	179	22	b.	b.	PROPN
gsrj-50	179	23	m.	m.	PROPN
gsrj-50	179	24	(	(	PUNCT
gsrj-50	179	25	2010	2010	NUM
gsrj-50	179	26	)	)	PUNCT
gsrj-50	179	27	.	.	PUNCT
gsrj-50	180	1	upregulation	upregulation	NOUN
gsrj-50	180	2	of	of	ADP
gsrj-50	180	3	poly	poly	ADJ
gsrj-50	180	4	(	(	PUNCT
gsrj-50	180	5	adp	adp	PROPN
gsrj-50	180	6	-	-	PUNCT
gsrj-50	180	7	ribose	ribose	NOUN
gsrj-50	180	8	)	)	PUNCT
gsrj-50	180	9	polymerase-1	polymerase-1	PROPN
gsrj-50	180	10	(	(	PUNCT
gsrj-50	180	11	parp1	parp1	PROPN
gsrj-50	180	12	)	)	PUNCT
gsrj-50	180	13	in	in	ADP
gsrj-50	180	14	triple	triple	ADJ
gsrj-50	180	15	-	-	PUNCT
gsrj-50	180	16	negative	negative	ADJ
gsrj-50	180	17	breast	breast	NOUN
gsrj-50	180	18	cancer	cancer	NOUN
gsrj-50	180	19	and	and	CCONJ
gsrj-50	180	20	other	other	ADJ
gsrj-50	180	21	primary	primary	ADJ
gsrj-50	180	22	human	human	ADJ
gsrj-50	180	23	tumor	tumor	NOUN
gsrj-50	180	24	types	type	NOUN
gsrj-50	180	25	.	.	PUNCT
gsrj-50	181	1	genes	gene	NOUN
gsrj-50	181	2	&	&	CCONJ
gsrj-50	181	3	cancer	cancer	NOUN
gsrj-50	181	4	,	,	PUNCT
gsrj-50	181	5	1(8	1(8	NUM
gsrj-50	181	6	)	)	PUNCT
gsrj-50	181	7	,	,	PUNCT
gsrj-50	181	8	812–821	812–821	NUM
gsrj-50	181	9	.	.	PUNCT
gsrj-50	181	10	https://doi.org/10.1177/1947601910383418	https://doi.org/10.1177/1947601910383418	NOUN
gsrj-50	181	11	12	12	NUM
gsrj-50	181	12	.	.	PUNCT
gsrj-50	182	1	wu	wu	PROPN
gsrj-50	182	2	,	,	PUNCT
gsrj-50	182	3	j.	j.	PROPN
gsrj-50	182	4	,	,	PUNCT
gsrj-50	182	5	lu	lu	PROPN
gsrj-50	182	6	,	,	PUNCT
gsrj-50	182	7	l.	l.	PROPN
gsrj-50	182	8	y.	y.	PROPN
gsrj-50	182	9	,	,	PUNCT
gsrj-50	182	10	&	&	CCONJ
gsrj-50	182	11	yu	yu	PROPN
gsrj-50	182	12	,	,	PUNCT
gsrj-50	182	13	x.	x.	NOUN
gsrj-50	182	14	(	(	PUNCT
gsrj-50	182	15	2010	2010	NUM
gsrj-50	182	16	)	)	PUNCT
gsrj-50	182	17	.	.	PUNCT
gsrj-50	183	1	the	the	DET
gsrj-50	183	2	role	role	NOUN
gsrj-50	183	3	of	of	ADP
gsrj-50	183	4	brca1	brca1	PROPN
gsrj-50	183	5	in	in	ADP
gsrj-50	183	6	dna	dna	PROPN
gsrj-50	183	7	damage	damage	NOUN
gsrj-50	183	8	response	response	NOUN
gsrj-50	183	9	.	.	PUNCT
gsrj-50	184	1	protein	protein	NOUN
gsrj-50	184	2	&	&	CCONJ
gsrj-50	184	3	cell	cell	PROPN
gsrj-50	184	4	,	,	PUNCT
gsrj-50	184	5	1(2	1(2	NUM
gsrj-50	184	6	)	)	PUNCT
gsrj-50	184	7	,	,	PUNCT
gsrj-50	184	8	117	117	NUM
gsrj-50	184	9	–	–	SYM
gsrj-50	184	10	123	123	NUM
gsrj-50	184	11	.	.	PUNCT
gsrj-50	185	1	https://doi.org/10.1007/s13238-010-0010-5	https://doi.org/10.1007/s13238-010-0010-5	NUM
gsrj-50	185	2	13	13	NUM
gsrj-50	185	3	.	.	PUNCT
gsrj-50	186	1	li	li	PROPN
gsrj-50	186	2	,	,	PUNCT
gsrj-50	186	3	d.	d.	PROPN
gsrj-50	186	4	,	,	PUNCT
gsrj-50	186	5	bi	bi	NOUN
gsrj-50	186	6	,	,	PUNCT
gsrj-50	186	7	f.-f	f.-f	NOUN
gsrj-50	186	8	.	.	PUNCT
gsrj-50	186	9	,	,	PUNCT
gsrj-50	186	10	chen	chen	PROPN
gsrj-50	186	11	,	,	PUNCT
gsrj-50	186	12	n.-n	n.-n	PROPN
gsrj-50	186	13	.	.	PROPN
gsrj-50	186	14	,	,	PUNCT
gsrj-50	186	15	cao	cao	PROPN
gsrj-50	186	16	,	,	PUNCT
gsrj-50	186	17	j.-m	j.-m	PROPN
gsrj-50	186	18	.	.	PROPN
gsrj-50	186	19	,	,	PUNCT
gsrj-50	186	20	sun	sun	PROPN
gsrj-50	186	21	,	,	PUNCT
gsrj-50	186	22	w.-p	w.-p	PROPN
gsrj-50	186	23	.	.	PROPN
gsrj-50	186	24	,	,	PUNCT
gsrj-50	186	25	zhou	zhou	PROPN
gsrj-50	186	26	,	,	PUNCT
gsrj-50	186	27	y.-m	y.-m	PROPN
gsrj-50	186	28	.	.	PROPN
gsrj-50	186	29	,	,	PUNCT
gsrj-50	186	30	li	li	PROPN
gsrj-50	186	31	,	,	PUNCT
gsrj-50	186	32	c.-y	c.-y	NOUN
gsrj-50	186	33	.	.	PUNCT
gsrj-50	186	34	,	,	PUNCT
gsrj-50	186	35	&	&	CCONJ
gsrj-50	186	36	yang	yang	PROPN
gsrj-50	186	37	,	,	PUNCT
gsrj-50	186	38	q.	q.	PROPN
gsrj-50	186	39	(	(	PUNCT
gsrj-50	186	40	2014	2014	NUM
gsrj-50	186	41	)	)	PUNCT
gsrj-50	186	42	.	.	PUNCT
gsrj-50	187	1	a	a	DET
gsrj-50	187	2	novel	novel	NOUN
gsrj-50	187	3	crosstalk	crosstalk	NOUN
gsrj-50	187	4	between	between	ADP
gsrj-50	187	5	brca1	brca1	NOUN
gsrj-50	187	6	and	and	CCONJ
gsrj-50	187	7	poly	poly	ADJ
gsrj-50	187	8	(	(	PUNCT
gsrj-50	187	9	adp	adp	PROPN
gsrj-50	187	10	-	-	PUNCT
gsrj-50	187	11	ribose	ribose	NOUN
gsrj-50	187	12	)	)	PUNCT
gsrj-50	187	13	polymerase	polymerase	NOUN
gsrj-50	187	14	1	1	NUM
gsrj-50	187	15	in	in	ADP
gsrj-50	187	16	breast	breast	NOUN
gsrj-50	187	17	cancer	cancer	NOUN
gsrj-50	187	18	.	.	PUNCT
gsrj-50	188	1	cell	cell	NOUN
gsrj-50	188	2	cycle	cycle	NOUN
gsrj-50	188	3	,	,	PUNCT
gsrj-50	188	4	13(21	13(21	NUM
gsrj-50	188	5	)	)	PUNCT
gsrj-50	188	6	,	,	PUNCT
gsrj-50	188	7	3442–3449	3442–3449	NOUN
gsrj-50	188	8	.	.	PUNCT
gsrj-50	189	1	https://doi.org/10.4161/15384101.2014.956507	https://doi.org/10.4161/15384101.2014.956507	PROPN
gsrj-50	189	2	14	14	NUM
gsrj-50	189	3	.	.	PUNCT
gsrj-50	190	1	ucsc	ucsc	PROPN
gsrj-50	190	2	,	,	PUNCT
gsrj-50	190	3	ucsc	ucsc	PROPN
gsrj-50	190	4	genomics	genomics	PROPN
gsrj-50	190	5	institute	institute	PROPN
gsrj-50	190	6	,	,	PUNCT
gsrj-50	190	7	ucsc	ucsc	PROPN
gsrj-50	190	8	computational	computational	ADJ
gsrj-50	190	9	genomics	genomic	NOUN
gsrj-50	190	10	laboratory	laboratory	NOUN
gsrj-50	190	11	,	,	PUNCT
gsrj-50	190	12	&	&	CCONJ
gsrj-50	190	13	ucsc	ucsc	PROPN
gsrj-50	190	14	xena	xena	PROPN
gsrj-50	190	15	.	.	PUNCT
gsrj-50	191	1	(	(	PUNCT
gsrj-50	191	2	n.d	n.d	PROPN
gsrj-50	191	3	.	.	PROPN
gsrj-50	191	4	)	)	PUNCT
gsrj-50	191	5	.	.	PUNCT
gsrj-50	192	1	xena	xena	PROPN
gsrj-50	192	2	functional	functional	ADJ
gsrj-50	192	3	genomics	genomic	NOUN
gsrj-50	192	4	explorer	explorer	PROPN
gsrj-50	192	5	.	.	PUNCT
gsrj-50	193	1	university	university	PROPN
gsrj-50	193	2	of	of	ADP
gsrj-50	193	3	california	california	PROPN
gsrj-50	193	4	santa	santa	PROPN
gsrj-50	193	5	cruz	cruz	PROPN
gsrj-50	193	6	.	.	PUNCT
gsrj-50	194	1	https://xenabrowser.net/heatmap/	https://xenabrowser.net/heatmap/	PROPN
gsrj-50	194	2	15	15	NUM
gsrj-50	194	3	.	.	PUNCT
gsrj-50	195	1	hurtado	hurtado	NOUN
gsrj-50	195	2	-	-	PUNCT
gsrj-50	195	3	bagès	bagès	PROPN
gsrj-50	195	4	,	,	PUNCT
gsrj-50	195	5	s.	s.	PROPN
gsrj-50	195	6	,	,	PUNCT
gsrj-50	195	7	knobloch	knobloch	PROPN
gsrj-50	195	8	,	,	PUNCT
gsrj-50	195	9	g.	g.	PROPN
gsrj-50	195	10	,	,	PUNCT
gsrj-50	195	11	ladurner	ladurner	PROPN
gsrj-50	195	12	,	,	PUNCT
gsrj-50	195	13	a.	a.	NOUN
gsrj-50	195	14	g.	g.	PROPN
gsrj-50	195	15	,	,	PUNCT
gsrj-50	195	16	&	&	CCONJ
gsrj-50	195	17	buschbeck	buschbeck	PROPN
gsrj-50	195	18	,	,	PUNCT
gsrj-50	195	19	m.	m.	NOUN
gsrj-50	195	20	(	(	PUNCT
gsrj-50	195	21	2020	2020	NUM
gsrj-50	195	22	)	)	PUNCT
gsrj-50	195	23	.	.	PUNCT
gsrj-50	196	1	the	the	DET
gsrj-50	196	2	taming	taming	NOUN
gsrj-50	196	3	of	of	ADP
gsrj-50	196	4	parp1	parp1	NOUN
gsrj-50	196	5	and	and	CCONJ
gsrj-50	196	6	its	its	PRON
gsrj-50	196	7	impact	impact	NOUN
gsrj-50	196	8	on	on	ADP
gsrj-50	196	9	nad+	nad+	PROPN
gsrj-50	196	10	metabolism	metabolism	NOUN
gsrj-50	196	11	.	.	PUNCT
gsrj-50	197	1	molecular	molecular	ADJ
gsrj-50	197	2	metabolism	metabolism	NOUN
gsrj-50	197	3	,	,	PUNCT
gsrj-50	197	4	38	38	NUM
gsrj-50	197	5	,	,	PUNCT
gsrj-50	197	6	100950	100950	NUM
gsrj-50	197	7	.	.	PUNCT
gsrj-50	198	1	https://doi.org/10.1016/j.molmet.2020.01.014	https://doi.org/10.1016/j.molmet.2020.01.014	PROPN
gsrj-50	198	2	16	16	NUM
gsrj-50	198	3	.	.	PUNCT
gsrj-50	199	1	zhang	zhang	PROPN
gsrj-50	199	2	,	,	PUNCT
gsrj-50	199	3	d.	d.	PROPN
gsrj-50	199	4	,	,	PUNCT
gsrj-50	199	5	hu	hu	PROPN
gsrj-50	199	6	,	,	PUNCT
gsrj-50	199	7	x.	x.	PROPN
gsrj-50	199	8	,	,	PUNCT
gsrj-50	199	9	li	li	PROPN
gsrj-50	199	10	,	,	PUNCT
gsrj-50	199	11	j.	j.	PROPN
gsrj-50	199	12	,	,	PUNCT
gsrj-50	199	13	et	et	PROPN
gsrj-50	199	14	al	al	PROPN
gsrj-50	199	15	.	.	PROPN
gsrj-50	199	16	(	(	PUNCT
gsrj-50	199	17	2019	2019	NUM
gsrj-50	199	18	)	)	PUNCT
gsrj-50	199	19	.	.	PUNCT
gsrj-50	200	1	dna	dna	PROPN
gsrj-50	200	2	damage	damage	NOUN
gsrj-50	200	3	-	-	PUNCT
gsrj-50	200	4	induced	induce	VERB
gsrj-50	200	5	parp1	parp1	NOUN
gsrj-50	200	6	activation	activation	NOUN
gsrj-50	200	7	confers	confer	NOUN
gsrj-50	200	8	cardiomyocyte	cardiomyocyte	PROPN
gsrj-50	200	9	dysfunction	dysfunction	NOUN
gsrj-50	200	10	through	through	ADP
gsrj-50	200	11	nad+	nad+	PROPN
gsrj-50	200	12	depletion	depletion	NOUN
gsrj-50	200	13	in	in	ADP
gsrj-50	200	14	experimental	experimental	ADJ
gsrj-50	200	15	atrial	atrial	ADJ
gsrj-50	200	16	fibrillation	fibrillation	NOUN
gsrj-50	200	17	.	.	PUNCT
gsrj-50	201	1	nature	nature	NOUN
gsrj-50	201	2	communications	communication	NOUN
gsrj-50	201	3	,	,	PUNCT
gsrj-50	201	4	10	10	NUM
gsrj-50	201	5	,	,	PUNCT
gsrj-50	201	6	1307	1307	NUM
gsrj-50	201	7	.	.	PUNCT
gsrj-50	202	1	https://doi.org/10.1038/s41467-019-09014-2	https://doi.org/10.1038/s41467-019-09014-2	NUM
gsrj-50	202	2	17	17	NUM
gsrj-50	202	3	.	.	PUNCT
gsrj-50	203	1	keung	keung	PROPN
gsrj-50	203	2	,	,	PUNCT
gsrj-50	203	3	m.	m.	NOUN
gsrj-50	203	4	,	,	PUNCT
gsrj-50	203	5	wu	wu	PROPN
gsrj-50	203	6	,	,	PUNCT
gsrj-50	203	7	y.	y.	PROPN
gsrj-50	203	8	,	,	PUNCT
gsrj-50	203	9	&	&	CCONJ
gsrj-50	203	10	vadgama	vadgama	PROPN
gsrj-50	203	11	,	,	PUNCT
gsrj-50	203	12	j.	j.	PROPN
gsrj-50	203	13	(	(	PUNCT
gsrj-50	203	14	2019	2019	NUM
gsrj-50	203	15	)	)	PUNCT
gsrj-50	203	16	.	.	PUNCT
gsrj-50	204	1	parp	parp	ADJ
gsrj-50	204	2	inhibitors	inhibitor	NOUN
gsrj-50	204	3	as	as	ADP
gsrj-50	204	4	a	a	DET
gsrj-50	204	5	therapeutic	therapeutic	ADJ
gsrj-50	204	6	agent	agent	NOUN
gsrj-50	204	7	for	for	ADP
gsrj-50	204	8	homologous	homologous	ADJ
gsrj-50	204	9	recombination	recombination	NOUN
gsrj-50	204	10	deficiency	deficiency	NOUN
gsrj-50	204	11	in	in	ADP
gsrj-50	204	12	breast	breast	NOUN
gsrj-50	204	13	cancers	cancer	NOUN
gsrj-50	204	14	.	.	PUNCT
gsrj-50	205	1	journal	journal	NOUN
gsrj-50	205	2	of	of	ADP
gsrj-50	205	3	clinical	clinical	ADJ
gsrj-50	205	4	medicine	medicine	NOUN
gsrj-50	205	5	,	,	PUNCT
gsrj-50	205	6	8(4	8(4	NUM
gsrj-50	205	7	)	)	PUNCT
gsrj-50	205	8	,	,	PUNCT
gsrj-50	205	9	435	435	NUM
gsrj-50	205	10	.	.	PUNCT
gsrj-50	206	1	https://doi.org/10.3390/jcm8040435	https://doi.org/10.3390/jcm8040435	VERB
gsrj-50	206	2	18	18	NUM
gsrj-50	206	3	.	.	PUNCT
gsrj-50	207	1	helleday	helleday	PROPN
gsrj-50	207	2	t.	t.	PROPN
gsrj-50	207	3	(	(	PUNCT
gsrj-50	207	4	2011	2011	NUM
gsrj-50	207	5	)	)	PUNCT
gsrj-50	207	6	.	.	PUNCT
gsrj-50	208	1	the	the	DET
gsrj-50	208	2	underlying	underlying	ADJ
gsrj-50	208	3	mechanism	mechanism	NOUN
gsrj-50	208	4	for	for	ADP
gsrj-50	208	5	the	the	DET
gsrj-50	208	6	parp	parp	NOUN
gsrj-50	208	7	and	and	CCONJ
gsrj-50	208	8	brca	brca	PROPN
gsrj-50	208	9	synthetic	synthetic	ADJ
gsrj-50	208	10	lethality	lethality	NOUN
gsrj-50	208	11	:	:	PUNCT
gsrj-50	208	12	clearing	clear	VERB
gsrj-50	208	13	up	up	ADP
gsrj-50	208	14	the	the	DET
gsrj-50	208	15	misunderstandings	misunderstanding	NOUN
gsrj-50	208	16	.	.	PUNCT
gsrj-50	209	1	molecular	molecular	ADJ
gsrj-50	209	2	oncology	oncology	NOUN
gsrj-50	209	3	,	,	PUNCT
gsrj-50	209	4	5(4	5(4	NUM
gsrj-50	209	5	)	)	PUNCT
gsrj-50	209	6	,	,	PUNCT
gsrj-50	209	7	387–393	387–393	NUM
gsrj-50	209	8	.	.	PUNCT
gsrj-50	210	1	https://doi.org/10.1016/j.molonc.2011.07.001	https://doi.org/10.1016/j.molonc.2011.07.001	NOUN
gsrj-50	210	2	19	19	NUM
gsrj-50	210	3	.	.	PUNCT
gsrj-50	211	1	shen	shen	PROPN
gsrj-50	211	2	,	,	PUNCT
gsrj-50	211	3	y.	y.	PROPN
gsrj-50	211	4	,	,	PUNCT
gsrj-50	211	5	aoyagi	aoyagi	NOUN
gsrj-50	211	6	-	-	PUNCT
gsrj-50	211	7	scharber	scharber	NOUN
gsrj-50	211	8	,	,	PUNCT
gsrj-50	211	9	m.	m.	NOUN
gsrj-50	211	10	,	,	PUNCT
gsrj-50	211	11	&	&	CCONJ
gsrj-50	211	12	wang	wang	PROPN
gsrj-50	211	13	,	,	PUNCT
gsrj-50	211	14	b.	b.	PROPN
gsrj-50	211	15	(	(	PUNCT
gsrj-50	211	16	2015	2015	NUM
gsrj-50	211	17	)	)	PUNCT
gsrj-50	211	18	.	.	PUNCT
gsrj-50	212	1	trapping	trap	VERB
gsrj-50	212	2	poly(adp	poly(adp	NOUN
gsrj-50	212	3	-	-	PUNCT
gsrj-50	212	4	ribose	ribose	NOUN
gsrj-50	212	5	)	)	PUNCT
gsrj-50	212	6	polymerase	polymerase	NOUN
gsrj-50	212	7	.	.	PUNCT
gsrj-50	213	1	the	the	DET
gsrj-50	213	2	journal	journal	NOUN
gsrj-50	213	3	of	of	ADP
gsrj-50	213	4	pharmacology	pharmacology	NOUN
gsrj-50	213	5	and	and	CCONJ
gsrj-50	213	6	experimental	experimental	ADJ
gsrj-50	213	7	therapeutics	therapeutic	NOUN
gsrj-50	213	8	,	,	PUNCT
gsrj-50	213	9	353(3	353(3	NUM
gsrj-50	213	10	)	)	PUNCT
gsrj-50	213	11	,	,	PUNCT
gsrj-50	213	12	446–457	446–457	NUM
gsrj-50	213	13	.	.	PUNCT
gsrj-50	214	1	https://doi.org/10.1124/jpet.114.222448	https://doi.org/10.1124/jpet.114.222448	X
gsrj-50	214	2	20	20	NUM
gsrj-50	214	3	.	.	PUNCT
gsrj-50	214	4	luo	luo	PROPN
gsrj-50	214	5	,	,	PUNCT
gsrj-50	214	6	x.	x.	PROPN
gsrj-50	214	7	,	,	PUNCT
gsrj-50	214	8	&	&	CCONJ
gsrj-50	214	9	kraus	kraus	PROPN
gsrj-50	214	10	,	,	PUNCT
gsrj-50	214	11	w.	w.	PROPN
gsrj-50	214	12	l.	l.	PROPN
gsrj-50	214	13	(	(	PUNCT
gsrj-50	214	14	2012	2012	NUM
gsrj-50	214	15	)	)	PUNCT
gsrj-50	214	16	.	.	PUNCT
gsrj-50	215	1	on	on	ADP
gsrj-50	215	2	par	par	NOUN
gsrj-50	215	3	with	with	ADP
gsrj-50	215	4	parp	parp	ADJ
gsrj-50	215	5	:	:	PUNCT
gsrj-50	215	6	cellular	cellular	ADJ
gsrj-50	215	7	stress	stress	NOUN
gsrj-50	215	8	signaling	signal	VERB
gsrj-50	215	9	through	through	ADP
gsrj-50	215	10	poly(adp	poly(adp	NOUN
gsrj-50	215	11	-	-	PUNCT
gsrj-50	215	12	ribose	ribose	NOUN
gsrj-50	215	13	)	)	PUNCT
gsrj-50	215	14	and	and	CCONJ
gsrj-50	215	15	parp-1	parp-1	PROPN
gsrj-50	215	16	.	.	NOUN
gsrj-50	216	1	genes	gene	NOUN
gsrj-50	216	2	&	&	CCONJ
gsrj-50	216	3	16	16	NUM
gsrj-50	216	4	georgetown	georgetown	PROPN
gsrj-50	216	5	scientific	scientific	PROPN
gsrj-50	216	6	research	research	PROPN
gsrj-50	216	7	journal	journal	PROPN
gsrj-50	216	8	development	development	PROPN
gsrj-50	216	9	,	,	PUNCT
gsrj-50	216	10	26(5	26(5	NUM
gsrj-50	216	11	)	)	PUNCT
gsrj-50	216	12	,	,	PUNCT
gsrj-50	216	13	417–432	417–432	X
gsrj-50	216	14	.	.	PUNCT
gsrj-50	217	1	https://doi.org/10.1101/gad.183509.111	https://doi.org/10.1101/gad.183509.111	PROPN
gsrj-50	217	2	21	21	NUM
gsrj-50	217	3	.	.	PUNCT
gsrj-50	217	4	pommier	pommier	NOUN
gsrj-50	217	5	,	,	PUNCT
gsrj-50	217	6	y.	y.	PROPN
gsrj-50	217	7	,	,	PUNCT
gsrj-50	217	8	o'connor	o'connor	PROPN
gsrj-50	217	9	,	,	PUNCT
gsrj-50	217	10	m.	m.	NOUN
gsrj-50	217	11	j.	j.	PROPN
gsrj-50	217	12	,	,	PUNCT
gsrj-50	217	13	&	&	CCONJ
gsrj-50	217	14	de	de	X
gsrj-50	217	15	bono	bono	X
gsrj-50	217	16	,	,	PUNCT
gsrj-50	217	17	j.	j.	PROPN
gsrj-50	217	18	(	(	PUNCT
gsrj-50	217	19	2016	2016	NUM
gsrj-50	217	20	)	)	PUNCT
gsrj-50	217	21	.	.	PUNCT
gsrj-50	218	1	laying	lay	VERB
gsrj-50	218	2	a	a	DET
gsrj-50	218	3	trap	trap	NOUN
gsrj-50	218	4	to	to	PART
gsrj-50	218	5	kill	kill	VERB
gsrj-50	218	6	cancer	cancer	NOUN
gsrj-50	218	7	cells	cell	NOUN
gsrj-50	218	8	:	:	PUNCT
gsrj-50	218	9	parp	parp	ADJ
gsrj-50	218	10	inhibitors	inhibitor	NOUN
gsrj-50	218	11	and	and	CCONJ
gsrj-50	218	12	their	their	PRON
gsrj-50	218	13	mechanisms	mechanism	NOUN
gsrj-50	218	14	of	of	ADP
gsrj-50	218	15	action	action	NOUN
gsrj-50	218	16	.	.	PUNCT
gsrj-50	219	1	science	science	NOUN
gsrj-50	219	2	translational	translational	ADJ
gsrj-50	219	3	medicine	medicine	NOUN
gsrj-50	219	4	,	,	PUNCT
gsrj-50	219	5	8(362	8(362	NUM
gsrj-50	219	6	)	)	PUNCT
gsrj-50	219	7	,	,	PUNCT
gsrj-50	219	8	362ps17	362ps17	NUM
gsrj-50	219	9	.	.	PUNCT
gsrj-50	220	1	https://doi.org/10.1126/scitranslmed.aaf9246	https://doi.org/10.1126/scitranslmed.aaf9246	PROPN
gsrj-50	220	2	22	22	NUM
gsrj-50	220	3	.	.	PUNCT
gsrj-50	221	1	diéras	diéras	PROPN
gsrj-50	221	2	,	,	PUNCT
gsrj-50	221	3	v.	v.	PROPN
gsrj-50	221	4	,	,	PUNCT
gsrj-50	221	5	han	han	PROPN
gsrj-50	221	6	,	,	PUNCT
gsrj-50	221	7	h.	h.	PROPN
gsrj-50	221	8	s.	s.	PROPN
gsrj-50	221	9	,	,	PUNCT
gsrj-50	221	10	kaufman	kaufman	PROPN
gsrj-50	221	11	,	,	PUNCT
gsrj-50	221	12	b.	b.	PROPN
gsrj-50	221	13	,	,	PUNCT
gsrj-50	221	14	wildiers	wildiers	PROPN
gsrj-50	221	15	,	,	PUNCT
gsrj-50	221	16	h.	h.	PROPN
gsrj-50	221	17	,	,	PUNCT
gsrj-50	221	18	friedlander	friedlander	NOUN
gsrj-50	221	19	,	,	PUNCT
gsrj-50	221	20	m.	m.	NOUN
gsrj-50	221	21	,	,	PUNCT
gsrj-50	221	22	ayoub	ayoub	PROPN
gsrj-50	221	23	,	,	PUNCT
gsrj-50	221	24	j.	j.	PROPN
gsrj-50	221	25	p.	p.	PROPN
gsrj-50	221	26	,	,	PUNCT
gsrj-50	221	27	puhalla	puhalla	PROPN
gsrj-50	221	28	,	,	PUNCT
gsrj-50	221	29	s.	s.	PROPN
gsrj-50	221	30	l.	l.	PROPN
gsrj-50	221	31	,	,	PUNCT
gsrj-50	221	32	bondarenko	bondarenko	PROPN
gsrj-50	221	33	,	,	PUNCT
gsrj-50	221	34	i.	i.	NOUN
gsrj-50	221	35	,	,	PUNCT
gsrj-50	221	36	campone	campone	NOUN
gsrj-50	221	37	,	,	PUNCT
gsrj-50	221	38	m.	m.	NOUN
gsrj-50	221	39	,	,	PUNCT
gsrj-50	221	40	jakobsen	jakobsen	PROPN
gsrj-50	221	41	,	,	PUNCT
gsrj-50	221	42	e.	e.	PROPN
gsrj-50	221	43	h.	h.	PROPN
gsrj-50	221	44	,	,	PUNCT
gsrj-50	221	45	jalving	jalving	NOUN
gsrj-50	221	46	,	,	PUNCT
gsrj-50	221	47	m.	m.	NOUN
gsrj-50	221	48	,	,	PUNCT
gsrj-50	221	49	oprean	oprean	ADJ
gsrj-50	221	50	,	,	PUNCT
gsrj-50	221	51	c.	c.	NOUN
gsrj-50	221	52	,	,	PUNCT
gsrj-50	221	53	palácová	palácová	NOUN
gsrj-50	221	54	,	,	PUNCT
gsrj-50	221	55	m.	m.	NOUN
gsrj-50	221	56	,	,	PUNCT
gsrj-50	221	57	park	park	NOUN
gsrj-50	221	58	,	,	PUNCT
gsrj-50	221	59	y.	y.	PROPN
gsrj-50	221	60	h.	h.	PROPN
gsrj-50	221	61	,	,	PUNCT
gsrj-50	221	62	shparyk	shparyk	PROPN
gsrj-50	221	63	,	,	PUNCT
gsrj-50	221	64	y.	y.	PROPN
gsrj-50	221	65	,	,	PUNCT
gsrj-50	221	66	yañez	yañez	PROPN
gsrj-50	221	67	,	,	PUNCT
gsrj-50	221	68	e.	e.	PROPN
gsrj-50	221	69	,	,	PUNCT
gsrj-50	221	70	khandelwal	khandelwal	PROPN
gsrj-50	221	71	,	,	PUNCT
gsrj-50	221	72	n.	n.	NOUN
gsrj-50	221	73	,	,	PUNCT
gsrj-50	221	74	kundu	kundu	NOUN
gsrj-50	221	75	,	,	PUNCT
gsrj-50	221	76	m.	m.	NOUN
gsrj-50	221	77	g.	g.	PROPN
gsrj-50	221	78	,	,	PUNCT
gsrj-50	221	79	dudley	dudley	PROPN
gsrj-50	221	80	,	,	PUNCT
gsrj-50	221	81	m.	m.	NOUN
gsrj-50	221	82	,	,	PUNCT
gsrj-50	221	83	ratajczak	ratajczak	PROPN
gsrj-50	221	84	,	,	PUNCT
gsrj-50	221	85	c.	c.	PROPN
gsrj-50	221	86	k.	k.	PROPN
gsrj-50	221	87	,	,	PUNCT
gsrj-50	221	88	…	…	PUNCT
gsrj-50	221	89	arun	arun	PROPN
gsrj-50	221	90	,	,	PUNCT
gsrj-50	221	91	b.	b.	PROPN
gsrj-50	221	92	k.	k.	PROPN
gsrj-50	221	93	(	(	PUNCT
gsrj-50	221	94	2020	2020	NUM
gsrj-50	221	95	)	)	PUNCT
gsrj-50	221	96	.	.	PUNCT
gsrj-50	222	1	veliparib	veliparib	NOUN
gsrj-50	222	2	with	with	ADP
gsrj-50	222	3	carboplatin	carboplatin	NOUN
gsrj-50	222	4	and	and	CCONJ
gsrj-50	222	5	paclitaxel	paclitaxel	PROPN
gsrj-50	222	6	in	in	ADP
gsrj-50	222	7	brca	brca	PROPN
gsrj-50	222	8	-	-	PUNCT
gsrj-50	222	9	mutated	mutate	VERB
gsrj-50	222	10	advanced	advanced	ADJ
gsrj-50	222	11	breast	breast	NOUN
gsrj-50	222	12	cancer	cancer	NOUN
gsrj-50	222	13	(	(	PUNCT
gsrj-50	222	14	brocade3	brocade3	VERB
gsrj-50	222	15	):	):	PUNCT
gsrj-50	222	16	a	a	DET
gsrj-50	222	17	randomised	randomised	ADJ
gsrj-50	222	18	,	,	PUNCT
gsrj-50	222	19	doubleblind	doubleblind	NOUN
gsrj-50	222	20	,	,	PUNCT
gsrj-50	222	21	placebo	placebo	NOUN
gsrj-50	222	22	-	-	PUNCT
gsrj-50	222	23	controlled	control	VERB
gsrj-50	222	24	,	,	PUNCT
gsrj-50	222	25	phase	phase	NOUN
gsrj-50	222	26	3	3	NUM
gsrj-50	222	27	trial	trial	NOUN
gsrj-50	222	28	.	.	PUNCT
gsrj-50	223	1	the	the	DET
gsrj-50	223	2	lancet	lancet	PROPN
gsrj-50	223	3	.	.	PUNCT
gsrj-50	224	1	oncology	oncology	NOUN
gsrj-50	224	2	,	,	PUNCT
gsrj-50	224	3	21(10	21(10	PROPN
gsrj-50	224	4	)	)	PUNCT
gsrj-50	224	5	,	,	PUNCT
gsrj-50	224	6	1269–1282	1269–1282	NUM
gsrj-50	224	7	.	.	PUNCT
gsrj-50	225	1	https://doi.org/10.1016/s1470-2045(20)30447-2	https://doi.org/10.1016/s1470-2045(20)30447-2	NOUN
gsrj-50	225	2	23	23	NUM
gsrj-50	225	3	.	.	PUNCT
gsrj-50	226	1	zhang	zhang	PROPN
gsrj-50	226	2	,	,	PUNCT
gsrj-50	226	3	j.	j.	PROPN
gsrj-50	226	4	,	,	PUNCT
gsrj-50	226	5	stevens	stevens	PROPN
gsrj-50	226	6	,	,	PUNCT
gsrj-50	226	7	m.	m.	PROPN
gsrj-50	226	8	f.	f.	PROPN
gsrj-50	226	9	,	,	PUNCT
gsrj-50	226	10	&	&	CCONJ
gsrj-50	226	11	bradshaw	bradshaw	PROPN
gsrj-50	226	12	,	,	PUNCT
gsrj-50	226	13	t.	t.	PROPN
gsrj-50	226	14	d.	d.	PROPN
gsrj-50	226	15	(	(	PUNCT
gsrj-50	226	16	2012	2012	NUM
gsrj-50	226	17	)	)	PUNCT
gsrj-50	226	18	.	.	PUNCT
gsrj-50	227	1	temozolomide	temozolomide	NOUN
gsrj-50	227	2	:	:	PUNCT
gsrj-50	227	3	mechanisms	mechanism	NOUN
gsrj-50	227	4	of	of	ADP
gsrj-50	227	5	action	action	NOUN
gsrj-50	227	6	,	,	PUNCT
gsrj-50	227	7	repair	repair	NOUN
gsrj-50	227	8	and	and	CCONJ
gsrj-50	227	9	resistance	resistance	NOUN
gsrj-50	227	10	.	.	PUNCT
gsrj-50	228	1	current	current	ADJ
gsrj-50	228	2	molecular	molecular	ADJ
gsrj-50	228	3	pharmacology	pharmacology	NOUN
gsrj-50	228	4	,	,	PUNCT
gsrj-50	228	5	5(1	5(1	NUM
gsrj-50	228	6	)	)	PUNCT
gsrj-50	228	7	,	,	PUNCT
gsrj-50	228	8	102–114	102–114	NUM
gsrj-50	228	9	.	.	PUNCT
gsrj-50	229	1	https://doi.org/10.2174/1874467211205010102	https://doi.org/10.2174/1874467211205010102	DET
gsrj-50	229	2	24	24	NUM
gsrj-50	229	3	.	.	PUNCT
gsrj-50	229	4	wang	wang	PROPN
gsrj-50	229	5	,	,	PUNCT
gsrj-50	229	6	d.	d.	PROPN
gsrj-50	229	7	,	,	PUNCT
gsrj-50	229	8	li	li	PROPN
gsrj-50	229	9	,	,	PUNCT
gsrj-50	229	10	c.	c.	PROPN
gsrj-50	229	11	,	,	PUNCT
gsrj-50	229	12	zhang	zhang	PROPN
gsrj-50	229	13	,	,	PUNCT
gsrj-50	229	14	y.	y.	PROPN
gsrj-50	229	15	,	,	PUNCT
gsrj-50	229	16	wang	wang	PROPN
gsrj-50	229	17	,	,	PUNCT
gsrj-50	229	18	m.	m.	NOUN
gsrj-50	229	19	,	,	PUNCT
gsrj-50	229	20	jiang	jiang	PROPN
gsrj-50	229	21	,	,	PUNCT
gsrj-50	229	22	n.	n.	PROPN
gsrj-50	229	23	,	,	PUNCT
gsrj-50	229	24	xiang	xiang	PROPN
gsrj-50	229	25	,	,	PUNCT
gsrj-50	229	26	l.	l.	PROPN
gsrj-50	229	27	,	,	PUNCT
gsrj-50	229	28	li	li	PROPN
gsrj-50	229	29	,	,	PUNCT
gsrj-50	229	30	t.	t.	PROPN
gsrj-50	229	31	,	,	PUNCT
gsrj-50	229	32	roberts	roberts	PROPN
gsrj-50	229	33	,	,	PUNCT
gsrj-50	229	34	t.	t.	NOUN
gsrj-50	229	35	m.	m.	NOUN
gsrj-50	229	36	,	,	PUNCT
gsrj-50	229	37	zhao	zhao	PROPN
gsrj-50	229	38	,	,	PUNCT
gsrj-50	229	39	j.	j.	PROPN
gsrj-50	229	40	j.	j.	PROPN
gsrj-50	229	41	,	,	PUNCT
gsrj-50	229	42	cheng	cheng	PROPN
gsrj-50	229	43	,	,	PUNCT
gsrj-50	229	44	h.	h.	PROPN
gsrj-50	229	45	,	,	PUNCT
gsrj-50	229	46	&	&	CCONJ
gsrj-50	229	47	liu	liu	PROPN
gsrj-50	229	48	,	,	PUNCT
gsrj-50	229	49	p.	p.	NOUN
gsrj-50	229	50	(	(	PUNCT
gsrj-50	229	51	2016	2016	NUM
gsrj-50	229	52	)	)	PUNCT
gsrj-50	229	53	.	.	PUNCT
gsrj-50	230	1	combined	combine	VERB
gsrj-50	230	2	inhibition	inhibition	NOUN
gsrj-50	230	3	of	of	ADP
gsrj-50	230	4	pi3k	pi3k	NOUN
gsrj-50	230	5	and	and	CCONJ
gsrj-50	230	6	parp	parp	NOUN
gsrj-50	230	7	is	be	AUX
gsrj-50	230	8	effective	effective	ADJ
gsrj-50	230	9	in	in	ADP
gsrj-50	230	10	the	the	DET
gsrj-50	230	11	treatment	treatment	NOUN
gsrj-50	230	12	of	of	ADP
gsrj-50	230	13	ovarian	ovarian	ADJ
gsrj-50	230	14	cancer	cancer	NOUN
gsrj-50	230	15	cells	cell	NOUN
gsrj-50	230	16	with	with	ADP
gsrj-50	230	17	wild	wild	ADJ
gsrj-50	230	18	-	-	PUNCT
gsrj-50	230	19	type	type	NOUN
gsrj-50	230	20	pik3ca	pik3ca	NOUN
gsrj-50	230	21	genes	gene	NOUN
gsrj-50	230	22	.	.	PUNCT
gsrj-50	231	1	gynecologic	gynecologic	ADJ
gsrj-50	231	2	oncology	oncology	NOUN
gsrj-50	231	3	,	,	PUNCT
gsrj-50	231	4	142(3	142(3	NUM
gsrj-50	231	5	)	)	PUNCT
gsrj-50	231	6	,	,	PUNCT
gsrj-50	231	7	548–556	548–556	NUM
gsrj-50	231	8	.	.	PUNCT
gsrj-50	232	1	https://doi.org/10.1016/j.ygyno.2016.07.092	https://doi.org/10.1016/j.ygyno.2016.07.092	PROPN
gsrj-50	232	2	25	25	NUM
gsrj-50	232	3	.	.	PUNCT
gsrj-50	233	1	mweempwa	mweempwa	PROPN
gsrj-50	233	2	,	,	PUNCT
gsrj-50	233	3	a.	a.	PROPN
gsrj-50	233	4	,	,	PUNCT
gsrj-50	233	5	&	&	CCONJ
gsrj-50	233	6	wilson	wilson	PROPN
gsrj-50	233	7	,	,	PUNCT
gsrj-50	233	8	m.	m.	PROPN
gsrj-50	233	9	k.	k.	PROPN
gsrj-50	233	10	(	(	PUNCT
gsrj-50	233	11	2019	2019	NUM
gsrj-50	233	12	)	)	PUNCT
gsrj-50	233	13	.	.	PUNCT
gsrj-50	234	1	mechanisms	mechanism	NOUN
gsrj-50	234	2	of	of	ADP
gsrj-50	234	3	resistance	resistance	NOUN
gsrj-50	234	4	to	to	ADP
gsrj-50	234	5	parp	parp	ADJ
gsrj-50	234	6	inhibitors	inhibitor	NOUN
gsrj-50	234	7	an	an	DET
gsrj-50	234	8	evolving	evolve	VERB
gsrj-50	234	9	challenge	challenge	NOUN
gsrj-50	234	10	in	in	ADP
gsrj-50	234	11	oncology	oncology	NOUN
gsrj-50	234	12	.	.	PUNCT
gsrj-50	235	1	cancer	cancer	NOUN
gsrj-50	235	2	drug	drug	NOUN
gsrj-50	235	3	resistance	resistance	NOUN
gsrj-50	235	4	(	(	PUNCT
gsrj-50	235	5	alhambra	alhambra	PROPN
gsrj-50	235	6	,	,	PUNCT
gsrj-50	235	7	calif	calif	PROPN
gsrj-50	235	8	.	.	PROPN
gsrj-50	235	9	)	)	PUNCT
gsrj-50	235	10	,	,	PUNCT
gsrj-50	235	11	2(3	2(3	NUM
gsrj-50	235	12	)	)	PUNCT
gsrj-50	235	13	,	,	PUNCT
gsrj-50	235	14	608–617	608–617	NUM
gsrj-50	235	15	.	.	PUNCT
gsrj-50	236	1	https://doi.org/10.20517/cdr.2019.50	https://doi.org/10.20517/cdr.2019.50	PRON
gsrj-50	237	1	26	26	NUM
gsrj-50	237	2	.	.	PUNCT
gsrj-50	238	1	chen	chen	PROPN
gsrj-50	238	2	a.	a.	PROPN
gsrj-50	238	3	(	(	PUNCT
gsrj-50	238	4	2011	2011	NUM
gsrj-50	238	5	)	)	PUNCT
gsrj-50	238	6	.	.	PUNCT
gsrj-50	239	1	parp	parp	ADJ
gsrj-50	239	2	inhibitors	inhibitor	NOUN
gsrj-50	239	3	:	:	PUNCT
gsrj-50	239	4	its	its	PRON
gsrj-50	239	5	role	role	NOUN
gsrj-50	239	6	in	in	ADP
gsrj-50	239	7	treatment	treatment	NOUN
gsrj-50	239	8	of	of	ADP
gsrj-50	239	9	cancer	cancer	NOUN
gsrj-50	239	10	.	.	PUNCT
gsrj-50	240	1	chinese	chinese	ADJ
gsrj-50	240	2	journal	journal	PROPN
gsrj-50	240	3	of	of	ADP
gsrj-50	240	4	cancer	cancer	NOUN
gsrj-50	240	5	,	,	PUNCT
gsrj-50	240	6	30(7	30(7	NUM
gsrj-50	240	7	)	)	PUNCT
gsrj-50	240	8	,	,	PUNCT
gsrj-50	240	9	463–471	463–471	NUM
gsrj-50	240	10	.	.	PUNCT
gsrj-50	240	11	https://doi.org/10.5732/cjc.011.1011	https://doi.org/10.5732/cjc.011.1011	PROPN
gsrj-50	240	12	17	17	NUM
gsrj-50	240	13	18	18	NUM